mRNA combination therapy for treatment of cancer
A combination of polynucleotides encoding immune response and costimulatory signal polypeptides, along with checkpoint inhibitors, provides a targeted and effective method to reduce tumor size and inhibit growth with improved safety, addressing the limitations of current cancer treatments.
Patent Information
- Application Number
- JP2024115498
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-10-04
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current cancer treatments, such as chemotherapy and radiotherapy, often result in undesirable immune responses and safety concerns due to random gene integration, while immunotherapies like DC vaccines and checkpoint inhibitors face low response rates and adverse side effects, necessitating a more targeted and effective approach.
Administering a combination of at least two polynucleotides encoding immune response priming and costimulatory signal polypeptides, along with checkpoint inhibitor polypeptides, to enhance tumor-specific immune activation and reduce tumor growth.
This approach significantly reduces tumor size and inhibits tumor growth by enhancing immune response efficacy with minimal adverse effects, as demonstrated in preclinical models.
Smart Images

Figure 2024160243000442 
Figure 2024160243000443 
Figure 2024160243000444
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation of U.S. Provisional Patent Application Nos. 62 / 338,496, filed May 18, 2016, 62 / 338,483, filed May 18, 2016, 62 / 338,501, filed May 18, 2016, 62 / 338,505, filed May 18, 2016, 62 / 338,506, filed May 18, 2016, and 20 This application claims the benefit of priority to US Patent No. 62 / 338,467, filed May 18, 2016, US Patent No. 62 / 338,507, filed May 18, 2016, US Patent No. 62 / 338,530, filed May 19, 2016, and US Patent No. 62 / 404,173, filed October 4, 2016, each of which is incorporated by reference in its entirety.
[0002] Reference to an electronically submitted sequence listing The contents of the electronically submitted Sequence Listing filed with this application as an ASCII text file (Name: 3529_120PC02_ST25_SQLST.txt, Size: 1,653,452 bytes, and Creation Date: May 18, 2017) are hereby incorporated by reference in their entirety. [Background technology]
[0003] Cancer is a disease characterized by uncontrolled cell division and proliferation in the body. In the United States, nearly one-third of all women and nearly half of all men will experience cancer in their lifetime. Polypeptides are involved in all aspects of the disease, including cancer cell biology (carcinogenesis, cell cycle suppression, DNA repair, and angiogenesis), treatment (immunotherapy, hormone manipulation, enzyme inhibition), and cancer type diagnosis and determination (e.g., molecular markers for breast, prostate, and cervical cancer). In hosts experiencing undesirable outcomes from current standard treatments, such as chemotherapy and radiation therapy, gene therapy, which manipulates disease-associated peptides and their functions, offers a more targeted approach to disease diagnosis, treatment, and management. However, gene therapy presents numerous challenges, including undesirable immune responses and safety concerns due to random gene integration into the genome.
[0004] Various cancer treatments are under development. For example, dendritic cell (DC) vaccines have been investigated as a potential anticancer therapy. However, DC vaccines require multiple steps: isolating DCs from a subject, ex vivo engineering the DCs to stimulate the cells for tumor antigen presentation, and then administering the engineered DCs back to the subject. Furthermore, the overall clinical response rate to DC vaccines has been reported to be low, as has their ability to induce cancer regression. See, for example, Kalkinski et al., "Dendritic cell-based therapeutic cancer vaccines: what we have and what we need," Future Oncol. 5(3):379-390 (2009).
[0005] An important goal in the field of immuno-oncology is to improve response rates and increase the number of tumor indications that respond to immunotherapy without increasing adverse side effects. One approach to achieving these goals is to use tumor-directed immunotherapy, that is, to focus immune activation on the most relevant part of the immune system. This can improve anti-tumor efficacy and reduce immune-related adverse events. Tumor-directed immune activation can be achieved by directly injecting immune modulators into the tumor or tumor area. Therapy focuses on targeted checkpoint inhibitors, and costimulatory receptors can generate tumor-specific T cell responses through localized immune activation.
[0006] In recent years, the introduction of therapeutic immune checkpoint inhibitors has revolutionized cancer treatment. Therapies featuring the combination of checkpoint inhibitors with other costimulatory or inhibitory molecules are of interest.
[0007] T cell regulation, i.e., activation or inhibition, is mediated through costimulatory or co-inhibitory signals. This interaction is exerted through ligand / receptor interactions. T cells possess numerous activating receptors, such as OX40, and inhibitory receptors (i.e., immune checkpoints), such as programmed death receptor 1 (PD-1) or cytotoxic T lymphocyte-associated protein 4 (CTLA-4) (Mellman et al. 2011 Nature.;480:480-489). Activation of these immune checkpoints results in T cell deactivation, and tumor cell hijacking of these pathways contributes to successful immune evasion.
[0008] Immune checkpoint inhibitors, such as pembrolizumab or nivolumab, which target the interaction between programmed death receptor 1 / programmed death ligand 1 (PD-1 / PD-L1) and PD-L2, have recently been approved for the treatment of various malignancies and are currently being investigated in clinical trials for cancers including melanoma and head and neck squamous cell carcinoma (HNSCC). Data from these trials have shown significant activity with favorable safety and toxicity profiles in these patient populations.
[0009] For example, checkpoint inhibitors are being tested in clinical trials for the treatment of melanoma. In particular, Phase III clinical trials have shown that therapies such as ipilimumab and pembrolizumab, which target the CTLA-4 and PD-1 immune checkpoints, respectively, increase 3-year patient survival rates for melanoma to approximately 70% and overall survival (>5 years) to approximately 30%.
[0010] Similarly, checkpoint inhibitors are being tested in clinical trials for the treatment of head and neck cancer. Preclinical studies have shown that 45–80% of HNSCC tumors express programmed cell death-ligand 1 (PD-L1) (Zandberg et al. (2014) Oral Oncol. 50:627–632). Currently, dozens of clinical trials exist evaluating the efficacy and safety of immune checkpoint inhibitors as monotherapy or in combination regimens in HNSCC. For example, clinical trials using PD1, PD-L1, and CTLA-4 inhibitors are being tested in HNSCC. Data from the Phase 1b Keynote-012 Phase I / II trial suggest that the PD-1 antibody pembrolizumab may be effective in patients with metastatic / recurrent (R / M) HNSCC (Cheng, oral presentation at ASCO 2015). More recently, data from the randomized CheckMate-141 Phase III clinical trial have been published (Gillison, oral presentation at AACR 2016). This study investigated the efficacy of nivolumab, a monoclonal PD-1 antibody, given every 2 weeks in patients with platinum-refractory R / M HNSCC. The study was stopped early due to superiority in the nivolumab arm of the study. Most available or in development immunotherapies rely on antibodies, which are cumbersome to manufacture and foreign proteins that frequently lead to the development of anti-drug neutralizing antibodies (ADA nAbs). See, e.g., Krishna & Nadler (2016) “Immunogenicity to Biotherapeutic—The role of Anti-drug Immune Complexes” Frontiers in Immunology 7:21; Schellekwn (2010) “The immunogenicity of therapeutic proteins” Discov. Med, 9:560-4. Thus, there remains a need for effective immunotherapies for the treatment of cancer. [Prior art documents] [Non-patent literature]
[0011] [Non-Patent Document 1] Kalkinski et al., “Dendritic cell-based therapeutic cancer vaccines: what we have and what we need,” Future Oncol.5(3):379-390(2009) [Non-patent document 2] Mellman et al.2011 Nature.;480:480-489 [Non-patent document 3] Zandberg et al.(2014)Oral Oncol.50:627-632 [Non-patent document 4] Krishna & Nadler (2016) “Immunogenicity to Biotherapeutic-The role of Anti-drug Immune Complexes”Frontiers in Immunology 7:21 [Non-patent document 5] Schellekwn (2010) “The immunogenicity of therapeutic proteins” Discov. Med, 9:560-4 Summary of the Invention [Means for solving the problem]
[0012] The present disclosure provides a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to the subject at least two polynucleotides and optionally a checkpoint inhibitor polypeptide, wherein the at least two polynucleotides are selected from the group consisting of: (i) a polynucleotide encoding an immune response primer polypeptide, (ii) a polynucleotide encoding an immune response costimulatory signal polypeptide, (iii) a polynucleotide encoding a checkpoint inhibitor polypeptide, and (iv) a combination thereof.
[0013] Also provided is a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to the subject at least one polynucleotide and a checkpoint inhibitor polypeptide, wherein the at least one polynucleotide is selected from the group consisting of: (i) a polynucleotide encoding an immune response primer polypeptide, (ii) a polynucleotide encoding an immune response costimulatory signal polypeptide, and (iii) a combination thereof.
[0014] In some embodiments, the immune response primer polypeptide comprises interleukin 12 (IL12), interleukin (IL23), toll-like receptor 4 (TLR4), interleukin 36 gamma (IL36 gamma), interleukin 18 (IL18), or a combination thereof. In some embodiments, the immune response costimulatory signal polypeptide comprises tumor necrosis factor receptor superfamily member 4 ligand (OX40L), cluster of differentiation 80 (CD80), interleukin 15 (IL15), or a combination thereof. In some embodiments, the checkpoint inhibitor polypeptide inhibits programmed cell death protein 1 (PD1), programmed cell death ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
[0015] In some embodiments of the methods disclosed above, (a) the first polynucleotide encodes an IL-23 polypeptide and the second polynucleotide encodes an IL18 polypeptide; (b) the first polynucleotide encodes an IL23 polypeptide and the second polynucleotide encodes an IL12 polypeptide; (c) the first polynucleotide encodes an IL23 polypeptide and the second polynucleotide encodes an OX40L polypeptide; or (d) the first polynucleotide encodes an IL12 polypeptide and the second polynucleotide encodes an OX40L polypeptide. (e) the first polynucleotide encodes an IL12 polypeptide and the second polynucleotide encodes an anti-PD-1 antibody or an anti-PD-L1 antibody; (f) the first polynucleotide encodes an IL23 polypeptide and the second polynucleotide encodes an anti-CTLA-4 antibody; (g) the first polynucleotide encodes an IL18 polypeptide and the second polynucleotide encodes an anti-PD-1 antibody or an anti-PD-L1 antibody; (h) the first polynucleotide encodes an IL18 polypeptide. , the second polynucleotide encodes an anti-CTLA-4 antibody; (i) the first polynucleotide encodes an IL18 polypeptide and the second polynucleotide encodes an OX40L polypeptide; (j) the first polynucleotide encodes an IL18 polypeptide and the second polynucleotide encodes a TLR4 polypeptide; (k) the first polynucleotide encodes an IL18 polypeptide and the second polynucleotide encodes an IL12 polypeptide; (l) the first polynucleotide encodes an OX40L polypeptide and the second polynucleotide encodes an IL12 polypeptide. (m) the first polynucleotide encodes an OX40L polypeptide and the second polynucleotide encodes an anti-PD-1 antibody or an anti-PD-L1 antibody; (n) the first polynucleotide encodes an OX40L polypeptide and the second polynucleotide encodes a TLR4 polypeptide; (o) the first polynucleotide encodes an OX40L polypeptide and the second polynucleotide encodes an IL23 polypeptide; (p) the first polynucleotide encodes an OX40L polypeptide;(q) the first polynucleotide encodes a CD80 polypeptide and the second polynucleotide encodes an anti-CTLA-4 antibody; (r) the first polynucleotide encodes a TLR4 polypeptide and the second polynucleotide encodes an anti-CTLA-4 antibody; (s) the first polynucleotide encodes an IL18 polypeptide and the second polynucleotide encodes IL12, and further comprises administration of a third polynucleotide encoding an IL23 polypeptide; (t) the first polynucleotide encodes an OX40L polypeptide and the second polynucleotide encodes a TLR4 polypeptide and further comprises administration of a third polynucleotide encoding an IL18 polypeptide; (u) the first polynucleotide encodes an OX40L polypeptide, the second polynucleotide encodes an IL12 polypeptide, and further comprises administration of a third polynucleotide encoding an IL23 polypeptide; (v) the first polynucleotide encodes an IL23 polypeptide and the second polynucleotide (w) the first polynucleotide encodes an IL23 polypeptide, the second polynucleotide encodes an IL18 polypeptide, and further comprises administering a third polynucleotide encoding an anti-CTLA-4 antibody; (x) the first polynucleotide encodes an IL23 polypeptide, the second polynucleotide encodes an IL12 polypeptide, and further comprises administering a third polynucleotide encoding an IL18 polypeptide and administering a fourth polynucleotide encoding an anti-CTLA-4 antibody; (y) the first polynucleotide encodes an IL23 polypeptide, the second polynucleotide encodes an IL12 polypeptide, and further comprises administering a third polynucleotide encoding an IL18 polypeptide and administering a fourth polynucleotide encoding an anti-PD-1 antibody or an anti-PD-L1 antibody; (z) the first polynucleotide encodes an OX40L polypeptide, the second polynucleotide encodes an IL18 polypeptide, and further comprises administering(aa) the first polynucleotide encodes an OX40L polypeptide and the second polynucleotide encodes an IL18 polypeptide, and further comprises administering a third polynucleotide encoding a TLR4 polypeptide and a fourth polynucleotide encoding an anti-PD-1 antibody or an anti-PD-L1 antibody.
[0016] In some embodiments of the methods disclosed above, the at least two polynucleotides are (i) a first polynucleotide encoding an immune response primer polypeptide and a second polynucleotide encoding an immune response primer polypeptide, (ii) a first polynucleotide encoding an immune response primer polypeptide and a second polynucleotide encoding an immune response costimulatory signal polypeptide, or (iii) (i) or (ii) further comprising a polynucleotide encoding a checkpoint inhibitor polypeptide.
[0017] Also provided is a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to the subject at least two polynucleotides encoding a first polypeptide and a second polypeptide, and optionally a checkpoint inhibitor polypeptide, wherein the first polypeptide and the second polypeptide are selected from the group consisting of: (i) an IL12 polypeptide, (ii) an IL23 polypeptide, (iii) an IL36 gamma polypeptide, (iv) an OX40L polypeptide, (v) a CD80 polypeptide, (vi) a TLR4 polypeptide, (vii) an IL18 polypeptide, (viii) an IL15 polypeptide, (ix) an anti-CTLA-4 antibody, and (x) a combination thereof.
[0018] Also provided is a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to the subject at least one polynucleotide encoding a first polypeptide in combination with a second polypeptide that is a checkpoint inhibitor polypeptide, wherein the first polypeptide is selected from the group consisting of: (i) an IL12 polypeptide, (ii) an IL23 polypeptide, (iii) an IL36 gamma polypeptide, (iv) an OX40L polypeptide, (v) a CD80 polypeptide, (vi) a TLR4 polypeptide, (vii) an IL18 polypeptide, (viii) an IL15 polypeptide, and (ix) a combination thereof.
[0019] Also provided is a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to the subject at least two polynucleotides comprising a first polynucleotide and a second polynucleotide, and optionally a checkpoint inhibitor polypeptide, wherein the first polynucleotide encodes an IL12 polypeptide and the second polynucleotide encodes a polypeptide selected from the group consisting of: (i) an immune response primer polypeptide, (ii) an immune response costimulatory signal polypeptide, (iii) a checkpoint inhibitor polypeptide, and (iv) any combination thereof.
[0020] Also provided are methods of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering (a) at least one polynucleotide encoding a first polypeptide and (b) a second polypeptide that is a checkpoint inhibitor polypeptide, wherein the first polypeptide comprises an IL12 polypeptide. In some embodiments, the method further comprises administering a third polynucleotide encoding a third polypeptide selected from the group consisting of an immune response primer polypeptide, an immune response costimulatory signal polypeptide, and a checkpoint inhibitor polypeptide.
[0021] Also provided is a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to the subject at least two polynucleotides comprising a first polynucleotide and a second polynucleotide, and optionally a checkpoint inhibitor polypeptide, wherein the first polynucleotide encodes an IL23 polypeptide and the second polynucleotide encodes a polypeptide selected from the group consisting of: (i) an immune response primer polypeptide, (ii) an immune response costimulatory signal polypeptide, (iii) a checkpoint inhibitor polypeptide, and (iv) any combination thereof.
[0022] Also provided are methods of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering (a) at least one polynucleotide encoding a first polypeptide and (b) a second polypeptide that is a checkpoint inhibitor polypeptide, wherein the first polypeptide comprises an IL23 polypeptide. In some embodiments, the method further comprises administering a third polynucleotide encoding a third polypeptide selected from the group consisting of an immune response primer polypeptide, an immune response costimulatory signal polypeptide, and a checkpoint inhibitor polypeptide.
[0023] Also provided is a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to the subject at least two polynucleotides comprising a first polynucleotide and a second polynucleotide, and optionally a checkpoint inhibitor polypeptide, wherein the first polynucleotide encodes an OX40L polypeptide and the second polynucleotide encodes a polypeptide selected from the group consisting of: (i) an immune response primer polypeptide, (ii) an immune response costimulatory signal polypeptide, (iii) a checkpoint inhibitor polypeptide, and (iv) any combination thereof.
[0024] Also provided are methods of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering (a) at least one polynucleotide encoding a first polypeptide and (b) a second polypeptide that is a checkpoint inhibitor polypeptide, wherein the first polypeptide comprises an OX40L polypeptide. In some embodiments, the method further comprises administering a third polynucleotide encoding a third polypeptide selected from the group consisting of an immune response primer polypeptide, an immune response costimulatory signal polypeptide, and a checkpoint inhibitor polypeptide.
[0025] Also provided is a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to the subject at least two polynucleotides comprising a first polynucleotide and a second polynucleotide, and optionally a checkpoint inhibitor polypeptide, wherein the first polynucleotide encodes a CD80 polypeptide and the second polynucleotide encodes a polypeptide selected from the group consisting of: (i) an immune response primer polypeptide, (ii) an immune response costimulatory signal polypeptide, (iii) a checkpoint inhibitor polypeptide, and (iv) any combination thereof.
[0026] Also provided are methods of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering (a) at least one polynucleotide encoding a first polypeptide and (b) a second polypeptide that is a checkpoint inhibitor polypeptide, wherein the first polypeptide comprises a CD80 polypeptide. In some embodiments, the method further comprises administering a third polynucleotide encoding a third polypeptide selected from the group consisting of an immune response primer polypeptide, an immune response costimulatory signal polypeptide, and a checkpoint inhibitor polypeptide.
[0027] Also provided is a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to the subject at least two polynucleotides comprising a first polynucleotide and a second polynucleotide, and optionally a checkpoint inhibitor polypeptide, wherein the first polynucleotide encodes a TLR4 polypeptide and the second polynucleotide encodes a polypeptide selected from the group consisting of: (i) an immune response primer polypeptide, (ii) an immune response costimulatory signal polypeptide, (iii) a checkpoint inhibitor polypeptide, and (iv) any combination thereof.
[0028] Also provided are methods of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering (a) at least one polynucleotide encoding a first polypeptide and (b) a second polypeptide that is a checkpoint inhibitor polypeptide, wherein the first polypeptide comprises a TLR4 polypeptide. In some embodiments, the method further comprises administering a third polynucleotide encoding a third polypeptide selected from the group consisting of an immune response primer polypeptide, an immune response costimulatory signal polypeptide, and a checkpoint inhibitor polypeptide.
[0029] Also provided is a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to the subject at least two polynucleotides comprising a first polynucleotide and a second polynucleotide, and optionally a checkpoint inhibitor polypeptide, wherein the first polynucleotide encodes an IL18 polypeptide and the second polynucleotide encodes a polypeptide selected from the group consisting of: (i) an immune response primer polypeptide, (ii) an immune response costimulatory signal polypeptide, (iii) a checkpoint inhibitor polypeptide, and (iv) any combination thereof.
[0030] Also provided are methods of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering (a) at least one polynucleotide encoding a first polypeptide and (b) a second polypeptide that is a checkpoint inhibitor polypeptide, wherein the first polypeptide comprises an IL18 polypeptide. In some embodiments, the method further comprises administering a third polynucleotide encoding a third polypeptide selected from the group consisting of an immune response primer polypeptide, an immune response costimulatory signal polypeptide, and a checkpoint inhibitor polypeptide.
[0031] Also provided is a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to the subject at least two polynucleotides comprising a first polynucleotide and a second polynucleotide, and optionally a checkpoint inhibitor polypeptide, wherein the first polynucleotide encodes an IL15 polypeptide and the second polynucleotide encodes a polypeptide selected from the group consisting of: (i) an immune response primer polypeptide, (ii) an immune response costimulatory signal polypeptide, (iii) a checkpoint inhibitor polypeptide, and (iv) any combination thereof.
[0032] Also provided are methods of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering (a) at least one polynucleotide encoding a first polypeptide and (b) a second polypeptide that is a checkpoint inhibitor polypeptide, wherein the first polypeptide comprises an IL15 polypeptide. In some embodiments, the method further comprises administering a third polynucleotide encoding a third polypeptide selected from the group consisting of an immune response primer polypeptide, an immune response costimulatory signal polypeptide, and a checkpoint inhibitor polypeptide.
[0033] Also provided is a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to the subject at least two polynucleotides comprising a first polynucleotide and a second polynucleotide, and optionally a checkpoint inhibitor polypeptide, wherein the first polynucleotide encodes an IL36 gamma polypeptide and the second polynucleotide encodes a polypeptide selected from the group consisting of: (i) an immune response primer polypeptide, (ii) an immune response costimulatory signal polypeptide, (iii) a checkpoint inhibitor polypeptide, and (iv) any combination thereof.
[0034] Also provided are methods of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering (a) at least one polynucleotide encoding a first polypeptide and (b) a second polypeptide that is a checkpoint inhibitor polypeptide, wherein the first polypeptide comprises an IL36 gamma polypeptide. In some embodiments, the method further comprises administering a third polynucleotide encoding a third polypeptide selected from the group consisting of an immune response primer polypeptide, an immune response costimulatory signal polypeptide, and a checkpoint inhibitor polypeptide.
[0035] In some embodiments of the methods disclosed above, the checkpoint inhibitor polypeptide is an antibody or a polynucleotide encoding an antibody. In some embodiments, the antibody is an anti-CTLA-4 antibody or antigen-binding fragment thereof that specifically binds to CTLA-4, an anti-PD1 antibody or antigen-binding fragment thereof that specifically binds to PD1, an anti-PD-L1 antibody or antigen-binding fragment thereof that specifically binds to PD-L1, or a combination thereof. In some embodiments, the anti-PD-L1 antibody is atezolizumab, avelumab, or durvalumab. In some embodiments, the anti-CTLA-4 antibody is tremelimumab or ipilimumab. In some embodiments, the anti-PD-1 antibody is nivolumab or pembrolizumab.
[0036] In some embodiments of the methods disclosed above, at least one or two polynucleotides reduce the size of or inhibit the growth of MC38(C)-derived tumors in mice when a 5 μg dose of each polynucleotide is administered to the mice. In some embodiments, at least one or two polynucleotides reduce the size of or inhibit the growth of MC38(M)-derived tumors in mice when a 5 μg dose of each polynucleotide is administered to the mice.
[0037] In some embodiments, one or more polynucleotides in the combination therapy comprise at least one chemically modified nucleoside. In some embodiments, the at least one chemically modified nucleoside is selected from the group consisting of any of those listed in Section X ("Chemical Modifications") and combinations thereof. In some embodiments, the at least one chemically modified nucleoside is selected from the group consisting of pseudouridine, N1-methylpseudouridine, 5-methylcytosine, 5-methoxyuridine, and combinations thereof. In some embodiments, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100% of the nucleosides in one or more polynucleotides are chemically modified.
[0038] In some embodiments, the chemically modified nucleosides in one or more polynucleotides are selected from the group consisting of uridine, adenine, cytosine, guanine, and any combination thereof. In some embodiments, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100% of the uridine nucleosides in one or more polynucleotides are chemically modified. In some embodiments, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100% of the adenosine nucleosides in one or more polynucleotides are chemically modified.
[0039] In some embodiments, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100% of the cytidine nucleosides in one or more polynucleotides are chemically modified, hi some embodiments, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100% of the guanosine nucleosides in one or more polynucleotides are chemically modified.
[0040] In some embodiments, one or more polynucleotides comprise an miRNA binding site. In some embodiments, the miRNA binding site is a miR-122 binding site. In some embodiments, the miRNA binding site is a miR-122-3p or miR-122-5p binding site. In some embodiments, the miRNA binding site comprises a nucleotide sequence at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to aacgccauua ucacacuaaa ua (SEQ ID NO: 1212), where the miRNA binding site binds to miR-122. In some embodiments, the miRNA binding site comprises a nucleotide sequence at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to uggaguguga caaugguguu ug (SEQ ID NO: 1214), where the miRNA binding site binds to miR-122. In some embodiments, the polynucleotides comprise different miRNA binding sites or the same miRNA binding site.
[0041] In some embodiments, the one or more polynucleotides comprise a 5' untranslated region (UTR). In some embodiments, the 5' UTR comprises a nucleic acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a sequence listed in Table 20. In some embodiments, the one or more polynucleotides comprise a 3' untranslated region (UTR). In some embodiments, the 3' UTR comprises a nucleic acid sequence at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a sequence listed in Table 4A or 4B. In some embodiments, an miRNA binding site is inserted within the 3' UTR. In some embodiments, the one or more polynucleotides comprise a spacer sequence fused to the miRNA binding site.
[0042] In some embodiments, the spacer sequence comprises at least about 10 nucleotides, at least about 20 nucleotides, at least about 30 nucleotides, at least about 40 nucleotides, at least about 50 nucleotides, at least about 60 nucleotides, at least about 70 nucleotides, at least about 80 nucleotides, at least about 90 nucleotides, or at least about 100 nucleotides.
[0043] In some embodiments, one or more polynucleotides comprise a 5'-end cap structure. In some embodiments, the 5'-end cap is Cap0, Cap1, ARCA, inosine, N1-methyl-guanosine, 2'fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, 2-azidoguanosine, Cap2, Cap4, 5'methyl G-cap, or an analog thereof. In some embodiments, one or more polynucleotides comprise a 3' poly-A tail. In some embodiments, one or more polynucleotides comprise at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten mRNA binding sites.
[0044] In some embodiments, one or more polynucleotides are codon-optimized. In some embodiments, one or more polynucleotides are in vitro transcribed (IVT). In some embodiments, one or more polynucleotides are chimeric. In some embodiments, one or more polynucleotides are circular. In some embodiments, one or more polynucleotides are formulated with a delivery agent. In some embodiments, the delivery agent includes a lipidoid, a liposome, a lipoplex, a lipid nanoparticle, a polymeric compound, a peptide, a protein, a cell, a nanoparticle mimic, a nanotube, or a conjugate. In some embodiments, the delivery agent is a lipid nanoparticle. In some embodiments, the lipid nanoparticle includes a lipid selected from the group consisting of DLin-DMA, DLin-K-DMA, 98N12-5, C12-200, DLin-MC3-DMA, DLin-KC2-DMA, DODMA, PLGA, PEG, PEG-DMG, a PEGylated lipid, an aminoalcohol lipid, KL22, and combinations thereof.
[0045] In some embodiments of the methods disclosed above, the delivery agent comprises a compound having formula (I): [ka] or a salt or stereoisomer thereof, wherein R1 is C 5~20 Alkyl, C 5~20 Alkenyl, -R * R2 and R3 are selected from the group consisting of H, C 1~14 Alkyl, C 2~14 Alkenyl, -R * YR”, -YR” and -R * OR”, or R2 and R3 together with the atoms to which they are attached form a heterocycle or a carbocycle, and R4 is C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -CHQR, -CQ(R)2 and unsubstituted C1~6 alkyl, where Q is a carbocycle, a heterocycle, -OR, -O(CH2) n and each n is independently selected from 1, 2, 3, 4, and 5; and each R is independently selected from C 1~3 Alkyl, C 2~3 alkenyl and H; each R6 is independently selected from the group consisting of C 1~3 Alkyl, C 2~3 R7 is independently selected from the group consisting of alkenyl and H; M and M' are independently selected from -C(O)O-, -OC(O)-, -C(O)N(R')-, -N(R')C(O)-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR')O-, -S(O)-, an aryl group, and a heteroaryl group; 1~3 Alkyl, C 2~3 alkenyl and H, and each R is selected from the group consisting of C 1~3 Alkyl, C 2~3 alkenyl and H, and each R' is C 1~18 Alkyl, C 2~18 Alkenyl, -R * independently selected from the group consisting of Y-R′, -Y-R′, and H, and each R′ is C 3~14 Alkyl and C 3~14 alkenyl, and each R * is C 1~12 Alkyl and C 2~12 alkenyl, and each Y is independently selected from the group consisting of C 3~6 carbocyclic ring, each X is independently selected from the group consisting of F, Cl, Br, and I, and m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, with the proviso that R is -(CH) n Q, -(CH2) nprovided that, when CHQR, -CHQR, or -CQ(R), (i) Q is not -N(R) when n is 1, 2, 3, 4, or 5, or (ii) Q is not a 5-, 6-, or 7-membered heterocycloalkyl when n is 1 or 2.
[0046] In some embodiments, the compound has the formula (IA): [ka] or a salt or stereoisomer thereof, wherein l is selected from 1, 2, 3, 4 and 5; m is selected from 5, 6, 7, 8 and 9; M is a bond or M′; and R is an unsubstituted C 1~3 Alkyl or -(CH2) n Q, where n is 1, 2, 3, 4, or 5; Q is OH, —NHC(S)N(R)2, or —NHC(O)N(R)2; M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —P(O)(OR′)O—, an aryl group, and a heteroaryl group; R2 and R3 are independently selected from H, C 1~14 Alkyl and C 2~14 In some embodiments, m is independently selected from the group consisting of aryl, aryl, arylsulfonyl ...
[0047] In some embodiments, the compound has the formula (II): [ka] or a salt or stereoisomer thereof, wherein l is selected from 1, 2, 3, 4 and 5; M1 is a bond or M'; and R4 is an unsubstituted C 1~3 Alkyl or -(CH2) nQ, where n is 2, 3, or 4; Q is —OH, —NHC(S)N(R)2, or —NHC(O)N(R)2; M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —P(O)(OR′)O—, an aryl group, and a heteroaryl group; R2 and R3 are independently selected from H, C 1~14 Alkyl and C 2~14 alkenyl.
[0048] In some embodiments, the compound is selected from Compound 1 through Compound 147, and salts and stereoisomers thereof.
[0049] In some embodiments, the compound has the formula (IIa): [ka] or a salt or stereoisomer thereof.
[0050] In some embodiments, the compound has the formula (IIb): [ka] or a salt or stereoisomer thereof.
[0051] In some embodiments, the compound has formula (IIc) or (IIe): [ka] or a salt or stereoisomer thereof.
[0052] In some embodiments, R4 is -(CH2) n Q and -(CH2) n CHQR, where Q, R and n are as defined above.
[0053] In some embodiments, the compound has the formula (IId): [ka] or a salt or stereoisomer thereof, wherein R2 and R3 are C 5~14 Alkyl and C 5~14 alkenyl, n is selected from 2, 3 and 4, and R', R", R, R and m are as defined above.
[0054] In some embodiments, R2 is C8 alkyl. In some embodiments, R3 is C5 alkyl, C6 alkyl, C7 alkyl, C8 alkyl, or C9 alkyl. In some embodiments, m is 5, 7, or 9. In some embodiments, each R5 is H. In some embodiments, each R6 is H.
[0055] In some embodiments, the delivery agent further comprises a phospholipid. In some embodiments, the phospholipid is 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-Hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexanoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16:0 PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, It is selected from the group consisting of 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), sphingomyelin, and mixtures thereof.
[0056] In some embodiments, the phospholipid is 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine (14:0-16:0 PC, MPPC), 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine (14:0-18:0 PC, MSPC), 1-palmitoyl-2-acetyl-sn-glycero-3-phosphocholine (16:0-2:0 PC), 1-palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine (16:0-14:0 PC, PMPC), 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine (16:0-18:0 PC, PSPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (16:0-18:0 PC, POPC), 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine (16:0-18:2 PC, PLPC), 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (16:0-20:4 PC), 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (14:0-22:6 PC), 1-Stearoyl-2-myristoyl-sn-glycero-3-phosphocholine (18:0-14:0 PC, SMPC), 1-Stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine (18:0-16:0 PC, SPPC), 1-Stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (18:0-18:1 PC, SOPC), 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine (18:0-18:2 PC), 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (18:0-20:4 PC), 1-Stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (18:0-22:6 PC), 1-oleoyl-2-myristoyl-sn-glycero-3-phosphocholine (18:1-14:0 PC, OMPC), 1-oleoyl-2-palmitoyl-sn-glycero-3-phosphocholine (18:1 to 16:0 PC, OPPC), 1-oleoyl-2-stearoyl-sn-glycero-3-phosphocholine (18:1-18:0 PC, OSPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (16:0-18:1 PE, POPE), 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine (16:0-18:2 PE), 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine (16:0 to 20:4 PE), 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine (16:0 to 22:6 PE), 1-Stearoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (18:0 to 18:1 PE), 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine (18:0-18:2 PE), 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine (18:0 to 20:4 PE), 1-Stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine (18:0 to 22:6 PE), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), and any combination thereof.
[0057] In some embodiments, the delivery agent further comprises a structured lipid, hi some embodiments, the structured lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and mixtures thereof.
[0058] In some embodiments, the delivery agent further comprises a PEG-lipid, in some embodiments, the PEG-lipid is selected from the group consisting of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol, and mixtures thereof.
[0059] In some embodiments, the delivery agent includes: 3-(didodecylamino)-N1,N1,4-tridodecyl-1-piperazineethanamine (KL10), N1-[2-(didodecylamino)ethyl]-N1,N4,N4-tridodecyl-1,4-piperazinediethanamine (KL22), 14,25-ditridecyl-15,18,21,24-tetraaza-octatriacontane (KL25), 1,2-Dilinoleyloxy-N,N-dimethylaminopropane (DLin-DMA), 2,2-Dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), Heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (DLin-MC3-DMA), 2,2-Dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA), 1,2-dioleyloxy-N,N-dimethylaminopropane (DODMA), 2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (octyl-CLinDMA), (2R)-2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA(2R)) and Further included is an ionic lipid selected from the group consisting of (2S)-2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA(2S)).
[0060] In some embodiments, the delivery agent further comprises a quaternary amine compound. In some embodiments, the quaternary amine compound is 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), 1-[2-(oleoyloxy)ethyl]-2-oleyl-3-(2-hydroxyethyl)imidazolinium chloride (DOTIM), 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE), N-(1,2-dioleoyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethylammonium bromide (DORIE), N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), 1,2-dilauroyl-sn-glycero-3-ethylphosphocholine (DLePC), 1,2-distearoyl-3-trimethylammonium-propane (DSTAP), 1,2-dipalmitoyl-3-trimethylammonium-propane (DPTAP), 1,2-dilinoleoyl-3-trimethylammonium-propane (DLTAP), 1,2-dimyristoyl-3-trimethylammonium-propane (DMTAP), 1,2-distearoyl-sn-glycero-3-ethylphosphocholine (DSePC), 1,2-dipalmitoyl-sn-glycero-3-ethylphosphocholine (DPePC), 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (DMePC), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOePC), 1,2-di-(9Z-tetradecenoyl)-sn-glycero-3-ethylphosphocholine (14:1 EPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-ethylphosphocholine (16:0 to 18:1 EPC) and It is selected from the group consisting of any combination thereof.
[0061] The present disclosure also provides compositions comprising (i) one or more of the polynucleotides disclosed above and a pharmaceutically acceptable carrier, or (ii) one or more of the polynucleotides disclosed above formulated with a delivery agent disclosed above. In some embodiments, the disclosed compositions comprise a delivery agent selected from a lipidoid, a liposome, a lipoplex, a lipid nanoparticle, a polymeric compound, a peptide, a protein, a cell, a nanoparticle mimic, a nanotube, or a conjugate. In some embodiments, the delivery agent comprises a lipid composition disclosed above.
[0062] The compositions disclosed herein can be used to reduce or decrease the size of a tumor or inhibit tumor growth in a subject in need thereof.
[0063] In some embodiments, the polynucleotide or composition disclosed herein is formulated for in vivo delivery. In some embodiments, the polynucleotide or composition is formulated for intramuscular, subcutaneous, intratumoral, or intradermal delivery. In some embodiments, the polynucleotide or composition is administered subcutaneously, intravenously, intramuscularly, intraarticularly, intrasynovially, intrasternally, intrathecally, intrahepatically, intralesionally, intracranially, intracerebroventricularly, orally, by inhalation spray, topically, rectally, nasally, bucally, vaginally, or via an implanted reservoir.
[0064] In some embodiments, administering the compositions disclosed above, for example by the methods disclosed above, treats cancer.In some embodiments, the cancer is adrenocortical carcinoma, advanced cancer, anal cancer, aplastic anemia, bile duct cancer, bladder cancer, bone cancer, bone metastasis, brain tumor, brain cancer, breast cancer, childhood cancer, cancer of unknown primary site, Castleman's disease, cervical cancer, colorectal cancer, endometrial cancer, esophageal cancer, Ewing's family of tumors, eye cancer, gallbladder cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, gestational trophoblastic disease, Hodgkin's disease, Kaposi's sarcoma, renal cell carcinoma, pharyngeal and hypopharyngeal cancer, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, liver cancer, hepatocellular carcinoma (HCC), non-small cell lung cancer, small cell lung cancer, The cancer is selected from the group consisting of lung carcinoid tumor, lymphoma of the skin, malignant mesothelioma, multiple myeloma, myelodysplastic syndrome, pharyngeal and hypopharyngeal cancer, nasopharyngeal carcinoma, neuroblastoma, non-Hodgkin's lymphoma, oral and oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, penile cancer, pituitary tumor, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, adult soft tissue sarcoma, basal and squamous cell skin cancer, melanoma, small intestine cancer, stomach cancer, testicular cancer, throat cancer, thymus cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom's macroglobulinemia, Wilms' tumor, secondary cancers resulting from cancer treatment, and any combination thereof.
[0065] In some embodiments, the polynucleotide or composition is delivered by a device comprising a pump, a patch, a drug reservoir, a short-needle device, a single-needle device, a multiple-needle device, a microneedle device, a jet injection device, a ballistic powder / particle delivery device, a catheter, a lumen, a cryoprobes, a cannula, a microcannula, or a device that utilizes heat, RF energy, electric current, or any combination thereof.
[0066] In some embodiments, the effective amount of the compositions disclosed herein is from about 0.10 mg / kg to about 1,000 mg / kg.
[0067] In some embodiments, the subject is a human.
[0068] The present disclosure also provides kits comprising any of the compositions disclosed above and instructions for use according to the methods disclosed above.
[0069] In some embodiments, the polynucleotide encoding an IL12 polypeptide comprises at least one polynucleotide comprising an ORF encoding an interleukin-12p40 subunit (IL12B) polypeptide and an interleukin-12p35 subunit (IL12A) polypeptide. In some embodiments, the IL12B polypeptide is operably linked to the IL12A polypeptide by a linker. In some embodiments, the polynucleotide encoding an IL12 polypeptide comprises a nucleic acid encoding a signal peptide. In some embodiments, the signal peptide is an IL12B signal peptide.
[0070] In some embodiments, the polynucleotide encoding an IL18 polypeptide comprises an ORF encoding a mature IL18 polypeptide. In some embodiments, the polynucleotide encoding an IL18 polypeptide comprises a nucleic acid encoding a signal peptide. In some embodiments, the signal peptide is a heterologous signal peptide. In some embodiments, the heterologous signal peptide is a tissue plasminogen activator (tPA) signal peptide or an interleukin-12 (IL12) signal peptide.
[0071] In some embodiments, the polynucleotide encoding the CD80 polypeptide comprises an ORF encoding the CD80 extracellular domain. In some embodiments, the polynucleotide encoding the CD80 polypeptide comprises a nucleic acid encoding an Fc portion. In some embodiments, the polynucleotide encoding the CD80 polypeptide comprises a nucleic acid encoding a signal peptide. In some embodiments, the signal peptide is the endogenous CD80 signal peptide.
[0072] In some embodiments, the polynucleotide encoding the TLR4 polypeptide comprises an ORF encoding a constitutively active TLR4 polypeptide comprising the intracellular domain and transmembrane region of TLR4. In some embodiments, the polynucleotide encoding the TLR4 polypeptide comprises a nucleic acid encoding a signal peptide. In some embodiments, the signal peptide is a heterologous signal peptide, and the heterologous signal peptide is a lysosomal membrane glycoprotein 1 (LAMP1) signal peptide.
[0073] In some embodiments, the polynucleotide encoding an IL15 polypeptide comprises at least one polynucleotide comprising an ORF encoding an IL15 polypeptide and an IL15R extracellular domain polypeptide. In some embodiments, the IL15 polypeptide is operably linked to the IL15R extracellular domain polypeptide via a linker. In some embodiments, the IL15 polypeptide further comprises an Fc domain. In some embodiments, the polynucleotide comprising an ORF encoding an IL15 polypeptide comprises a nucleic acid encoding a signal peptide. In some embodiments, the signal peptide is a heterologous signal peptide. In some embodiments, the heterologous signal peptide is a tPA signal peptide.
[0074] In some embodiments, the polynucleotide encoding an IL23 polypeptide comprises an ORF encoding an IL12p40 polypeptide and an IL23p19 polypeptide. In some embodiments, the IL12p40 polypeptide is operably linked to the IL23p19 polypeptide by a linker. In some embodiments, the polynucleotide encoding an IL23 polypeptide comprises a nucleic acid encoding a signal peptide. In some embodiments, the signal peptide is an IL12p40 signal peptide or an IL23p19 signal peptide.
[0075] In some embodiments, the polynucleotide encoding an IL36 gamma polypeptide comprises an ORF encoding an IL36 gamma polypeptide. In some embodiments, the ORF of the polynucleotide encoding the mature IL36 gamma polypeptide further comprises a nucleic acid encoding a signal peptide. In some embodiments, the signal peptide is a heterologous signal peptide. In some embodiments, the heterologous signal peptide is a hIgKV4 signal peptide.
[0076] The present disclosure also provides pharmaceutical compositions comprising at least two mRNAs and a pharmaceutically acceptable carrier, wherein the mRNAs are selected from (i) one or more mRNAs having an open reading frame encoding an immune response primer polypeptide, (ii) one or more mRNAs having an open reading frame encoding an immune response costimulatory signal polypeptide, and (iii) one or more mRNAs having an open reading frame encoding a checkpoint inhibitor polypeptide. In some embodiments, the pharmaceutical composition comprises (i) an mRNA having an open reading frame encoding an immune response primer polypeptide and (ii) an mRNA having an open reading frame encoding an immune response costimulatory signal polypeptide. In some embodiments, the pharmaceutical composition comprises two mRNAs, each having an open reading frame encoding an immune response primer polypeptide. In some embodiments, the pharmaceutical composition comprises (i) an mRNA having an open reading frame encoding an immune response costimulatory signal polypeptide and (ii) an mRNA having an open reading frame encoding a checkpoint inhibitor signal polypeptide. In some embodiments, the pharmaceutical composition comprises (i) an mRNA having an open reading frame encoding an immune response costimulatory signal polypeptide, (ii) an mRNA having an open reading frame encoding an immune response costimulatory signal polypeptide, and (iii) an mRNA having an open reading frame encoding a checkpoint inhibitor polypeptide.
[0077] In some embodiments, the immune response primer polypeptide comprises interleukin 12 (IL12), interleukin (IL23), toll-like receptor 4 (TLR4), interleukin 36 gamma (IL36 gamma), interleukin 18 (IL18), or a combination thereof. In some embodiments, the immune response costimulatory signal polypeptide comprises tumor necrosis factor receptor superfamily member 4 ligand (OX40L), cluster of differentiation 80 (CD80), interleukin 15 (IL15), or a combination thereof. In some embodiments, the checkpoint inhibitor polypeptide inhibits programmed cell death protein 1 (PD1), programmed cell death ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
[0078] In some embodiments, the pharmaceutical composition comprises (a) an mRNA comprising: (i) a 5'-untranslated region (5'-UTR); (ii) an open reading frame (ORF) encoding at least one immune response primer polypeptide, immune response costimulatory signal polypeptide, checkpoint inhibitor polypeptide, or a combination thereof, and comprising at least one chemically modified nucleobase, sugar, backbone, or any combination thereof; (iii) at least one stop codon; (iv) a microRNA (miRNA) binding site; (v) a 3'-untranslated region (3'-UTR); and (vi) a poly-A tail; and (b) a lipid nanoparticle carrier.
[0079] In some embodiments of the pharmaceutical compositions disclosed herein, (a) the first mRNA encodes an IL-23 polypeptide and the second mRNA encodes an IL18 polypeptide; (b) the first mRNA encodes an IL23 polypeptide and the second mRNA encodes an IL12 polypeptide; (c) the first mRNA encodes an IL23 polypeptide and the second mRNA encodes an OX40L polypeptide; (d) the first mRNA encodes an IL12 polypeptide and the second mRNA encodes an anti-CTLA-4 antibody; (e) the first mRNA encodes an IL12 polypeptide and the second mRNA encodes an anti-CTLA-4 antibody; (f) the first mRNA encodes an IL12 polypeptide and the second mRNA encodes an anti-PD-1 antibody or an anti-PD-L1 antibody; (g) the first mRNA encodes an IL18 polypeptide and the second mRNA encodes an anti-PD-1 antibody or an anti-PD-L1 antibody; (h) the first mRNA encodes an IL18 polypeptide and the second mRNA encodes an anti-CTLA-4 antibody; (i) the first mRNA encodes an IL18 polypeptide and the second mRNA encodes an anti-PD-1 antibody or an anti-PD-L1 antibody. (j) the first mRNA encodes an IL18 polypeptide and the second mRNA encodes a TLR4 polypeptide; (k) the first mRNA encodes an IL18 polypeptide and the second mRNA encodes an IL12 polypeptide; (l) the first mRNA encodes an OX40L polypeptide and the second mRNA encodes an anti-CTLA-4 antibody; (m) the first mRNA encodes an OX40L polypeptide and the second mRNA encodes an anti-PD-1 antibody or an anti-PD-L1 antibody; (n) the first mRNA is (o) the first mRNA encodes an OX40L polypeptide and the second mRNA encodes a TLR4 polypeptide; (p) the first mRNA encodes an OX40L polypeptide and the second mRNA encodes an IL23 polypeptide; (q) the first mRNA encodes a CD80 polypeptide and the second mRNA encodes an anti-CTLA-4 antibody; (r) the first mRNA encodes a TLR4 polypeptide and the second mRNA encodes an anti-CTLA-4 antibody;(s) the first mRNA encodes an IL18 polypeptide, the second mRNA encodes IL12, and further comprises a third mRNA encoding an IL23 polypeptide; (t) the first mRNA encodes an OX40L polypeptide, the second mRNA encodes a TLR4 polypeptide, and further comprises a third mRNA encoding an IL18 polypeptide; (u) the first mRNA encodes an OX40L polypeptide, the second mRNA encodes an IL12 polypeptide, and further comprises a third mRNA encoding an IL23 polypeptide. (v) the first mRNA encodes an IL23 polypeptide, the second mRNA encodes an IL12 polypeptide, and a third mRNA encoding an anti-CTLA-4 antibody; (w) the first mRNA encodes an IL23 polypeptide, the second mRNA encodes an IL18 polypeptide, and a third mRNA encoding an anti-CTLA-4 antibody; and (x) the first mRNA encodes an IL23 polypeptide. (y) the first polynucleotide encodes an IL23 polypeptide, the second mRNA encodes an IL12 polypeptide, and further comprises a third mRNA encoding an IL18 polypeptide and a fourth mRNA encoding an anti-CTLA-4 antibody; (z) the first mRNA encodes an OX40L polypeptide, the second mRNA encodes an IL18 polypeptide, and further comprises a third mRNA encoding a TLR4 polypeptide and a fourth mRNA encoding an anti-CTLA-4 antibody; or (aa) the first mRNA encodes an OX40L polypeptide, the second mRNA encodes an IL18 polypeptide, and further comprises a third mRNA encoding a TLR4 polypeptide and a fourth mRNA encoding an anti-PD-1 antibody or an anti-PD-L1 antibody.
[0080] In some embodiments of the pharmaceutical compositions disclosed herein, the compositions comprise two, three, four, five, six, or more mRNAs, each of which comprises at least one ORF. In some embodiments, the pharmaceutical compositions comprise at least one chemically modified nucleobase, sugar, backbone, or any combination thereof. In some embodiments, each mRNA is formulated in the same lipid nanoparticle carrier. In some embodiments, each mRNA is formulated in a different lipid nanoparticle carrier. In some embodiments, the lipid nanoparticle carrier comprises a lipid selected from the group consisting of DLin-DMA, DLin-K-DMA, 98N12-5, C12-200, DLin-MC3-DMA, DLin-KC2-DMA, DODMA, PLGA, PEG, PEG-DMG, PEGylated lipids, aminoalcohol lipids, KL22, and combinations thereof.
[0081] In some embodiments of the pharmaceutical compositions disclosed herein, the lipid nanoparticle carrier has the formula (I): [ka] or a salt or stereoisomer thereof, wherein R1 is C 5~20 Alkyl, C 5~20 Alkenyl, -R * R2 and R3 are selected from the group consisting of H, C 1~14 Alkyl, C 2~14 Alkenyl, -R * YR”, -YR” and -R * OR”, or R2 and R3 together with the atoms to which they are attached form a heterocycle or a carbocycle, and R4 is C 3~6 Carbocyclic ring, -(CH2) n Q, -(CH2) n CHQR, -CHQR, -CQ(R)2 and unsubstituted C 1~6 alkyl, where Q is a carbocycle, a heterocycle, -OR, -O(CH2) nand each n is independently selected from 1, 2, 3, 4, and 5; and each R is independently selected from C 1~3 Alkyl, C 2~3 alkenyl and H; each R6 is independently selected from the group consisting of C 1~3 Alkyl, C 2~3 R7 is independently selected from the group consisting of alkenyl and H; M and M' are independently selected from -C(O)O-, -OC(O)-, -C(O)N(R')-, -N(R')C(O)-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR')O-, -S(O)-, an aryl group, and a heteroaryl group; 1~3 Alkyl, C 2~3 alkenyl and H, and each R is selected from the group consisting of C 1~3 Alkyl, C 2~3 alkenyl and H, and each R' is C 1~18 Alkyl, C 2~18 Alkenyl, -R * independently selected from the group consisting of Y-R′, -Y-R′, and H, and each R′ is C 3~14 Alkyl and C 3~14 alkenyl, and each R * is C 1~12 Alkyl and C 2~12 alkenyl, and each Y is independently selected from the group consisting of C 3~6 carbocyclic ring, each X is independently selected from the group consisting of F, Cl, Br, and I, and m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13, with the proviso that R is -(CH) n Q, -(CH2) nprovided that, when CHQR, -CHQR, or -CQ(R), (i) Q is not -N(R) when n is 1, 2, 3, 4, or 5, or (ii) Q is not a 5-, 6-, or 7-membered heterocycloalkyl when n is 1 or 2.
[0082] In some embodiments of the pharmaceutical compositions disclosed herein, the compound has the formula (IA): [ka] or a salt or stereoisomer thereof, wherein l is selected from 1, 2, 3, 4 and 5; m is selected from 5, 6, 7, 8 and 9; M is a bond or M′; and R is an unsubstituted C 1~3 Alkyl or -(CH2) n Q, where n is 1, 2, 3, 4, or 5; Q is OH, —NHC(S)N(R)2, or —NHC(O)N(R)2; M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —P(O)(OR′)O—, an aryl group, and a heteroaryl group; R2 and R3 are independently selected from H, C 1~14 Alkyl and C 2~14 In some embodiments, m is independently selected from the group consisting of aryl, aryl, arylsulfonyl ...
[0083] In some embodiments of the pharmaceutical compositions disclosed herein, the compound has the formula (II): [ka] or a salt or stereoisomer thereof, wherein l is selected from 1, 2, 3, 4 and 5; M1 is a bond or M'; and R4 is an unsubstituted C 1~3 Alkyl or -(CH2) nQ, where n is 2, 3, or 4; Q is OH, —NHC(S)N(R)2, or —NHC(O)N(R)2; M and M′ are independently selected from —C(O)O—, —OC(O)—, —C(O)N(R′)—, —P(O)(OR′)O—, an aryl group, and a heteroaryl group; R2 and R3 are independently selected from H, C 1~14 Alkyl and C 2~14 alkenyl.
[0084] In some embodiments of the pharmaceutical compositions disclosed herein, the compound is selected from Compound 1 to Compound 147, and salts and stereoisomers thereof.
[0085] In some embodiments of the pharmaceutical compositions disclosed herein, the compound has the formula (IIa): [ka] or a salt or stereoisomer thereof.
[0086] In some embodiments of the pharmaceutical compositions disclosed herein, the compound has the formula (IIb): [ka] or a salt or stereoisomer thereof.
[0087] In some embodiments of the pharmaceutical compositions disclosed herein, the compound has the formula (IIc) or (IIe): [ka] or a salt or stereoisomer thereof.
[0088] In some embodiments, R4 is -(CH2) n Q and -(CH2) nCHQR, where Q, R and n are as defined above.
[0089] In some embodiments of the pharmaceutical compositions disclosed herein, the compound has the formula (IId): [ka] or a salt or stereoisomer thereof, In the formula, R2 and R3 are C 5~14 Alkyl and C 5~14 alkenyl, n is selected from 2, 3 and 4, and R', R", R, R and m are as defined above.
[0090] In some embodiments, R2 is C8 alkyl. R3 is C5 alkyl, C6 alkyl, C7 alkyl, C8 alkyl, or C9 alkyl. In some embodiments, m is 5, 7, or 9. In some embodiments, each R5 is H. In some embodiments, each R6 is H.
[0091] In some embodiments of the pharmaceutical compositions disclosed herein, the lipid nanoparticle carrier further comprises a phospholipid. In some embodiments, the phospholipid is 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-Hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexanoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16:0 PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, It is selected from the group consisting of 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), sphingomyelin, and mixtures thereof.
[0092] In some embodiments, the phospholipid is 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine (14:0-16:0 PC, MPPC), 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine (14:0-18:0 PC, MSPC), 1-palmitoyl-2-acetyl-sn-glycero-3-phosphocholine (16:0-2:0 PC), 1-palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine (16:0-14:0 PC, PMPC), 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine (16:0-18:0 PC, PSPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (16:0-18:0 PC, POPC), 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine (16:0-18:2 PC, PLPC), 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (16:0-20:4 PC), 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (14:0-22:6 PC), 1-Stearoyl-2-myristoyl-sn-glycero-3-phosphocholine (18:0-14:0 PC, SMPC), 1-Stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine (18:0-16:0 PC, SPPC), 1-Stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (18:0-18:1 PC, SOPC), 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine (18:0-18:2 PC), 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (18:0-20:4 PC), 1-Stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (18:0-22:6 PC), 1-oleoyl-2-myristoyl-sn-glycero-3-phosphocholine (18:1-14:0 PC, OMPC), 1-oleoyl-2-palmitoyl-sn-glycero-3-phosphocholine (18:1 to 16:0 PC, OPPC), 1-oleoyl-2-stearoyl-sn-glycero-3-phosphocholine (18:1-18:0 PC, OSPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (16:0-18:1 PE, POPE), 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine (16:0-18:2 PE), 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine (16:0 to 20:4 PE), 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine (16:0 to 22:6 PE), 1-Stearoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (18:0 to 18:1 PE), 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine (18:0-18:2 PE), 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine (18:0 to 20:4 PE), 1-Stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine (18:0 to 22:6 PE), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC) and It is selected from the group consisting of any combination thereof.
[0093] In some embodiments of the pharmaceutical compositions disclosed herein, the lipid nanoparticle carrier further comprises a structured lipid, hi some embodiments, the structured lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and mixtures thereof.
[0094] In some embodiments of the pharmaceutical compositions disclosed herein, the lipid nanoparticle carrier further comprises a PEG-lipid, in some embodiments, the PEG-lipid is selected from the group consisting of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol, and mixtures thereof.
[0095] In some embodiments of the pharmaceutical compositions disclosed herein, the lipid nanoparticle carrier comprises: 3-(didodecylamino)-N1,N1,4-tridodecyl-1-piperazineethanamine (KL10), N1-[2-(didodecylamino)ethyl]-N1,N4,N4-tridodecyl-1,4-piperazinediethanamine (KL22), 14,25-ditridecyl-15,18,21,24-tetraaza-octatriacontane (KL25), 1,2-Dilinoleyloxy-N,N-dimethylaminopropane (DLin-DMA), 2,2-Dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), Heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (DLin-MC3-DMA), 2,2-Dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA), 1,2-dioleyloxy-N,N-dimethylaminopropane (DODMA), 2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (octyl-CLinDMA), (2R)-2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA(2R)) and The composition further comprises an ionic lipid selected from the group consisting of (2S)-2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA(2S)).
[0096] In some embodiments of the pharmaceutical compositions disclosed herein, the lipid nanoparticle carrier further comprises a quaternary amine compound. In some embodiments, the quaternary amine compound is 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), 1-[2-(oleoyloxy)ethyl]-2-oleyl-3-(2-hydroxyethyl)imidazolinium chloride (DOTIM), 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE), N-(1,2-dioleoyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethylammonium bromide (DORIE), N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), 1,2-dilauroyl-sn-glycero-3-ethylphosphocholine (DLePC), 1,2-distearoyl-3-trimethylammonium-propane (DSTAP), 1,2-dipalmitoyl-3-trimethylammonium-propane (DPTAP), 1,2-dilinoleoyl-3-trimethylammonium-propane (DLTAP), 1,2-dimyristoyl-3-trimethylammonium-propane (DMTAP), 1,2-distearoyl-sn-glycero-3-ethylphosphocholine (DSePC), 1,2-dipalmitoyl-sn-glycero-3-ethylphosphocholine (DPePC), 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (DMePC), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOePC), 1,2-di-(9Z-tetradecenoyl)-sn-glycero-3-ethylphosphocholine (14:1 EPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-ethylphosphocholine (16:0 to 18:1 EPC) and It is selected from the group consisting of any combination thereof.
[0097] In some embodiments of the compositions, pharmaceutical compositions, or kits disclosed above, administering the polynucleotide, composition, or pharmaceutical composition to a subject in need thereof reduces tumor size or inhibits tumor growth at least 1.5-fold, at least 2-fold, at least 2.5-fold, at least 3-fold, at least 3.5-fold, at least 4-fold, at least 4.5-fold, or at least 5-fold better than monotherapy consisting of administering only one polynucleotide in the composition or pharmaceutical composition. [Brief explanation of the drawings]
[0098] [Figure 1]Total IgG (mIgG) for active CTLA-4 binding (mCTLA-4 binding) is shown in HeLa cells expressing mRNA-encoded 9D9 antibodies, HC-2Aa:LC (9D9 IgG2a antibody) and HC-2B:LC (9D9 IgG2b antibody). [Figure 2] Figures 2A-2C show positive / negative efficacy control data in the CT26 carcinoma model with three doses of 5 mg / kg anti-CTLA-4 protein (Figure 2B) or 0.5 mg / kg NST FIX (Figure 2C) administered on days 3, 6, and 9 compared to untreated animals (Figure 2A). NST FIX is a negative control mRNA (mRNA encoding untranslated ("non-primed") factor IX). [Figure 3-1] Figures 3A-3F show treatment with one, two, or three doses of mRNA encoding the anti-CTLA-4 (9D9 2b) antibody. Figures 3A and 3B show data corresponding to the control samples NST FIX and 9D9 2b anti-CTLA-4 antibody administered on day 3, respectively. Figures 3C and 3D show data corresponding to the control samples NST FIX and 9D9 2b anti-CTLA-4 antibody administered on days 3 and 9, respectively. Figures 3E and 3F show data corresponding to the control samples NST FIX and 9D9 2b anti-CTLA-4 antibody administered on days 3, 6, and 9, respectively. [Figure 3-2] Figures 3A-3F show treatment with one, two, or three doses of mRNA encoding the anti-CTLA-4 (9D9 2b) antibody. Figures 3A and 3B show data corresponding to the control samples NST FIX and 9D9 2b anti-CTLA-4 antibody administered on day 3, respectively. Figures 3C and 3D show data corresponding to the control samples NST FIX and 9D9 2b anti-CTLA-4 antibody administered on days 3 and 9, respectively. Figures 3E and 3F show data corresponding to the control samples NST FIX and 9D9 2b anti-CTLA-4 antibody administered on days 3, 6, and 9, respectively. [Figure 3-3]Figures 3A-3F show treatment with one, two, or three doses of mRNA encoding the anti-CTLA-4 (9D9 2b) antibody. Figures 3A and 3B show data corresponding to the control samples NST FIX and 9D9 2b anti-CTLA-4 antibody administered on day 3, respectively. Figures 3C and 3D show data corresponding to the control samples NST FIX and 9D9 2b anti-CTLA-4 antibody administered on days 3 and 9, respectively. Figures 3E and 3F show data corresponding to the control samples NST FIX and 9D9 2b anti-CTLA-4 antibody administered on days 3, 6, and 9, respectively. [Figure 4-1] Figures 4A-4F show treatment with one, two, or three doses of mRNA encoding anti-CTLA-4 (9D9 2a). Figures 4A and 4B show data corresponding to the control samples NST FIX and 9D9 2a anti-CTLA-4 antibody administered on day 3, respectively. Figures 4C and 4D show data corresponding to the control samples NST FIX and 9D9 2a anti-CTLA-4 antibody administered on days 3 and 9, respectively. Figures 4E and 4F show data corresponding to the control samples NST FIX and 9D9 2a anti-CTLA-4 antibody administered on days 3, 6, and 9, respectively. [Figure 4-2] Figures 4A-4F show treatment with one, two, or three doses of mRNA encoding anti-CTLA-4 (9D9 2a). Figures 4A and 4B show data corresponding to the control samples NST FIX and 9D9 2a anti-CTLA-4 antibody administered on day 3, respectively. Figures 4C and 4D show data corresponding to the control samples NST FIX and 9D9 2a anti-CTLA-4 antibody administered on days 3 and 9, respectively. Figures 4E and 4F show data corresponding to the control samples NST FIX and 9D9 2a anti-CTLA-4 antibody administered on days 3, 6, and 9, respectively. [Figure 4-3]Figures 4A-4F show treatment with one, two, or three doses of mRNA encoding anti-CTLA-4 (9D9 2a). Figures 4A and 4B show data corresponding to the control samples NST FIX and 9D9 2a anti-CTLA-4 antibody administered on day 3, respectively. Figures 4C and 4D show data corresponding to the control samples NST FIX and 9D9 2a anti-CTLA-4 antibody administered on days 3 and 9, respectively. Figures 4E and 4F show data corresponding to the control samples NST FIX and 9D9 2a anti-CTLA-4 antibody administered on days 3, 6, and 9, respectively. [Figure 5] Figures 5A and 5B show the efficacy of 9D9 2b anti-CTLA-4 antibody protein in a CT26 carcinoma model (Figure 5B) compared to untreated controls (Figure 5A). 9D9 2b anti-CTLA-4 antibody was administered on days 3, 6, and 9 after tumor implantation. [Figure 6] Shown are serum levels of anti-CTLA-4 9D9 antibody after administration of a 5 mg / kg dose (observed at 24 hours (left bar), 48 hours (middle bar), and 72 hours (right bar)), or serum levels after administration of 0.5 mg / kg of mRNA encoding the 9D9 2b antibody, mRNA encoding the 9D9 2a antibody, or control (NST FIX or DPBS) (observed at 24 hours, 48 hours, 72 hours, and 7 days, from left to right, respectively). [Figure 7] Figures 7A and 7B show individual tumor growth curves for untreated animals (Figure 7A) and control animals treated with NST FIX / LNP (Figure 7B). Negative control NST FIX-encoding mRNA was administered at 0.5 mg RNA / kg on days 3, 6, and 9 after tumor implantation. [Figure 8] Individual tumor growth curves for animals treated with three doses of 5 mg / kg anti-CTLA-4 9D9 antibody protein administered on days 3, 6, and 9 after tumor implantation are shown. [Figure 9]1 shows individual tumor growth curves for animals treated with three doses of mRNA designed to express the anti-CTLA-4 9D9 2b antibody. Doses of 0.5 mg mRNA / kg were administered on days 3, 6, and 9 after tumor implantation. [Figure 10] Figure 1 shows individual tumor growth curves for animals treated with three doses of mRNA designed to express the anti-CTLA-4 9D9 2a antibody. Doses of 0.5 mg mRNA / kg were administered on days 3, 6, and 9 after tumor implantation. [Figure 11] Figures 11A and 11B show individual tumor growth curves for animals treated with NST FIX mRNA control (Figure 11A) and animals treated with mRNA designed to express anti-CTLA-4 9D9 2b (Figure 11B). mRNA was administered at 0.5 mg RNA on days 3 and 9 after tumor implantation. [Figure 12] Figures 12A and 12B show individual tumor growth curves for animals treated with NST FIX mRNA control (Figure 12A) and animals treated with mRNA designed to express anti-CTLA-4 9D9 2a (Figure 12B). mRNA was administered at 0.5 mg RNA on day 3 after tumor implantation. [Figure 13] 1 shows the survival benefit of treatment with mRNA encoding a CTLA-4 antibody. [Figure 14]
[0023] Figure 1 is a diagram of the structure of a chimeric CD80Fc polypeptide. Such chimeric polypeptides are dimers, with each monomer containing the extracellular domain of CD80 and an Fc domain (which itself contains two CH2 domains and a hinge region). The CD89Fc dimer is held together by a disulfide bond within the hinge region of the Fc. [Figure 15] 1 is a graph showing the efficacy of CD80Fc ("B7.1-Fc") in treating a mouse model of colon cancer. Colon 26 cells were established in the abdomen of C57BL / 6J mice, and mean tumor volume over time was measured after repeated treatment with a range of CD80Fc concentrations. [Figure 16]Expression levels of mouse and human modified mRNAs encoding CD80Fc constructs are shown. [Figure 17] The ability of the expressed CD80Fc constructs to bind to CTLA-4 was tested. [Figure 18]
[0023] Figure 1 is a graph showing IL-2 secretion after CD80Fc-mediated costimulation of Jurkat cells. Jurkat cells were treated with PHA to provide a primary T cell receptor activation signal, and then treated with CD80Fc polypeptides. Each chimeric polypeptide was administered at a range of concentrations, including 62.5 ng / mL, 125 ng / mL, 250 ng / mL, 500 ng / mL, and 1000 ng / mL. [Figure 19] Figures 19A, 19B, and 19C contain graphs of the in vivo efficacy of modified mRNA encoding a chimeric CD80Fc polypeptide in a B cell lymphoma model. A20 B cell lymphoma cells were established subcutaneously in BALB / c mice (n=12), followed by six 12.5 μg doses of modified mRNA administered every seven days. Mice were administered modified mRNA encoding chimeric CD80Fc (Figures 19B and 19C) or control mRNA (Figure 19A). Graphs represent individual plots of growth over time for each tumor, starting at day 18 after implantation. [Figure 20] The structures of full-length wild-type ("wt") TLR4 and caTLR4 are shown. Full-length wtTLR4 contains a signal peptide ("sp") at the amino terminus ("N"), an extracellular leucine-rich repeat domain ("LRR"), a transmembrane domain ("TM"), and an intracellular toll / interleukin-1 receptor-like domain ("TIR") at the carboxy terminus ("C"). caTLR4 lacks the wild-type signal peptide and LRR and instead contains either human lysosomal membrane protein 1 (hLAMP1) or mouse immunoglobulin kappa variable ("mIgk") signal peptide. The remaining structure of caTLR4 is identical to that of wtTLR4. [Figure 21]This figure shows the expression of caTLR4 mRNA in cell-free translation by QC. Lane "1" is an RNA ladder showing sizes of 20 and 25 kilodaltons ("kDa"). Lane 2 is a negative control showing the absence of bands when mRNA is not included in the cell-free translation system. Lane 3 shows human caTLR4 expressed from mRNA without a microRNA ("miR") target site ("HS caTLR4 miRless"). Lane 4 shows human caTLR4 expressed from mRNA containing a miR122 target site ("Hs caTLR4 miR122"). Lane 5 shows mouse caTLR4 expressed from mRNA containing a miR122 target site (Mm caTLR4 miR122"). [Figure 22] 1 is a graph showing alkaline phosphatase activity 6 and 18 hours after transfection of THP1-Blue™ NF-κB cells with control mRNA, Hs caTLR4 mRless, Hs caTLR4 miR122, or Mm caTLR4 miR122 after infection with Listeria monocytogenes or exposure to lipopolysaccharide ("LPS"). [Figure 23] Figures 23A and 23B are graphs showing tumor volume (mm3) in 12 individual mice ("n=12") after subcutaneous implantation of mouse A20 B-cell lymphoma cells and intratumoral doses of either 12.5 μg of NST FIX (Figure 23A) or 12.5 μg of mRNA encoding mouse caTLR4 and containing the miR122 target site ("mouse caTLR4_miR122", Figure 23B) at 18, 25, and 32 days after implantation. [Figure 24] Figures 24A-24C are graphs showing tumor volume (mm3) in 12 individual mice following subcutaneous implantation of A20 B-cell lymphoma cells and intratumoral administration of either 3 μg of NST2001 (Figure 24A), 0.5 μg of interleukin-12 ("IL12") plus 2.5 μg of NST FIX (Figure 24B), or 0.5 μg of IL12 plus 2.5 μg of mRNA encoding caTLA4 (Figure 24C) after implantation. [Figure 25]An example of an OX40L-encoding polynucleotide (mRNA) is shown below. The mRNA can consist of a 5' cap, a 5' UTR, an ORF (mRNA) encoding the OX40L polypeptide, a 3' UTR, a miR122 binding site, and a poly-A tail. [Figure 26] 1 shows the expression of OX40L on the surface of B16F10 cells after treatment with a polynucleotide containing mRNA encoding the OX40L polypeptide. The left peak represents controls (mock-treated or treated with a negative control mRNA (a non-translated version of the same mRNA containing multiple stop codons)). The four right peaks represent the expression of OX40L following administration of 6.3 ng, 12.5 ng, 25 ng, or 50 ng of OX40L mRNA. [Figure 27-1](Figure 27A) Expression of OX40L on the surface of HeLa cells after treatment with a polynucleotide containing mRNA encoding an OX40L polypeptide, treatment was in the absence of mitomycin C. (Figure 27B) Expression of OX40L on the surface of MC-38 cells after treatment with a polynucleotide containing mRNA encoding an OX40L polypeptide, treatment was in the absence of mitomycin C. Peak 1 in Figures 27A and 27B represents surface expression in mock-treated cells. Peaks 2-6 represent surface expression on days 1, 2, 3, 5, and 7 (respectively) after treatment with a polynucleotide containing mRNA encoding an OX40L polypeptide. (Figure 27C) Expression of OX40L on the surface of HeLa cells after treatment with a polynucleotide containing mRNA encoding an OX40L polypeptide, treatment was in the presence of mitomycin C. (Figure 27D) Expression of OX40L on the surface of MC-38 cells after treatment with a polynucleotide containing mRNA encoding an OX40L polypeptide, treatment was in the presence of mitomycin C. Peak 1 in Figures 27C and 27D shows surface expression in mock-treated cells. Peaks 2-6 show surface expression on days 1, 2, 3, 5, and 7 (respectively) after treatment with a polynucleotide containing mRNA encoding an OX40L polypeptide. (Figure 27E) Shows expression of OX40L on the surface of HeLa cells after treatment with a polynucleotide containing mRNA encoding a human OX40L polypeptide. Peak 1 shows surface expression in mock-treated cells. Peaks 2-6 show surface expression on days 1, 2, 3, 4, and 5 (respectively) after treatment with a polynucleotide containing mRNA encoding an OX40L polypeptide. [Figure 27-2] (Figure 27F) Quantification of mouse OX40L protein in cell lysates and cell culture supernatants after treatment of HeLa cells with a polynucleotide containing mRNA encoding the OX40L polypeptide. (Figure 27G) Quantification of human OX40L protein in cell lysates and cell culture supernatants after treatment of HeLa cells with a polynucleotide containing mRNA encoding the OX40L polypeptide. The y-axis of Figures 27F and 27G shows the amount of protein per well in nanograms (ng). [Figure 28-1] Figures 28A-28E show the costimulatory biological activity of OX40L expressed on the surface of cells treated with OX40L mRNA. Figure 28A shows a schematic diagram of a T cell activation assay. OX40-expressing B16F10 cells or HeLa cells were co-cultured with CD4+ T cells and anti-mouse CD3 antibody (B16F10 cells) or Dynabeads human T activator (HeLa cells). IL-2 production was measured using ELISA as a correlate of T cell activation. Figure 28B shows the results of a T cell activation assay measured with mouse IL-2. Figure 28C shows the results of a T cell activation assay measured with human IL-2. The y-axis shows mIL-2 expression in ng / ml. Figure 28D shows the data from Figure 28C, with a schematic diagram illustrating the addition of OX40L-expressing cells to a naive T cell activation assay. FIG. 28E shows a T cell activation assay using pre-stimulated T cells cultured in the presence or absence of OX40L-expressing HeLa cells and in the presence or absence of anti-human CD3 antibody. [Figure 28-2] Figures 28A-28E show the costimulatory biological activity of OX40L expressed on the surface of cells treated with OX40L mRNA. Figure 28A shows a schematic diagram of a T cell activation assay. OX40-expressing B16F10 cells or HeLa cells were co-cultured with CD4+ T cells and anti-mouse CD3 antibody (B16F10 cells) or Dynabeads human T activator (HeLa cells). IL-2 production was measured using ELISA as a correlate of T cell activation. Figure 28B shows the results of a T cell activation assay measured with mouse IL-2. Figure 28C shows the results of a T cell activation assay measured with human IL-2. The y-axis shows mIL-2 expression in ng / ml. Figure 28D shows the data from Figure 28C, with a schematic diagram illustrating the addition of OX40L-expressing cells to a naive T cell activation assay. FIG. 28E shows a T cell activation assay using pre-stimulated T cells cultured in the presence or absence of OX40L-expressing HeLa cells and in the presence or absence of anti-human CD3 antibody. [Figure 28-3]Figures 28A-28E show the costimulatory biological activity of OX40L expressed on the surface of cells treated with OX40L mRNA. Figure 28A shows a schematic diagram of a T cell activation assay. OX40-expressing B16F10 cells or HeLa cells were co-cultured with CD4+ T cells and anti-mouse CD3 antibody (B16F10 cells) or Dynabeads human T activator (HeLa cells). IL-2 production was measured using ELISA as a correlate of T cell activation. Figure 28B shows the results of a T cell activation assay measured with mouse IL-2. Figure 28C shows the results of a T cell activation assay measured with human IL-2. The y-axis shows mIL-2 expression in ng / ml. Figure 28D shows the data from Figure 28C, with a schematic diagram illustrating the addition of OX40L-expressing cells to a naive T cell activation assay. FIG. 28E shows a T cell activation assay using pre-stimulated T cells cultured in the presence or absence of OX40L-expressing HeLa cells and in the presence or absence of anti-human CD3 antibody. [Figure 29] Figure 1 shows luciferase flux levels in tumor tissue compared to liver tissue from animals treated with a polynucleotide containing mRNA encoding a luciferase polypeptide. Representative symbols are as follows: open inverted triangle, open star, open diamond, filled diamond, and open circle represent luciferase flux in tumor tissue after administration of 50 μg, 25 μg, 12.5 μg, 6.25 μg, and 3.125 μg of mOX40L_miR122 mRNA (respectively). Filled inverted triangle, filled star, open square, filled square, and open triangle represent luciferase flux in liver tissue after administration of 50 μg, 25 μg, 12.5 μg, 6.25 μg, and 3.125 μg of mOX40L_miR122 mRNA (respectively). The filled circles and triangles indicate the luciferase flux in tumor tissue (filled circles) and liver tissue (filled triangles) after administration of the PBS control. [Figure 30]1 shows the amount of OX40L polypeptide present in melanoma tumor tissue from animals treated with a polynucleotide containing mRNA encoding the OX40L polypeptide, the left panel shows 8 hours after treatment, and the right panel shows 24 hours after treatment. [Figure 31-1] (Figure 31A) The amount of OX40L polypeptide present in colon adenocarcinoma tumor tissue in animals treated with a polynucleotide containing mRNA encoding OX40L polypeptide, treated with a polynucleotide containing mRNA encoding NST-OX40L (untranslated OX40L mRNA), or not treated. OX40L expression was measured at 3, 6, 24, 48, 72, and 168 hours. (Figure 31B) The amount of OX40L polypeptide (top) and mRNA (bottom) present in tumor tissue after administration of increasing doses of a polynucleotide containing mRNA encoding OX40L polypeptide. [Figure 31-2] (Figure 31C) The amount of OX40L polypeptide (top) and mRNA (bottom) present in liver tissue after administration of the same polynucleotide. (Figure 31D) The amount of OX40L polypeptide (top) and mRNA (bottom) present in spleen tissue after administration of the same polynucleotide. [Figure 32-1] Figures 32A-32C show the in vivo efficacy (measured on day 42) of administration of a polynucleotide containing mRNA encoding an OX40L polypeptide in a colon adenocarcinoma model. Figure 32A shows tumor growth in animals treated with control mRNA (NT OX40L_miR122 control). Figure 32B shows tumor growth in animals treated with a polynucleotide containing mRNA encoding an OX40L polypeptide (OX40L_miR122). Figure 32C shows Kaplan-Meier survival curves for all treatment groups (OX40L_miR122, NST_OX40L_miR122, and PBS). [Figure 32-2]Figures 32A-32C show the in vivo efficacy (measured on day 42) of administration of a polynucleotide containing mRNA encoding an OX40L polypeptide in a colon adenocarcinoma model. Figure 32A shows tumor growth in animals treated with control mRNA (NT OX40L_miR122 control). Figure 32B shows tumor growth in animals treated with a polynucleotide containing mRNA encoding an OX40L polypeptide (OX40L_miR122). Figure 32C shows Kaplan-Meier survival curves for all treatment groups (OX40L_miR122, NST_OX40L_miR122, and PBS). [Figure 33] Figures 33A-33C show OX40L expression in A20 B-cell lymphoma tumors in animals treated with a polynucleotide containing mRNA encoding an OX40L polypeptide. Figure 33A shows OX40L expression quantified in nanograms per gram in tumor tissue as measured by ELISA. Figure 33B shows OX40L expression on the cell surface of tumor cells as measured by flow cytometry. Figure 33C shows OX40L expression on the cell surface of tumor cells as measured by flow cytometry. [Figure 34] Figures 34A and 34B show the infiltration of natural killer (NK) cells into the tumor microenvironment in animals treated with a polynucleotide containing mRNA encoding the OX40L polypeptide. Figure 34A shows the average percentage of live NK cells present in the tumor microenvironment. The left bar shows the percentage of NK cells increased after administration of mOX40L_mRNA. The right bar shows the percentage of NK cells increased after administration of NST mOX40L_mRNA. Figure 34B shows individual animal data from the same study. [Figure 35-1]Figures 35A-35D show the in vivo efficacy of administration of a polynucleotide containing mRNA encoding an OX40L polypeptide in a B-cell lymphoma tumor model. Figure 35A shows tumor growth in animals treated with control mRNA (NST-FIX control). Figure 35B shows tumor growth in animals treated with a polynucleotide containing mRNA encoding an OX40L polypeptide (OX40L_miR122). Figure 35C shows the mean tumor volume for each group measured on day 35. Figure 35D shows the Kaplan-Meier survival curve for each treatment group. Squares represent tumor volume after administration of OX40L_miR122. Triangles represent tumor volume after administration of NST-FIX (control). [Figure 35-2] Figures 35A-35D show the in vivo efficacy of administration of a polynucleotide containing mRNA encoding an OX40L polypeptide in a B-cell lymphoma tumor model. Figure 35A shows tumor growth in animals treated with control mRNA (NST-FIX control). Figure 35B shows tumor growth in animals treated with a polynucleotide containing mRNA encoding an OX40L polypeptide (OX40L_miR122). Figure 35C shows the mean tumor volume for each group measured on day 35. Figure 35D shows the Kaplan-Meier survival curve for each treatment group. Squares represent tumor volume after administration of OX40L_miR122. Triangles represent tumor volume after administration of NST-FIX (control). [Figure 36] Figures 36A and 36B show in vivo immune responses after administration of a polynucleotide containing mRNA encoding the OX40L polypeptide. Mice were inoculated with MC-38 colon adenocarcinoma cells. When tumors reached a palpable size, the mice were administered a polynucleotide containing mRNA encoding the OX40L polypeptide (OX40L_122, triangles), a control nonsense mRNA (NST-OX40L_122, inverted triangles), or PBS (squares). Sixty days after polypeptide administration, the mice were rechallenged with a second inoculation of MC-38 tumor cells. Figure 36A shows tumors from individual animals in the first stage through day 60. Figure 36B shows the number of animals exhibiting tumor growth 23 days after rechallenge. [Figure 37]1 shows OX40L expression in A20 tumors at various time points after administration of a first and / or second dose of a polynucleotide comprising mRNA encoding an OX40L polypeptide, with expression shown 24 hours, 72 hours, 7 days, and 14 days after administration of the first dose of the polynucleotide, and 24 hours, 72 hours, and 7 days after administration of the second dose of the polynucleotide. [Figure 38] Figures 38A-38C show different cell types present in the tumor microenvironment after administration of a polypeptide containing mRNA encoding the OX40L polypeptide. Figure 38A shows the percentage of OX40L-expressing cells in A20 tumors, which are cancer cells, immune cells, non-cancer / non-immune cells, and cells of myeloid lineage. Figure 38B shows the percentage of OX40L-expressing cells in MC38 tumors, which are tumor cells, immune cells, and cells of myeloid lineage. Figure 38C shows the percentage of OX40L-expressing myeloid cells in the tumor microenvironment after administration of the polynucleotide. [Figure 39-1] Figures 39A-39D show different types of immune cells infiltrating the tumor microenvironment of A20 tumors after administration of a polypeptide containing mRNA encoding an OX40L polypeptide. Figure 39A shows the percentage of NK cells in the tumor infiltrate 24 hours after treatment, as detected by the DX5 marker. Figure 39B shows the percentage of CD4+ T cells in the tumor infiltrate 14 days after treatment, as detected by the CD4 marker. Figure 39C shows the percentage of CD8+ T cells in the tumor infiltrate 14 days after treatment, as detected by the CD8 marker. Figure 39D shows the percentage of CD8+ T cells in the tumor infiltrate of MC38 tumors 24 and 72 hours after the first and second doses of a polynucleotide containing mRNA encoding an OX40L polypeptide. [Figure 39-2]Figures 39A-39D show different types of immune cells infiltrating the tumor microenvironment of A20 tumors after administration of a polypeptide containing mRNA encoding an OX40L polypeptide. Figure 39A shows the percentage of NK cells in the tumor infiltrate 24 hours after treatment, as detected by the DX5 marker. Figure 39B shows the percentage of CD4+ T cells in the tumor infiltrate 14 days after treatment, as detected by the CD4 marker. Figure 39C shows the percentage of CD8+ T cells in the tumor infiltrate 14 days after treatment, as detected by the CD8 marker. Figure 39D shows the percentage of CD8+ T cells in the tumor infiltrate of MC38 tumors 24 and 72 hours after the first and second doses of a polynucleotide containing mRNA encoding an OX40L polypeptide. [Figure 40] Figures 40A and 40B show the in vivo efficacy of administration of a polynucleotide containing mRNA encoding the OX40L polypeptide in A20 tumors. Figure 40A shows tumor volume (measured in mm3) over time. Treatments are indicated as follows: mOX40L_miR122 (filled circle), control mRNA (NST) (open square), PBS (open triangle), and no treatment (open circle). Figure 40B shows Kaplan-Meier survival curves for the same animals. [Figure 41] Figures 41A and 41B show OX40L protein expression in primary human hepatocytes, human hepatoma cells (Hep3B), and human cervical cancer cells (HeLa) 6, 24, and 48 hours after transfection. Figure 41A shows human OX40L polypeptide expression, measured in nanograms per well. Figure 41B shows mouse OX40L polypeptide expression, measured in nanograms per well. [Figure 42]Figures 42A-42E show the in vivo antitumor efficacy of mOX40L_miR122 delivered intratumorally or intravenously. Figure 42A shows tumor growth in animals treated intravenously with PBS (arrow indicates day of injection). Figure 42B shows tumor growth in animals treated intravenously with control mRNA ("NST-OX40L") (arrow indicates day of injection). Figure 42C shows tumor growth in animals treated intravenously with mOX40L_miR122 mRNA ("OX40L-miR122") (arrow indicates day of injection). [Figure 43] 1 shows survival curves for animals treated intravenously with PBS, negative control mRNA ("NST-OX40L"), or mOX40L-miR122 mRNA ("OX40L"). Dose dates are indicated by arrows. [Figure 44] The percent change in body weight over time for animals treated intravenously with PBS (filled circles), negative control mRNA (filled squares), and OX40L-miR122 mRNA (open circles) is shown. [Figure 45] 1 is a table showing the increase in protein expression of different sequence-optimized IL12 mRNAs relative to the wild-type mRNA encoding IL12. [Figure 46] 1 is a graph depicting the robust efficacy of a single intravenous (IV) dose of IL12 mRNA with lipid nanoparticles (LNPs) at doses of 0.1 mg / kg (Group 4) and 0.05 mg / kg (Group 5) (indicated by the line with an inverted triangle) compared to Groups 1 (PBS), 2 (IL12 protein), 7 and 8 (control NST-FIX, 0.1 mg / kg and 0.05 mg / kg, respectively). [Figure 47](Figure 47A) A graph depicting the higher AUC and Cmax of IL12 plasma levels observed after administration of IL12 mRNA via lipid nanoparticles (LNPs) compared to the corresponding IL12 recombinant protein. (Figure 47B) A graph depicting the higher AUC and Cmax of IFNγ plasma levels observed after administration of IL12 mRNA administered via lipid nanoparticles (LNPs) compared to IL12 recombinant protein. (Figure 47C) A table depicting the higher AUC levels of IL12 and IFNγ plasma levels observed after treatment with IL12 mRNA administered via lipid nanoparticles (LNPs) at 0.1 mpk and 0.05 mpk compared to treatment with IL12 recombinant protein at approximately 0.05 mpk. Numbers in parentheses indicate the x-fold increase in mRNA relative to protein. [Figure 48-1] Figures 48A-48F are graphs depicting the mean tumor volume and number of complete responses (CRs) observed after single intravenous (IV) dose administration of IL12 mRNA delivered by lipid nanoparticles (LNPs) at 0.1 mg / kg (Group 4) (Figure 48F) and 0.05 mg / kg (Group 5) (Figure 48E), PBS (Group 1) (Figure 48A), IL12 protein (Group 2) (Figure 48D), and control NST-FIX at 0.1 mg / kg and 0.05 mg / kg (Groups 7 and 8, respectively) (Figures 48C and 48B, respectively). Complete responses (CRs) are shown only in Figures 48E and 48F. Figure 48E shows that 6 of 8 CRs were observed in Group 5 (IL12 mRNA delivered by lipid nanoparticles (LNPs) at a dose of 0.05 mg / kg). Figure 48F shows that 5 out of 9 CRs were observed in Group 4 (IL12 mRNA with lipid nanoparticles (LNP) at a dose of 0.1 mg / kg). Except for the IL12 mRNA group, no CRs were observed in any other groups. [Figure 48-2]Figures 48A-48F are graphs depicting the mean tumor volume and number of complete responses (CRs) observed after single intravenous (IV) dose administration of IL12 mRNA delivered by lipid nanoparticles (LNPs) at 0.1 mg / kg (Group 4) (Figure 48F) and 0.05 mg / kg (Group 5) (Figure 48E), PBS (Group 1) (Figure 48A), IL12 protein (Group 2) (Figure 48D), and control NST-FIX at 0.1 mg / kg and 0.05 mg / kg (Groups 7 and 8, respectively) (Figures 48C and 48B, respectively). Complete responses (CRs) are shown only in Figures 48E and 48F. Figure 48E shows that 6 of 8 CRs were observed in Group 5 (IL12 mRNA delivered by lipid nanoparticles (LNPs) at a dose of 0.05 mg / kg). Figure 48F shows that 5 out of 9 CRs were observed in Group 4 (IL12 mRNA with lipid nanoparticles (LNP) at a dose of 0.1 mg / kg). Except for the IL12 mRNA group, no CRs were observed in any other groups. [Figure 49] 1 is a graph depicting the survival benefit at day 47 after tumor implantation of a single intravenous (IV) dose of IL12 mRNA in lipid nanoparticles (LNPs) at a dose of 0.05 mg / kg (Group 5) and 0.1 mg / kg (Group 4) compared to a single IV dose of 1 μg (approximately 0.05 mg / kg) (Group 2) of IL12 protein, 0.1 mg / kg (Group 7) or 0.05 mg / kg (Group 8) of NST-FIX, or PBS (Group 1). [Figure 50] 1 is a table depicting the tolerability advantage of local (intratumoral) administration of IL12 mRNA compared with systemic (intravenous) administration. Nine of 10 mice receiving intratumoral IL12 mRNA at 0.2 mg / kg (fixed 4 μg) were alive at day 20, compared with three of 12 mice receiving intravenous IL12 mRNA at 0.2 mg / kg. Intravenous administration resulted in approximately 18-fold higher plasma levels of IL12 (ng / ml) 24 hours after the dose than intratumoral administration (1592 ng / ml vs. 89 ng / ml). [Figure 51]Figures 51A and 51B are graphs showing the in vivo antitumor efficacy of a single intratumoral dose of lipid nanoparticle (LNP)-mediated IL12 mRNA (4 μg) administered to mice bearing adenocarcinoma (MC38) tumors. Figure 51A shows the mean tumor volume (mm3) starting from day 10 post-implantation through day 24. Group 1 (circles) represents mice (n=7) administered 4 μg of IL12 mRNA LNPs on day 10 post-implantation, group 2 (squares) represents mice (n=7) administered 4 μg of control mRNA encoding non-translated factor IX (NST-FIX LNPs), and group 3 (triangles) represents another control group of mice (n=7) administered PB. Figure 51B shows the individual tumor volumes (mm3) in each group of mice starting from day 10 post-implantation through day 47. Complete responses (CR) were achieved in 3 of 7 animals (44%) receiving 4 μg of IL12 mRNA LNPs (round). [Figure 52] Figures 52A and 52B are graphs showing the in vivo antitumor efficacy of an intratumoral dose of IL12 mRNA (5 μg) administered by MC3-based lipid nanoparticles (LNPs) to mice bearing A20 B-cell lymphoma tumors. Figure 52A shows the individual tumor volumes (mm3) of mice (n=12) administered 5 μg of non-translated control mRNA (NST). Figure 52B shows the individual tumor volumes of mice (n=12) administered 5 μg of IL12 (miRless) mRNA. Complete responses (CR) were achieved in 5 of 12 animals receiving IL12 mRNA. [Figure 53]Figures 53A and 53B are graphs showing the in vivo antitumor efficacy of IL12 mRNA (5 μg) containing the miR122 binding site (Figure 53A) compared to miRless IL12 mRNA (Figure 53B) in a B cell lymphoma tumor model (A20). Both IL12 mRNAs (with and without the miR122 binding site (i.e., miRless)) were formulated in MC3-based lipid nanoparticles (LNPs). IL-12 mRNA was administered to mice bearing A20 B cell lymphoma tumors. Complete responses (CRs) were achieved in 5 of 12 mice in the IL12 miRless group (Figure 53A) and 6 of 12 mice in the IL12 miR122 group (Figure 53B). [Figure 54] Figures 54A and 54B are graphs showing the in vivo antitumor efficacy of a single dose of 0.5 μg of IL12 mRNA administered by MC3-based lipid nanoparticles (LNPs) to mice bearing A20 B-cell lymphoma tumors. Complete responses (CRs) were achieved in 4 of 12 mice in the IL12 miRless (0.5 μg) group (Figure 54A) and 3 of 12 mice in the IL12 miR122 (0.5 μg) group (Figure 54B). [Figure 55] Figures 55A and 55B are graphs showing enhanced in vivo antitumor efficacy in a B-cell lymphoma tumor model (A20) by administering multiple doses of 0.5 μg of IL12 mRNA in MC3-based lipid nanoparticles (LNPs) to mice bearing this tumor. Complete responses (CRs) were achieved in 3 of 12 mice administered a single dose of 0.5 μg of IL12 miR122 (Figure 55A) and in 5 of 12 mice administered 0.5 μg of IL12 miR122 every 7 days for 6 weekly doses (Figure 55B). [Figure 56]Figures 56A and 56B are graphs showing that the in vivo antitumor efficacy of a weekly intratumoral dose of 0.5 μg of IL12 mRNA (i.e., compound 18) delivered by lipid nanoparticles (LNPs) administered to mice bearing A20 B-cell lymphoma tumors is similar to that of 0.5 μg of IL12 mRNA delivered by MC3-based LNPs. Figure 56A shows the individual tumor volumes (mm3) of 12 mice administered 0.5 μg of IL12 miR122 delivered by MC3-based LNPs six times every seven days. Complete responses (CR) were achieved in five of the 12 animals. Figure 56B shows the individual tumor volumes of 12 mice administered 0.5 μg of IL12 mRNA delivered by compound 18-based LNPs six times every seven days. Complete responses (CR) were also achieved in five of the 12 animals. [Figure 57] Figures 57A and 57B are graphs showing tumor growth in mice bearing A20 tumors administered weekly (six times every seven days) of 0.5 μg of non-translated negative control mRNA (NST) delivered by MC3-based lipid nanoparticles (LNPs) (Figure 57A) and 0.5 μg of non-translated negative control mRNA (NST) delivered by compound 18-based LNPs (Figure 57B). [Figure 58] Figures 58A and 58B are graphs showing dose-dependent levels of IL12 in plasma (Figure 58A) and tumors (Figure 58B) 6 and 24 hours after intratumoral administration of the indicated doses of IL12 mRNA into mice bearing A20 tumors. From left to right, mice received: (i) PBS, (ii) 0.5 μg NST, (iii) 2.5 μg NST, (iv) 5 μg NST, (v) 0.5 μg IL12, (vi) 2.5 μg IL12, (vii) 5 μg IL12, (viii) 0.5 μg IL12 miR122, (ix) 2.5 μg IL12 miR122, and (x) 5 μg IL12 miR122. [Figure 59]Figures 59A-59C are graphs showing elevated plasma and intratumor levels of IL12 after administration of the indicated doses of IL12 mRNA with Compound 18-based LNPs compared to IL12 mRNA with MC3-based LNPs. Figure 59A shows plasma IL12 levels at 6 and 24 hours, and Figure 59B shows tumor IL12 levels at 6 and 24 hours. From left to right, mice received (i) PBS, (ii) 0.5 μg NST with MC3, (iii) 2.5 μg NST with MC3, (iv) 5 μg IL12 miR122 with MC3, (v) 2.5 μg IL12 miR122 with MC3, (vi) 0.5 μg NST with Compound 18, (vii) 2.5 μg NST with Compound 18, (viii) 5 μg IL12 miR122, (ix) 0.5 μg IL12 miR122 with Compound 18, and (x) 2.5 μg IL12 miR122 with Compound 18. Figure 59C shows the fold increase in IL12 with the Compound 18-formulated composition compared to the MC3-formulated composition. [Figure 60] Figures 60A and 60B are graphs showing increased levels of IFNγ in plasma (Figure 60A) and tumors (Figure 60B) at 6 and 24 hours after IL12 mRNA was administered to mice bearing A20 tumors. From left to right, mice received (i) PBS, (ii) 0.5 μg NST with MC3, (iii) 2.5 μg NST with MC3, (iv) 5 μg NST with MC3, (v) 0.5 μg IL12 with MC3, (vi) 2.5 μg IL12 with MC3, (vii) 5 μg IL12 with MC3, (viii) 0.5 μg IL12 miR122 with MC3, (ix) 2.5 μg IL12 miR122 with MC3, (x) 5 μg IL12 miR122 with MC3, (xi) 0.5 μg NST with compound 18, (xii) 2.5 μg NST with compound 18, (xiii) 0.5 μg IL12 miR122 with compound 18, and (xiv) 2.5 μg IL12 with compound 18. miR122 was given. [Figure 61]Figures 61A and 61B are graphs showing increased levels of IP10 in plasma (Figure 61A) and tumors (Figure 61B) at 6 and 24 hours after IL12 mRNA was administered to mice bearing A20 tumors. From left to right, mice received (i) PBS, (ii) 0.5 μg NST with MC3, (iii) 2.5 μg NST with MC3, (iv) 5 μg NST with MC3, (v) 0.5 μg IL12 with MC3, (vi) 2.5 μg IL12 with MC3, (vii) 5 μg IL12 with MC3, (viii) 0.5 μg IL12 miR122 with MC3, (ix) 2.5 μg IL12 miR122 with MC3, (x) 5 μg IL12 miR122 with MC3, (xi) 0.5 μg NST with compound 18, (xii) 2.5 μg NST with compound 18, (xiii) 0.5 μg IL12 miR122 with compound 18, and (xiv) 2.5 μg IL12 with compound 18. miR122 was given. [Figure 62] Figures 62A and 62B are graphs showing reduced levels of IL6 in plasma (Figure 62A) and tumors (Figure 62B) at 6 and 24 hours after administration of IL12 mRNA. From left to right, mice received (i) PBS, (ii) 0.5 μg NST with MC3, (iii) 2.5 μg NST with MC3, (iv) 5 μg NST with MC3, (v) 0.5 μg IL12 with MC3, (vi) 2.5 μg IL12 with MC3, (vii) 5 μg IL12 with MC3, (viii) 0.5 μg IL12 miR122 with MC3, (ix) 2.5 μg IL12 miR122 with MC3, (x) 5 μg IL12 miR122 with MC3, (xi) 0.5 μg NST with compound 18, (xii) 2.5 μg NST with compound 18, (xiii) 0.5 μg IL12 miR122 with compound 18, and (xiv) 2.5 μg IL12 with compound 18. miR122 was given. [Figure 63]Figures 63A and 63B are graphs showing reduced levels of G-CSF in plasma (Figure 63A) and tumors (Figure 63B) at 6 and 24 hours after administration of IL12 mRNA. From left to right, mice received (i) PBS, (ii) 0.5 μg NST with MC3, (iii) 2.5 μg NST with MC3, (iv) 5 μg NST with MC3, (v) 0.5 μg IL12 with MC3, (vi) 2.5 μg IL12 with MC3, (vii) 5 μg IL12 with MC3, (viii) 0.5 μg IL12 miR122 with MC3, (ix) 2.5 μg IL12 miR122 with MC3, (x) 5 μg IL12 miR122 with MC3, (xi) 0.5 μg NST with compound 18, (xii) 2.5 μg NST with compound 18, (xiii) 0.5 μg IL12 miR122 with compound 18, and (xiv) 2.5 μg IL12 with compound 18. miR122 was given. [Figure 64] Figures 64A and 64B are graphs showing reduced levels of GORa in plasma (Figure 64A) and tumors (Figure 64B) at 6 and 24 hours after administration of IL12 mRNA. From left to right, mice received (i) PBS, (ii) 0.5 μg NST with MC3, (iii) 2.5 μg NST with MC3, (iv) 5 μg NST with MC3, (v) 0.5 μg IL12 with MC3, (vi) 2.5 μg IL12 with MC3, (vii) 5 μg IL12 with MC3, (viii) 0.5 μg IL12 miR122 with MC3, (ix) 2.5 μg IL12 miR122 with MC3, (x) 5 μg IL12 miR122 with MC3, (xi) 0.5 μg NST with compound 18, (xii) 2.5 μg NST with compound 18, (xiii) 0.5 μg IL12 miR122 with compound 18, and (xiv) 2.5 μg IL12 with compound 18. miR122 was given. [Figure 65] Figures 65A and 65B are graphs showing individual tumor volumes by day 35 after A20 tumor-induced disease following treatment with IL12_miR122 mRNA (Figure 65B) compared to negative control mRNA (Figure 65A). [Figure 66] Figures 66A and 66B are graphs showing individual body weight measurements of mice up to day 35 after A20 tumor-induced disease following treatment with IL12_miR122 mRNA (Figure 66B) compared to negative control mRNA (Figure 66A). [Figure 67] Graph depicting bioluminescence (BL) as a surrogate for tumor burden at day 22 after disease induced by luciferase-enabled MC38 colon cancer cell line in mice. From left to right, mice received no treatment, 2 μg mIL12_miRless, 2 μg mIL12_miR122, 2 μg NST_OX40L_122, 4 μg mIL12_miRless, 4 μg mIL12_miR122, 4 μg NST_OX40L_122, and 1 μg rm IL12. [Figure 68] Kaplan-Meier curve showing survival of mice treated with LNPs carrying IL12 mRNA compared to the NST-OX40L negative control. The graph shows survival up to day 60 after implantation of A20 tumors. [Figure 69] (Figure 69A) A diagrammatic representation of the Fc-IL15R-IL15 fusion construct is shown. The construct consists of (i) a signal peptide, (ii) an Fc region, and (iii) an IL15R linked at its 3' end to the 5' end of IL15 via a linker. (Figure 69B) Body weight change is shown following administration of modified mRNA encoding wild-type IL15 (hOptIL15) with or without another agent. Other agents include modified mRNA encoding either wild-type IL15Ra or IL15RaECD (mouse or human), recombinant IL15 protein, or NST-OX40L. Body weight change was measured at various time points up to 2 weeks after administration. [Figure 70] 1 shows the levels of IL15 protein measured in plasma after a single IV administration of modified mRNA encoding wild-type IL15 (hOptIL15) with or without another agent. [Figure 71]FIG. 1 shows spleen weights after a single IV co-administration of modified mRNA encoding wild-type IL15 (hOptIL15) with modified mRNA encoding wild-type IL15Ra. [Figure 72] Figure 1 shows splenocyte counts after a single IV co-administration of modified mRNA encoding wild-type IL15 (hOptIL15) with modified mRNA encoding wild-type IL15Ra. Splenocytes were further classified into CD8a+ T cells, NK T cells, NK cells, CD4+ T cells, and B cells. [Figure 73] 1 is a diagram of IL18 polypeptides used herein. IL18WT polypeptide represents wild-type IL18 polypeptide (SEQ ID NO: 564). The vertical line represents the cleavage site where caspase-1 removes the 35 amino acid signal peptide. tPA-IL18 polypeptide is wild-type IL18 mature peptide (SEQ ID NO: 572) with a tissue plasminogen activator signal peptide at the N-terminus. IL2sp-IL18 peptide is wild-type IL18 mature peptide (SEQ ID NO: 574) with an IL12 signal peptide at the N-terminus. [Figure 74] Figure 74A is a plot showing the expression of both human IL18 (hIL18) and murine IL18 (mIL18) in HeLa cells. Detection of IL18 polypeptide was performed as described in the Examples below. Mock represents cells transfected with control mRNA. mRNA encoding wild-type IL18 (IL18WT), IL18 with a tissue plasminogen activator signal peptide (tPA-IL18), and IL18 with an IL12 signal peptide (IL2sp-IL18) were transfected as indicated. The presence of IL18 polypeptide in HeLa cell lysates indicates that the polypeptide was not secreted from the cells, whereas the presence of IL18 polypeptide in the supernatant indicates that the polypeptide was secreted. Figure 74B is a plot showing the biological activity of both mIL2sp-mIL18 and mIL18 polypeptides upon contact with CTLL2 in the presence of IL12. Bioactivity was measured by determining the amount of IFN-γ present in the supernatant of CTLL2 cells, as described in the Examples. [Figure 75] Figures 75A and 75B show graphs of the in vivo efficacy of IL23- and IL18-modified mRNA in a B cell lymphoma model. A20 B cell lymphoma cells were established subcutaneously in BALB / c mice, followed by administration of 12.5 μg mRNA doses on days 18, 25, and 32 after tumor implantation. Mice were administered either IL23 mRNA (Figure 75A) or a mixture of IL23 and IL18 mRNA (Figure 75B). The graphs represent individual plots of the growth of each tumor over time, starting on day 18 after implantation. [Figure 76] 1 shows a schematic diagram of a single-chain IL12B linker (G6S)-IL23A fusion protein comprising an IL12B polypeptide linked at its 3' end to the 5' end of an IL23A polypeptide by a GS linker. [Figure 77] Figures 77A and 77B provide graphs of the in vivo efficacy of mIL23-encoded mRNA in a B cell lymphoma model. A20 B cell lymphoma cells were established subcutaneously in BALB / c mice, followed by administration of 12.5 μg mRNA doses on days 18, 25, and 32 after tumor implantation. Mice were administered either IL23 mRNA (Figure 77B) or control mRNA, i.e., NST FIX (Figure 77A). The graphs represent individual plots of the growth of each tumor over time, starting on day 18 after implantation. [Figure 78] Figures 78A and 78B provide graphs showing the efficacy of interleukins in a mouse model of melanoma, as depicted by Wang et al., J. Dermatological Sci. 36:66-68 (2004). B16 melanoma cells were established subcutaneously in C57BL / 6J mice and subsequently administered plasmid vectors designed to express IL12 (pcDNA-IL12), IL18 (pcDNA-mproIL18 / mouse), IL23 (pcDNA-IL23), or a GFP control (phGFP-105-C1). Figure 78A shows the mean tumor volume for each group. Final Kaplan-Meier survival curves were generated and are shown in Figure 78B. [Figure 79] Figures 79A and 79B provide graphs of the in vivo efficacy of mRNA encoding IL23 and mRNA encoding IL18 in a B cell lymphoma model. A20 B cell lymphoma cells were established subcutaneously in BALB / c mice, followed by administration of 12.5 μg mRNA doses on days 18, 25, and 32 after tumor implantation. Mice were administered either IL23 mRNA alone (Figure 79A) or a mixture of IL23 and IL18 mRNA (Figure 79B). The graphs represent individual plots of the growth of each tumor over time, starting on day 18 after implantation. [Figure 80]Figures 80A-103A represent metrics of RNA composition, such as (U) metric, (G) metric, (C) metric, (G / C) metric, and G / C composition bias at codon positions 1, 2, and 3. The column labeled "U Content (%)" corresponds to the parameter %UTL. The column labeled "U Content vs. WT (%)" corresponds to %UWT. The column labeled "U Content vs. Theoretical Min (%)" corresponds to %UTM. The column labeled "G Content (%)" corresponds to %GTL. The column labeled "G Content vs. WT (%)" corresponds to %GWT. The column labeled "G Content vs. Theoretical Max (%)" corresponds to %GTMX. The column labeled "C Content (%)" corresponds to %CTL. The column labeled "C Content vs. WT (%)" corresponds to %CWT. The column labeled "C content vs. theoretical maximum (%)" corresponds to %CTMX. The column labeled "G / C content (%)" corresponds to %G / CTL. The column labeled "G / C content vs. WT (%)" corresponds to %G / CWT. The column labeled "G / C content vs. theoretical maximum (%)" corresponds to %G / CTMX. The statistical descriptions (maximum, minimum, mean, median, and standard deviation) in each table correspond to the population of sequence-optimized polynucleotides. For example, in Figure 80A, the first row under the heading "Protein" indicates the construct analyzed ("Treme-LC-VL"), followed by the amino acid length of the protein construct ("107"), the theoretical minimum U content (%) of the encoding nucleic acid ("11.21%), the theoretical minimum U (absolute) content of the encoding nucleic acid ("36"), and the number of phenylalanine-encoding codons ("5"). The first row under the heading "Nucleic Acid" again contains the name of the construct, its nucleobase length, and a compositional description. The remaining rows provide the distribution of different compositional parameters (maximum, minimum, mean, median, and standard deviation) of the population of 25 sequence-optimized polynucleotides encoding the particular construct. The same structure is used in the remaining composition tables in Figures 80A-103A.The same structure applies to codon bias tables such as Figure 88A, except that instead of nucleobase composition values, the columns correspond to the total GC content in the polynucleotide ("GC") and the GC content at positions 1, 2, and 3 of each codon in the polynucleotide. Figure 80A shows the uracil (U) metric corresponding to the VL domain of the light chain of tremelimumab and 25 sequence-optimized polynucleotides corresponding to that domain. Figure 80B shows the guanine (G) metric corresponding to the VL domain of the light chain of tremelimumab and 25 sequence-optimized polynucleotides corresponding to that domain. Figure 80C shows the cytosine (C) metric corresponding to the VL domain of the light chain of tremelimumab and 25 sequence-optimized polynucleotides corresponding to that domain. Figure 80D shows the guanine plus cytosine (G / C) metric corresponding to the VL domain of the light chain of tremelimumab and 25 sequence-optimized polynucleotides corresponding to that domain. [Figure 81] Figure 81A shows the uracil (U) metric for the VH domain of the heavy chain of tremelimumab and the corresponding 50 sequence-optimized polynucleotides for that domain. Figure 81B shows the guanine (G) metric for the VH domain of the heavy chain of tremelimumab and the corresponding 50 sequence-optimized polynucleotides for that domain. Figure 81C shows the cytosine (C) metric for the VH domain of the heavy chain of tremelimumab and the corresponding 50 sequence-optimized polynucleotides for that domain. Figure 81D shows the guanine + cytosine (G / C) metric for the VH domain of the heavy chain of tremelimumab and the corresponding 50 sequence-optimized polynucleotides for that domain. [Figure 82]Figure 82A shows the uracil (U) metric for the VL domain of the light chain of ipilimumab and the 25 sequence-optimized polynucleotides corresponding to that domain. Figure 82B shows the guanine (G) metric for the VL domain of the light chain of ipilimumab and the 25 sequence-optimized polynucleotides corresponding to that domain. Figure 82C shows the cytosine (C) metric for the VL domain of the light chain of ipilimumab and the 25 sequence-optimized polynucleotides corresponding to that domain. Figure 82D shows the guanine + cytosine (G / C) metric for the VL domain of the light chain of ipilimumab and the 25 sequence-optimized polynucleotides corresponding to that domain. [Figure 83] Figure 83A shows the uracil (U) metric for the VH domain of the heavy chain of ipilimumab and the corresponding 25 sequence-optimized polynucleotides for that domain. Figure 83B shows the guanine (G) metric for the VH domain of the heavy chain of ipilimumab and the corresponding 25 sequence-optimized polynucleotides for that domain. Figure 83C shows the cytosine (C) metric for the VH domain of the heavy chain of ipilimumab and the corresponding 25 sequence-optimized polynucleotides for that domain. Figure 83D shows the guanine + cytosine (G / C) metric for the VH domain of the heavy chain of ipilimumab and the corresponding 25 sequence-optimized polynucleotides for that domain. [Figure 84]Figure 84A shows the uracil (U) metric for the light chain constant domain (CL) used in the tremelimumab and ipilimumab constructs, along with the corresponding 25 sequence-optimized polynucleotides. Figure 84B shows the guanine (G) metric for the light chain constant domain (CL) used in the tremelimumab and ipilimumab constructs, along with the corresponding 25 sequence-optimized polynucleotides. Figure 84C shows the cytosine (C) metric for the light chain constant domain (CL) used in the tremelimumab and ipilimumab constructs, along with the corresponding 25 sequence-optimized polynucleotides. Figure 84D shows the guanine + cytosine (G / C) metric for the light chain constant domain (CL) used in the tremelimumab and ipilimumab constructs, along with the corresponding 25 sequence-optimized polynucleotides. [Figure 85] Figure 85A shows the uracil (U) metric for 25 sequence-optimized polynucleotides corresponding to the IgG2 heavy chain constant region (CH) and its domains used in tremelimumab constructs. Figure 85B shows the guanine (G) metric for 25 sequence-optimized polynucleotides corresponding to the IgG2 heavy chain constant region (CH) and its domains used in tremelimumab constructs. Figure 85C shows the cytosine (C) metric for 25 sequence-optimized polynucleotides corresponding to the IgG2 heavy chain constant region (CH) and its domains used in tremelimumab constructs. Figure 85D shows the guanine + cytosine (G / C) metric for 25 sequence-optimized polynucleotides corresponding to the IgG2 heavy chain constant region (CH) and its domains used in tremelimumab constructs. [Figure 86]Figure 86A shows the uracil (U) metric for the IgG1 heavy chain constant region (CH) used in tremelimumab and ipilimumab constructs, as well as the corresponding 50 sequence-optimized polynucleotides for that domain. Figure 86B shows the guanine (G) metric for the IgG1 heavy chain constant region (CH) used in tremelimumab and ipilimumab constructs, as well as the corresponding 50 sequence-optimized polynucleotides for that domain. Figure 86C shows the cytosine (C) metric for the IgG1 heavy chain constant region (CH) used in tremelimumab and ipilimumab constructs, as well as the corresponding 50 sequence-optimized polynucleotides for that domain. Figure 86D shows the guanine + cytosine (G / C) metric for the IgG1 heavy chain constant region (CH) used in tremelimumab and ipilimumab constructs, as well as the corresponding 50 sequence-optimized polynucleotides for that domain. [Figure 87-1] Figures 87A and 87B show the uracil (U) metric corresponding to wild-type CD80 and 25 sequence-optimized CD80 polynucleotides (Figure 87A), and wild-type Fc region and 25 sequence-optimized Fc region polynucleotides (Figure 87B). Figures 87C and 87D show the guanine (G) metric corresponding to wild-type CD80 and 25 sequence-optimized CD80 polynucleotides (Figure 87C), and wild-type Fc region and 25 sequence-optimized Fc region polynucleotides (Figure 87D). Figures 87E and 87F show the cytosine (C) metric corresponding to wild-type CD80 and 25 sequence-optimized CD80 polynucleotides (Figure 87E), and wild-type Fc region and 25 sequence-optimized Fc region polynucleotides (Figure 87F). Figures 87G and 87H show the guanine plus cytosine (G / C) metric corresponding to wild-type CD80 and 25 sequence-optimized CD80 polynucleotides (Figure 87G), and wild-type Fc region and 25 sequence-optimized Fc region polynucleotides (Figure 87H). [Figure 87-2]Figures 87A and 87B show the uracil (U) metric corresponding to wild-type CD80 and 25 sequence-optimized CD80 polynucleotides (Figure 87A), and wild-type Fc region and 25 sequence-optimized Fc region polynucleotides (Figure 87B). Figures 87C and 87D show the guanine (G) metric corresponding to wild-type CD80 and 25 sequence-optimized CD80 polynucleotides (Figure 87C), and wild-type Fc region and 25 sequence-optimized Fc region polynucleotides (Figure 87D). Figures 87E and 87F show the cytosine (C) metric corresponding to wild-type CD80 and 25 sequence-optimized CD80 polynucleotides (Figure 87E), and wild-type Fc region and 25 sequence-optimized Fc region polynucleotides (Figure 87F). Figures 87G and 87H show the guanine plus cytosine (G / C) metric corresponding to wild-type CD80 and 25 sequence-optimized CD80 polynucleotides (Figure 87G), and wild-type Fc region and 25 sequence-optimized Fc region polynucleotides (Figure 87H). [Figure 88] Figures 88A and 88B show a comparison of the G / C composition bias at codon positions 1, 2, and 3 corresponding to wild-type CD80 and 25 sequence-optimized CD80 polynucleotides (Figure 88A), and wild-type Fc region and 25 sequence-optimized Fc region polynucleotides (Figure 88B). [Figure 89] Figure 89A shows the uracil (U) metric corresponding to wild-type caTLR4 and 25 sequence-optimized caTLR4 polynucleotides. Figure 89B shows the guanine (G) metric corresponding to wild-type caTLR4 and 25 sequence-optimized caTLR4 polynucleotides. Figure 89C shows the cytosine (C) metric corresponding to wild-type caTLR4 and 25 sequence-optimized caTLR4 polynucleotides. Figure 89D shows the guanine plus cytosine (G / C) metric corresponding to wild-type caTLR4 and 25 sequence-optimized caTLR4 polynucleotides. [Figure 90] Figure 90 shows a comparison of G / C composition bias at codon positions 1, 2, and 3 corresponding to wild-type caTLR4 (TLR4ca-WT row) and 25 sequence-optimized caTLR4 polynucleotides (total rows). [Figure 91]Figure 91A shows the uracil (U) metric corresponding to wild-type IL12B and 20 sequence-optimized IL12B polynucleotides (hIL12AB_001 to hIL12AB_020). Figure 91B shows the guanine (G) metric corresponding to wild-type IL12B and 20 sequence-optimized IL12B polynucleotides (hIL12AB_001 to hIL12AB_020). Figure 91C shows the cytosine (C) metric corresponding to wild-type IL12B and 20 sequence-optimized IL12B polynucleotides (hIL12AB_001 to hIL12AB_020). Figure 91D shows the guanine plus cytosine (G / C) metric corresponding to wild-type IL12B and 20 sequence-optimized IL12B polynucleotides (hIL12AB_001 to hIL12AB_020). [Figure 92] Figure 92A shows the uracil (U) metric corresponding to wild-type IL12B and 20 sequence-optimized IL12B polynucleotides (hIL12AB_021 to hIL12AB_040). Figure 92B shows the guanine (G) metric corresponding to wild-type IL12B and 20 sequence-optimized IL12B polynucleotides (hIL12AB_021 to hIL12AB_040). Figure 92C shows the cytosine (C) metric corresponding to wild-type IL12B and 20 sequence-optimized IL12B polynucleotides (hIL12AB_021 to hIL12AB_040). Figure 92D shows the guanine plus cytosine (G / C) metric corresponding to wild-type IL12B and 20 sequence-optimized IL12B polynucleotides (hIL12AB_021 to hIL12AB_040). [Figure 93]Figure 93A shows the uracil (U) metric corresponding to wild-type IL12A and 20 sequence-optimized IL12A polynucleotides (hIL12AB_001 to hIL12AB_020). Figure 93B shows the guanine (G) metric corresponding to wild-type IL12A and 20 sequence-optimized IL12A polynucleotides (hIL12AB_001 to hIL12AB_020). Figure 93C shows the cytosine (C) metric corresponding to wild-type IL12A and 20 sequence-optimized IL12A polynucleotides (hIL12AB_001 to hIL12AB_020). Figure 93D shows the guanine plus cytosine (G / C) metric corresponding to wild-type IL12A and 20 sequence-optimized IL12A polynucleotides (hIL12AB_001 to hIL12AB_020). [Figure 94] Figure 94A shows the uracil (U) metric corresponding to wild-type IL12A and 20 sequence-optimized IL12A polynucleotides (hIL12AB_021 to hIL12AB_040). Figure 94B shows the guanine (G) metric corresponding to wild-type IL12A and 20 sequence-optimized IL12A polynucleotides (hIL12AB_021 to hIL12AB_040). Figure 94C shows the cytosine (C) metric corresponding to wild-type IL12A and 20 sequence-optimized IL12A polynucleotides (hIL12AB_021 to hIL12AB_040). Figure 94D shows the guanine plus cytosine (G / C) metric corresponding to wild-type IL12A and 20 sequence-optimized IL12A polynucleotides (hIL12AB_021 to hIL12AB_040). The column labeled "G / C content (%)" corresponds to the % G / CTL. [Figure 95]Figure 95A shows a comparison of the G / C composition bias at codon positions 1, 2, and 3 corresponding to wild-type IL12B and 20 sequence-optimized IL12B polynucleotides (hIL12AB_001 to hIL12AB_020). Figure 95B shows a comparison of the G / C composition bias at codon positions 1, 2, and 3 corresponding to wild-type IL12B and 20 sequence-optimized IL12B polynucleotides (hIL12AB_021 to hIL12AB_040). Figure 95C shows a comparison of the G / C composition bias at codon positions 1, 2, and 3 corresponding to wild-type IL12A and 20 sequence-optimized IL12A polynucleotides (hIL12AB_0-1 to hIL12AB_020). Figure 95D shows a comparison of G / C composition bias at codon positions 1, 2, and 3 corresponding to wild-type IL12A and 20 sequence-optimized IL12A polynucleotides (hIL12AB_021 to hIL12AB_040). [Figure 96]Figure 96A shows the uracil (U) metric corresponding to wild-type IL15 in IL15opt-tPa6 and 50 sequence-optimized IL15opt-tPa6 polynucleotides (IL15opt-tPa6-CO01 to IL15opt-tPa6-CO50). Figure 96B shows the guanine (G) metric corresponding to wild-type IL15 in IL15opt-tPa6 and 50 sequence-optimized IL15opt-tPa6 polynucleotides (IL15opt-tPa6-CO01 to IL15opt-tPa6-CO50). Figure 96C shows the cytosine (C) metric corresponding to wild-type IL15 in IL15opt-tPa6 and 50 sequence-optimized IL15opt-tPa6 polynucleotides (IL15opt-tPa6-CO01 to IL15opt-tPa6-CO50). Figure 96D shows the guanine plus cytosine (G / C) metric corresponding to wild-type IL15 in IL15opt-tPa6 and 50 sequence-optimized IL15opt-tPa6 polynucleotides (IL15opt-tPa6-CO01 to IL15opt-tPa6-CO50). Figure 96E shows a comparison of the G / C composition bias at codon positions 1, 2, and 3 corresponding to wild-type IL15 in IL15opt-tPa6 and 50 sequence-optimized IL15opt-tPa6 polynucleotides (IL15opt-tPa6-CO01 to IL15opt-tPa6-CO50). [Figure 97]Figure 97A shows the uracil (U) metric corresponding to the Sushi domain of wild-type IL15Ra in 25 sequence-optimized IL15_RLI (IL15_RLI-CO01 to IL15_RLI-CO25) and 25 sequence-optimized IL15_Fc_RLI (IL15_Fc_RLI-CO01 to IL15_Fc_RLI-CO25) polynucleotides. Figure 97B shows the guanine (G) metric corresponding to the Sushi domain of wild-type IL15Ra in 25 sequence-optimized IL15_RLI (IL15_RLI-CO01 to IL15_RLI-CO25) and 25 sequence-optimized IL15_Fc_RLI (IL15_Fc_RLI-CO01 to IL15_Fc_RLI-CO25) polynucleotides. Figure 97C shows the cytosine (C) metric corresponding to the Sushi domain of wild-type IL15Ra in 25 sequence-optimized IL15_RLI (IL15_RLI-CO01 to IL15_RLI-CO25) and 25 sequence-optimized IL15_Fc_RLI (IL15_Fc_RLI-CO01 to IL15_Fc_RLI-CO25) polynucleotides. Figure 97D shows the guanine plus cytosine (G / C) metric corresponding to the Sushi domain of wild-type IL15Ra in 25 sequence-optimized IL15_RLI (IL15_RLI-CO01 to IL15_RLI-CO25) and 25 sequence-optimized IL15_Fc_RLI (IL15_Fc_RLI-CO01 to IL15_Fc_RLI-CO25) polynucleotides. Figure 97E shows a comparison of the G / C composition bias at codon positions 1, 2, and 3, corresponding to the Sushi domain of wild-type IL15Ra, in 25 sequence-optimized IL15_RLI (IL15_RLI-CO01 to IL15_RLI-CO25) and 25 sequence-optimized IL15_Fc_RLI (IL15_Fc_RLI-CO01 to IL15_Fc_RLI-CO25). [Figure 98]Figure 98A shows the uracil (U) metric corresponding to wild-type IL15Ra in IL15Ra_WT_miR122 and 25 sequence-optimized IL15Ra_WT_miR122 polynucleotides (IL15Ra_WT_miR122-CO01 to IL15Ra_WT_miR122-CO25). Figure 98B shows the guanine (G) metric corresponding to wild-type IL15Ra in IL15Ra_WT_miR122 and 25 sequence-optimized IL15Ra_WT_miR122 polynucleotides (IL15Ra_WT_miR122-CO01 to IL15Ra_WT_miR122-CO25). Figure 98C shows the cytosine (C) metric corresponding to wild-type IL15Ra in IL15Ra_WT_miR122 and 25 sequence-optimized IL15Ra_WT_miR122 polynucleotides (IL15Ra_WT_miR122-CO01 to IL15Ra_WT_miR122-CO25). Figure 98D shows the guanine plus cytosine (G / C) metric corresponding to wild-type IL15Ra in IL15Ra_WT_miR122 and 25 sequence-optimized IL15Ra_WT_miR122 polynucleotides (IL15Ra_WT_miR122-CO01 to IL15Ra_WT_miR122-CO25). Figure 98E shows a comparison of the G / C composition bias at codon positions 1, 2, and 3 corresponding to wild-type IL15Ra in IL15Ra_WT_miR122 and 25 sequence-optimized IL15Ra_WT_miR122 polynucleotides (IL15Ra_WT_miR122-CO01 to IL15Ra_WT_miR122-CO25). [Figure 99]Figure 99A shows uracil (U) metric corresponding to wild-type IL15 in 25 IL15-RLI sequence-optimized (IL15-RLI-CO01 to IL15-RLI-CO25) and 25 IL15-Fc-RLI sequence-optimized (IL15_Fc_RLI-CO01 to IL15_Fc_RLI-CO25) polynucleotides, wild-type IL15Rα, and 20 sequence-optimized IL15Rα polynucleotides (hIL15RαB_021 to hIL15RαB_040). Figure 99B shows the guanine (G) metric corresponding to wild-type IL15 in 25 IL15-RLI sequence-optimized (IL15-RLI-CO01 to IL15-RLI-CO25) and 25 IL15-Fc-RLI sequence-optimized (IL15_Fc_RLI-CO01 to IL15_Fc_RLI-CO25) polynucleotides. Figure 99C shows the cytosine (C) metric corresponding to wild-type IL15 in 25 IL15-RLI sequence-optimized (IL15-RLI-CO01 to IL15-RLI-CO25) and 25 IL15-Fc-RLI sequence-optimized (IL15_Fc_RLI-CO01 to IL15_Fc_RLI-CO25) polynucleotides. Figure 99D shows the guanine plus cytosine (G / C) metric corresponding to wild-type IL15 in 25 IL15-RLI sequence-optimized (IL15-RLI-CO01 to IL15-RLI-CO25) and 25 IL15-Fc-RLI sequence-optimized (IL15_Fc_RLI-CO01 to IL15_Fc_RLI-CO25) polynucleotides. Figure 99E shows a comparison of the G / C composition bias at codon positions 1, 2, and 3 corresponding to the Sushi domain of wild-type IL15 in 25 IL15-RLI sequence-optimized (IL15-RLI-CO01 to IL15-RLI-CO25) and 25 IL15-Fc-RLI sequence-optimized (IL15_Fc_RLI-CO01 to IL15_Fc_RLI-CO25) polynucleotides. [Figure 100]Figure 100A shows the uracil (U) metric corresponding to the wild-type IL18 mature peptide (tPANIL18wt) with an N-terminal tissue plasminogen activator (tPA) signal peptide and 25 sequence-optimized IL18 polynucleotides with the tPA signal peptide. Figure 100B shows the guanine (G) metric corresponding to tPANIL18wt and 25 sequence-optimized IL18 polynucleotides with the tPA signal peptide. Figure 100C shows the cytosine (C) metric corresponding to tPANIL18wt and 25 sequence-optimized IL18 polynucleotides with the tPA signal peptide. Figure 100D shows the guanine + cytosine (G / C) metric corresponding to tPANIL18wt and 25 sequence-optimized IL18 polynucleotides with the tPA signal peptide. FIG. 100E shows a comparison of G / C composition bias at codon positions 1, 2, and 3 corresponding to tPANIL18wt and 25 sequence-optimized IL18 polynucleotides with the tPA signal peptide. [Figure 101] Figure 101A shows the uracil (U) metric corresponding to the wild-type IL18 mature peptide (IL2spIL18wt) with an N-terminal interleukin-2 signal peptide (IL2sp) and 25 sequence-optimized IL18 polynucleotides with an IL2 signal peptide. Figure 101B shows the guanine (G) metric corresponding to IL2spIL18wt and 25 sequence-optimized IL18 polynucleotides with an IL2 signal peptide. Figure 101C shows the cytosine (C) metric corresponding to IL2spIL18wt and 25 sequence-optimized IL18 polynucleotides with an IL2 signal peptide. Figure 101D shows the guanine + cytosine (G / C) metric corresponding to IL2spIL18wt and 25 sequence-optimized IL18 polynucleotides with an IL2 signal peptide. FIG. 101E shows a comparison of G / C composition bias at codon positions 1, 2, and 3 corresponding to IL2spIL18wt and 25 sequence-optimized IL18 polynucleotides with the IL2 signal peptide. [Figure 102]Figure 102A shows uracil (U) metric values corresponding to wild-type IL12B and 25 sequence-optimized IL12B polynucleotides. Figure 102B shows guanine (G) metric values corresponding to wild-type IL12B and 25 sequence-optimized IL12B polynucleotides. Figure 102C shows cytosine (C) metric values corresponding to wild-type IL12B and 25 sequence-optimized IL12B polynucleotides. Figure 102D shows guanine + cytosine (G / C) metric values corresponding to wild-type isoform 1 of IL12 and 25 sequence-optimized IL12 polynucleotides. Figure 102E shows a comparison of G / C composition bias at codon positions 1, 2, and 3 corresponding to wild-type IL12B and 25 sequence-optimized IL12B polynucleotides. [Figure 103] Figure 103A shows uracil (U) metric values corresponding to wild-type IL23A and 25 sequence-optimized IL23A polynucleotides. Figure 103B shows guanine (G) metric values corresponding to wild-type IL23A and 25 sequence-optimized IL23A polynucleotides. Figure 103C shows cytosine (C) metric values corresponding to wild-type IL23A and 25 sequence-optimized IL23A polynucleotides. Figure 103D shows guanine + cytosine (G / C) metric values corresponding to wild-type IL23A and 25 sequence-optimized IL23A polynucleotides. Figure 103E shows a comparison of G / C composition bias at codon positions 1, 2, and 3 corresponding to wild-type IL23A and 25 sequence-optimized IL23A polynucleotides. [Figure 104] Figure 104A shows the uracil (U) metric corresponding to wild-type OX40L and 25 sequence-optimized OX40L polynucleotides. Figure 104B shows the guanine (G) metric corresponding to wild-type OX40L and 25 sequence-optimized OX40L polynucleotides. Figure 104C shows the cytosine (C) metric corresponding to wild-type OX40L and 25 sequence-optimized OX40L polynucleotides. Figure 104D shows the guanine + cytosine (G / C) metric corresponding to wild-type OX40L and 25 sequence-optimized OX40L polynucleotides. Figure 104E shows a comparison of G / C composition bias at codon positions 1, 2, and 3 corresponding to wild-type OX40L and 25 sequence-optimized OX40L polynucleotides. [Figure 105] Figures 105A-105D show the protein sequence (Figure 105A, SEQ ID NO: 471), a table of domain characteristics (Figure 105B), and the nucleic acid sequence (Figure 105C, SEQ ID NO: 472) of CD80 (wtCD80). Isoform 2 of wtCD80 has a substitution of amino acids 234-266 of SEQ ID NO: 471 with a Ser residue, and isoform 3 of wtCD80 lacks amino acids 141-266 of SEQ ID NO: 471. [Figure 106] Figures 106A and 106B show CD80-Fc fusion constructs. Figure 106A shows the protein sequence of the CD80-Fc fusion construct (SEQ ID NO: 473). The signal peptide (e.g., the CD80 signal peptide) is in italics, the extracellular (EC) domain of CD80 is underlined, and the Fc region is in bold. Figure 106B shows the corresponding wild-type nucleotide sequence (SEQ ID NO: 474) encoding the CD80-Fc fusion protein. [Figure 107] Figures 107A-107C show the protein sequence (Figure 107A, SEQ ID NO: 523), a table of domain characteristics (Figure 107B), and the nucleic acid sequence (Figure 107C, SEQ ID NO: 524) of wild-type TLR4 (wtTLR4) isoform 1. Isoform 2 of wtTLR4 lacks amino acids 1-40 of SEQ ID NO: 523, and isoform 3 of wtTLR4 lacks amino acids 1-200 of SEQ ID NO: 523. [Figure 108] Figures 108A and 108B show constitutively active TLR4 (caTLR4) constructs. Figure 108A shows the protein sequence (SEQ ID NO: 525). The signal peptide (e.g., lysosomal membrane glycoprotein 1 (LAMP1) signal peptide) is italicized, the extracellular domain is underlined, the transmembrane domain is bold, and the cytoplasmic domain is dotted underlined. Figure 108B shows the corresponding wild-type nucleotide sequence (SEQ ID NO: 526) encoding the signal peptide of LAMP1 and the caTLR4 polypeptide. [Figure 109](Figure 109A) From top to bottom, (1) the wild-type IL12B amino acid sequence (SEQ ID NO: 1035), (2) the wild-type nucleic acid encoding wtIL12B (SEQ ID NO: 1036), (3) the wild-type IL12A amino acid sequence (SEQ ID NO: 1037), (4) the wild-type nucleic acid encoding wtIL12A (SEQ ID NO: 1038), (5) the wild-type IL12B signal peptide amino acid sequence (SEQ ID NO: 1039), and (6) the wild-type nucleic acid encoding wtIL12B signal peptide (SEQ ID NO: 1040). (Figure 109B) A table showing the amino acid numbering in the SEQ ID NO, the nucleotide numbering in the SEQ ID NO, the 5'UTR, the IL12B signal peptide, the mature IL12A and IL12B peptides, and the linker. [Figure 110-1] Figure 110A shows the wild-type IL15Ra amino acid sequence (SEQ ID NO: 808), Figure 110B shows the wild-type nucleic acid encoding wild-type IL15Ra (SEQ ID NO: 809), Figure 110C shows the wild-type IL15 amino acid sequence (SEQ ID NO: 810), and Figure 110D shows the wild-type nucleic acid encoding wild-type IL15 (SEQ ID NO: 811). The signal peptides of wild-type IL15Ra (Figure 110A) and IL15 (Figure 110C) are in italics. The Sushi domain of wild-type IL15Ra and the propeptide of wild-type IL15 are underlined in Figure 110A (double underline) and Figure 110C (bold underline), respectively. Figure 110E shows the wild-type IL15-tPA amino acid sequence (SEQ ID NO: 812). In Figure 110E, the signal peptide is in italics, and mature IL15 is represented by a dotted underline. Figure 110F shows the amino acid sequence of the wild-type Fc-IL15R-IL15 fusion construct (SEQ ID NO: 813). The signal peptide is in italics, the Fc region is shaded, the IL15R polypeptide is double underlined, the linker is in bold, and the IL15 polypeptide is single underlined. [Figure 110-2]Figure 110A shows the wild-type IL15Ra amino acid sequence (SEQ ID NO: 808), Figure 110B shows the wild-type nucleic acid encoding wild-type IL15Ra (SEQ ID NO: 809), Figure 110C shows the wild-type IL15 amino acid sequence (SEQ ID NO: 810), and Figure 110D shows the wild-type nucleic acid encoding wild-type IL15 (SEQ ID NO: 811). The signal peptides of wild-type IL15Ra (Figure 110A) and IL15 (Figure 110C) are in italics. The Sushi domain of wild-type IL15Ra and the propeptide of wild-type IL15 are underlined in Figure 110A (double underline) and Figure 110C (bold underline), respectively. Figure 110E shows the wild-type IL15-tPA amino acid sequence (SEQ ID NO: 812). In Figure 110E, the signal peptide is in italics, and mature IL15 is represented by a dotted underline. Figure 110F shows the amino acid sequence of the wild-type Fc-IL15R-IL15 fusion construct (SEQ ID NO: 813). The signal peptide is in italics, the Fc region is shaded, the IL15R polypeptide is double underlined, the linker is in bold, and the IL15 polypeptide is single underlined. [Figure 111] Figures 111A-111C show the wild-type IL18 protein sequence (Figure 111A, SEQ ID NO: 564), a table of domain characteristics (Figure 111B) and the wild-type IL18 nucleic acid sequence (Figure 111C, SEQ ID NO: 565), (Figure 111D) of isoform 1 of IL18 (wtIL18). [Figure 112] Figures 112A-112C show the wild-type IL18 protein sequence (Figure 112A, SEQ ID NO: 566), a table of domain characteristics (Figure 112B), and the wild-type IL18 nucleic acid sequence (Figure 112C, SEQ ID NO: 567) of isoform 2 of wtIL18. Isoform 2 of wtIL18 lacks amino acids 27-30 of SEQ ID NO: 564. [Figure 113]Figure 113A shows the amino acid sequence of tPA-IL18 (SEQ ID NO: 572). The signal peptide is underlined and the mature protein sequence is in bold. Figure 113B shows the nucleotide sequence of tPA-IL18 (SEQ ID NO: 573). Figure 113C shows the amino acid sequence of IL2-IL18 (SEQ ID NO: 574). Figure 113D shows the nucleotide sequence of IL2-IL18 (SEQ ID NO: 575). [Figure 114] Figure 114A shows the amino acid sequence of IgLC-IL18 (SEQ ID NO: 576). Figure 114B shows the amino acid sequence of IL-1ra-IL18 (SEQ ID NO: 577). Figure 114C shows the amino acid sequence of the IL18 double mutant, containing amino acid substitutions at D71S and D71N (SEQ ID NO: 578). [Figure 115] Figure 115A shows the wild-type IL12B amino acid sequence (SEQ ID NO: 979), Figure 115B shows the wild-type nucleic acid encoding the IL12B polypeptide (SEQ ID NO: 980), Figure 115C shows the wild-type IL23A amino acid sequence (SEQ ID NO: 981), and Figure 115D shows the wild-type nucleic acid encoding the IL23A polypeptide (SEQ ID NO: 982). The signal peptides of both the IL12B and IL23A polypeptides are underlined. [Figure 116] Figure 116A provides the amino acid sequence of the IL12B-linker(G6S)-IL23A fusion protein (SEQ ID NO: 983). Figure 116B provides a table identifying the characteristics of the various domains of the single-chain IL12B-linker(G6S)-IL23A fusion protein. Figure 116C provides the nucleic acid sequence encoding the single-chain IL12B-linker(G6S)-IL23A fusion protein (SEQ ID NO: 984). DETAILED DESCRIPTION OF THE INVENTION
[0099] A particularly exciting approach to treating cancer involves preventing or treating the disease with substances that stimulate the immune response, known as cancer immunotherapy. Cancer immunotherapy, also referred to in the art as immuno-oncology, has begun to revolutionize cancer treatment by introducing therapies that target the host immune system rather than the tumor. These therapies have unique pharmacological responses and therefore represent potentially curative therapies for different types of cancer. Cancers of the lung, kidney, bladder, and skin, among others, have reaped substantial benefits from treatment with immuno-oncology in terms of survival or tumor response, with melanoma potentially showing the greatest benefit. Cancer immunotherapy is often characterized by checkpoint inhibitor treatment using an exciting new class of biologics known as checkpoint inhibitor antibodies.
[0100] The present disclosure provides compositions and methods for the treatment of cancer, particularly cancer immunotherapy combinations and methods. In particular, the present disclosure relates to compositions and methods for cancer treatment using a combinatorial approach featuring mRNAs encoding at least two polypeptides that can promote or enhance an immune response against tumors. Without being bound by theory, it is believed that stimulating an anti-cancer immune response is possible by administering, for example, a first polynucleotide (e.g., mRNA) that includes an open reading frame encoding a first protein (e.g., IL12 or IL23) that is important for stimulating T cells or natural killer cells. Such a priming compound can be administered in combination with, for example, a second polynucleotide (e.g., mRNA) that includes an open reading frame encoding a second protein (e.g., OXL) that provides a second stimulatory signal (i.e., a costimulatory signal) and thus amplifies the immune response elicited by the primer. The combination can include a third component, e.g., a third polynucleotide (e.g., mRNA) that includes an open reading frame encoding a third protein (e.g., anti-CTLA-4) that blocks or inhibits a checkpoint in the immune system (e.g., CTLA-4 or PD-1). Inhibition of the checkpoint further amplifies the immune response.
[0101] In some embodiments, the immunotherapeutic compositions and methods disclosed herein can enhance an immune response and / or induce or enhance anti-cancer memory. Preferred aspects of the present disclosure feature treatment with at least two polynucleotides (e.g., mRNAs) selected from the group consisting of: (i) a polynucleotide (e.g., mRNA) comprising an open reading frame (ORF) encoding an immune response primer polypeptide (e.g., an IL12 or IL23 polypeptide), (ii) a polynucleotide (e.g., mRNA) comprising an ORF encoding an immune response costimulatory signal polypeptide (e.g., an OX40L polypeptide), (iii) a polynucleotide (e.g., mRNA) comprising an ORF encoding a checkpoint inhibitor polypeptide or a checkpoint inhibitor polypeptide (e.g., an anti-CTLA-4 antibody), and combinations thereof.
[0102] Exemplary embodiments feature treatment with the above-described combinations or mRNA (i.e., mRNA encoding an immune response primer polypeptide, an immune response costimulatory signal polypeptide, a checkpoint inhibitor polypeptide, or a combination thereof) encapsulated in lipid nanoparticles (LNPs). In some exemplary embodiments, these LNPs are cationic lipid-based LNPs and can be administered, for example, intratumorally.
[0103] Thus, the present disclosure is directed to, for example, compositions, pharmaceutical formulations comprising such compositions, and methods for treating cancer (e.g., methods for reducing or decreasing tumor size or inhibiting tumor growth in a subject in need thereof), comprising administering to a subject in need thereof compositions or formulations disclosed herein. In particular, the present disclosure provides methods for treating cancer (e.g., tumors), comprising administering to a subject in need thereof an effective amount of a combination of mRNAs encoding, for example, an immune response primer polypeptide, an immune response costimulatory signal polypeptide, a checkpoint inhibitor polypeptide, or a combination thereof. In certain embodiments, the mRNA in the therapies disclosed herein is encapsulated in an LNP comprising an ionizable amino lipid of Formula (I), as disclosed below, e.g., Compounds 18, 25, 26, or 48.
[0104] The headings provided herein are not limitations on various aspects or embodiments of the disclosure, but can be defined by reference to the specification as a whole. Accordingly, the immediately following defined terms are more fully defined by reference to the specification in its entirety. Before describing the present disclosure in detail, it is to be understood that this disclosure is not limited to specific compositions or process steps, as these may vary.
[0105] I. Definition In order that this disclosure may be more readily understood, certain terms are first defined. As used in this application, unless otherwise expressly provided herein, each of the following terms shall have the meaning set forth below. Additional definitions are set forth throughout this application.
[0106] The present disclosure includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relates to a given product or process. The present disclosure includes embodiments in which more than one, or all, members of the group are present in, employed in, or otherwise relate to a given product or process.
[0107] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. The term "a" (or "an"), as well as the terms "one or more" and "at least one," can be used interchangeably herein. In certain embodiments, the term "a" or "an" means "one." In other embodiments, the term "a" or "an" includes "two or more" or "plurality."
[0108] Furthermore, "and / or," as used herein, is to be interpreted as a specific disclosure of two specific features or components, each with or without the other feature or component. Thus, the term "and / or" when used in phrases such as "A and / or B" herein is intended to include "A and B," "A or B," "A" (only), and "B" (only). Similarly, the term "and / or" when used in phrases such as "A, B, and / or C" is intended to encompass each of the following aspects: A, B, and C, A, B, or C, A or C, A or B, B or C, A and C, A and B, B and C, A (only), B (only), and C (only).
[0109] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. For example, Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and Oxford Dictionary of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press provide those skilled in the art with a general dictionary of many of the terms used in this disclosure.
[0110] Wherever an embodiment is described herein with the language "comprising," other similar embodiments are also provided that are described with the terms "consisting of" and / or "consisting essentially of."
[0111] Units, prefixes, and symbols are expressed in the form accepted by the International System of Units (SI). Numerical ranges are inclusive of the numbers defining the range. When a range of values is recited, each intervening integer value, and each portion between the recited upper and lower limits of that range, is to be understood as also being specifically disclosed, along with each subrange between such values. The upper and lower limits of any range can be independently included or excluded from the range, and each range in which either, neither, or both of the ranges are included is also included within the scope of the disclosure. When values are explicitly recited, values that are approximately the same quantity or amount as the recited value are to be understood as also being within the scope of the disclosure. When a combination is disclosed, each subcombination of the elements of that combination is also specifically disclosed and is within the scope of the disclosure. Conversely, when different elements or groups of elements are individually disclosed, combinations of those elements are also disclosed. Where any element of the invention is disclosed as having multiple alternatives, embodiments of the invention in which each alternative is excluded singly or in any combination with the other alternatives are also disclosed herein; more than one element of the invention may have such an exclusion, and all combinations of elements with such an exclusion are disclosed herein.
[0112] Nucleotides are represented by their commonly accepted single-letter codes. Unless otherwise specified, nucleic acids are written from left to right in a 5' to 3' orientation. Nucleotides are represented herein by their commonly known single-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Thus, A represents adenine, C represents cytosine, G represents guanine, T represents thymine, and U represents uracil.
[0113] Amino acids are referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Unless otherwise noted, amino acid sequences are written left to right in amino to carboxy direction.
[0114] About: Throughout the specification and claims, the term "about" used in conjunction with numerical values refers to a margin of accuracy known and accepted by those of ordinary skill in the art. Generally, such margin of accuracy is ±10%.
[0115] Further, unless otherwise stated or otherwise apparent from the context and the understanding of one of ordinary skill in the art, values expressed as ranges can be taken to the tenth of the unit of the lower limit of that range, any specific value or subrange within the range set forth in different embodiments of the invention, unless the context clearly dictates otherwise.
[0116] Administered in Combination: As used herein, the term "administered in combination" or "co-administration" means that two or more agents (e.g., mRNAs) are administered to a subject simultaneously or at intervals such that there is an overlap in the effects of each agent. In some embodiments, the agents are administered within about 60, 30, 15, 10, 5, or 1 minute of each other. In some embodiments, the administration of the agents is spaced sufficiently close together to result in a combined (e.g., synergistic) effect. In some embodiments, the co-administration can be simultaneous (i.e., all mRNAs are administered as part of one formulation, or different mRNAs in different formulations are administered simultaneously) or sequential (e.g., several mRNAs in several formulations are administered sequentially).
[0117] Amino acid substitution: The term "amino acid substitution" refers to the substitution of an amino acid residue present in a parent sequence (e.g., a consensus sequence) with another amino acid residue. Amino acids can be substituted in a parent sequence, for example, by chemical peptide synthesis or by recombinant methods known in the art. Thus, a reference to a "substitution at position X" refers to the substitution of the amino acid present at position X with an alternative amino acid residue. In some embodiments, substitution patterns can be described according to the scheme AnY, where A is the one-letter code corresponding to the amino acid naturally or originally present at position n, and Y is the replacement amino acid residue. In other embodiments, substitution patterns can be described according to the scheme An(YZ), where A is the one-letter code corresponding to the amino acid residue substituting for the amino acid naturally or originally present at position X, and Y and Z are the replacement amino acid residues.
[0118] In the context of the present disclosure, substitutions (sometimes referred to as amino acid substitutions) are made at the nucleic acid level, i.e., the substitution of an amino acid residue with an alternative amino acid residue is performed by replacing a codon encoding a first amino acid with a codon encoding a second amino acid.
[0119] Animal: As used herein, the term "animal" refers to any member of the animal kingdom. In some embodiments, "animal" refers to a human at any stage of development. In some embodiments, "animal" refers to a non-human animal at any stage of development. In certain embodiments, the non-human animal is a mammal (e.g., a rodent, mouse, rat, rabbit, monkey, dog, cat, sheep, cow, primate, or pig). In some embodiments, animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, and worms. In some embodiments, the animal is a transgenic animal, a genetically engineered animal, or a clone.
[0120] Approximately: As used herein, the term "approximately" as applied to one or more target values refers to a value similar to a stated reference value. In certain embodiments, the term "approximately" refers to a range of values that is within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction of (above or below) the stated reference value, unless otherwise stated or otherwise clear from the context (except when such number exceeds 100% of possible values).
[0121] Associated with: As used herein with respect to a disease, the term "associated with" means that the symptom, measurement, characteristic, or condition in question is associated with the diagnosis, onset, presence, or progression of the disease. The association may, but need not necessarily, be causally related to the disease. For example, symptoms, sequelae, or any effects that cause a decrease in the quality of life of cancer patients are considered to be cancer-associated, and in some embodiments of the present disclosure, can be treated, ameliorated, or prevented by administering a polynucleotide of the present disclosure to a subject in need thereof.
[0122] The terms "associated with," "conjugated," "bound," "attached," and "tethered," when used in reference to two or more moieties, mean that the moieties are physically associated or connected to one another, either directly or through one or more additional moieties that function as linking agents, to form a structure that is sufficiently stable so that the moieties remain physically associated under the conditions in which the structure is used, e.g., physiological conditions. An "association" need not be strictly through a direct covalent chemical bond. Ionic or hydrogen bonding, or hybridization-based connectivity that is sufficiently stable so that the "associated" elements remain physically associated can also be indicated.
[0123] Bifunctional: As used herein, the term "bifunctional" refers to any substance, molecule, or moiety capable of or maintaining at least two functions. The functions may affect the same or different results. The structures that produce the functions may be the same or different. For example, a bifunctional modified RNA of the present disclosure may include a sequence encoding a CD80 polypeptide (first function), which may be therapeutically active, linked to a sequence encoding Fc (second function), which may extend the half-life of the RNA. In this example, delivery of the bifunctional modified RNA to a subject in need thereof not only produces a peptide or protein molecule that may ameliorate or treat a disease or condition, but also maintains the population of active molecules encoded by the mRNA present in the subject for a longer period of time. In other embodiments, the bifunctional modified mRNA may be a chimeric molecule comprising an mRNA encoding a therapeutically active IL15 polypeptide (first function), which also encodes a second polypeptide (second function), such as IL15Ralpha, either fused to or co-expressed with the first polypeptide.
[0124] Biocompatible: As used herein, the term "biocompatible" means compatible with living cells, tissues, organs, or systems, posing little or no risk of injury, toxicity, or rejection by the immune system.
[0125] Biodegradable: As used herein, the term "biodegradable" means capable of being broken down into non-toxic products by the action of living organisms.
[0126] Biologically active: As used herein, the phrase "biologically active" refers to the characteristic of any substance that has activity in a biological system and / or organism. For example, a substance is considered to be biologically active if, upon administration to an organism, it has a biological effect on that organism. In certain embodiments, polynucleotides of the present disclosure can be considered biologically active even if a portion of the polynucleotide mimics an activity that is considered biologically active or biologically relevant.
[0127] Chimera: As used herein, a "chimera" is an entity having two or more non-identical or heterogeneous parts or regions. For example, a chimeric molecule can include a first part including an IL12B polypeptide, an IL23A polypeptide, or both an IL12B and an IL23A polypeptide, and a second part (e.g., genetically fused to the first part) that includes a second therapeutic protein (e.g., a protein having a specific enzymatic activity, an antigen-binding site, or a part that can extend the plasma half-life of the IL12B and / or IL23A polypeptide, e.g., an Fc region of an antibody).
[0128] Codon substitution: "Codon substitution" or "codon replacement," in the context of codon optimization, refers to the replacement of a codon present in a candidate nucleotide sequence (e.g., an mRNA encoding the heavy or light chain of an antibody or fragment thereof) with another codon. Codons can be replaced within a candidate nucleic acid sequence, for example, by chemical peptide synthesis or by recombinant methods known in the art. Thus, reference to a "substitution" or "replacement" at a particular position within a nucleic acid sequence (e.g., an mRNA) or within a particular region or subsequence of a nucleic acid sequence (e.g., an mRNA) refers to the replacement of a codon at such position or region with an alternative codon.
[0129] A candidate nucleic acid sequence can be codon-optimized by replacing all or some of the codons according to a substitution table map. As used herein, the terms "candidate nucleic acid sequence" and "candidate nucleotide sequence" refer to a nucleotide sequence (e.g., a nucleotide sequence encoding an antibody or functional fragment thereof) whose translational efficiency can be improved by codon optimization. In some embodiments, the candidate nucleotide sequence is optimized to improve translational efficiency after in vivo administration.
[0130] As used herein, the terms "coding region" and "coding region," and grammatical variations thereof, refer to the open reading frame (ORF) of a polynucleotide, which, upon expression, results in a polypeptide or protein.
[0131] Combination therapy: As used herein, the term "combination therapy," and variations such as "therapy administered in combination" or "co-administration," means that two or more agents are administered to a subject simultaneously or at intervals such that there is an overlap in the effects of each agent on the patient. In some embodiments, the agents are administered within about 60, 30, 15, 10, 5, or 1 minute of each other. In some embodiments, the administration of the agents is spaced sufficiently close together so as to result in a combined (e.g., synergistic) effect.
[0132] Compound: As used herein, the term "compound" is meant to include all stereoisomers and isotopes of a depicted structure. As used herein, the term "stereoisomer" refers to any geometric isomer (e.g., cis and trans isomers), enantiomers, or diastereomers of a compound. The present disclosure encompasses any and all stereoisomers of the compounds described herein, including stereomerically pure forms (e.g., geometrically pure, enantiomerically pure, or diastereomeric pure) as well as enantiomeric and stereoisomeric mixtures (e.g., racemates). Enantiomeric and stereoisomeric mixtures of compounds and methods for resolving them into their component optical isomers or stereoisomers are well known. "Isotope" refers to atoms having the same atomic number but different mass numbers due to different numbers of neutrons in their nuclei. For example, isotopes of hydrogen include tritium and deuterium. Additionally, compounds, salts, or complexes of the present disclosure can be prepared in routine combination with solvents or water molecules to form solvates and hydrates.
[0133] Conservative amino acid substitution: A "conservative amino acid substitution" is a substitution in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Amino acid residues with similar side chains have been defined in the art and include those with basic side chains (e.g., lysine, arginine, or histidine), acidic side chains (e.g., aspartic acid or glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, or cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, or tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, or histidine). Therefore, when an amino acid in a polypeptide is replaced with another amino acid with the same side chain, the amino acid substitution is considered conservative. In another embodiment, a string of amino acids can be conservatively replaced by a structurally similar string that differs in the order and / or composition of the side chain companion members.
[0134] Non-conservative amino acid substitutions: Non-conservative amino acid substitutions include (i) substitutions of a residue having a positively charged side chain (e.g., Arg, His, or Lys) with (by) a negatively charged residue (e.g., Glu, or Asp); (ii) substitutions of a hydrophilic residue (e.g., Ser or Thr) with (by) a hydrophobic residue (e.g., Ala, Leu, Ile, Phe, or Val); (iii) substitutions of cysteine or proline with (by) any other residue; or (iv) substitutions of a residue having a bulky hydrophobic or aromatic side chain (e.g., Val, His, Ile, or Trp) with (by) a residue having a smaller side chain (e.g., Ala, or Ser) or no side chain (e.g., Gly).
[0135] Other amino acid substitutions can be readily identified by those skilled in the art. For example, for the amino acid alanine, substitutions can be made from any one of D-alanine, glycine, beta-alanine, L-cysteine, and D-cysteine. For lysine, substitutions can be made from any one of D-lysine, arginine, D-arginine, homoarginine, methionine, D-methionine, ornithine, or D-ornithine. Generally, substitutions in functionally important regions that can be expected to cause changes in the properties of an isolated polypeptide include: (i) polar residues, such as serine or threonine, substituted with hydrophobic residues, such as leucine, isoleucine, phenylalanine, or alanine; (ii) cysteine residues substituted with any other residue; (iii) residues with positively charged side chains, such as lysine, arginine, or histidine, substituted with residues with negatively charged side chains, such as glutamic acid or aspartic acid; or (iv) residues with bulky side chains, such as phenylalanine, substituted with residues without such side chains, such as glycine. The likelihood that one of the aforementioned non-conservative substitutions can change the functional properties of a protein also correlates with the substitution location relative to the functionally important region of the protein; therefore, some non-conservative substitutions may have little or no effect on biological properties.
[0136] Conserved: As used herein, the term "conserved" refers to nucleotides or amino acid residues, respectively, of a polynucleotide or polypeptide sequence that are not altered in the same position in two or more sequences being compared. A relatively conserved nucleotide or amino acid is one that is more closely related and conserved within a sequence than a nucleotide or amino acid that appears elsewhere in the sequence.
[0137] In some embodiments, two or more sequences can be said to be "completely conserved" if they are 100% identical to each other. In some embodiments, two or more sequences can be said to be "highly conserved" if they are at least 70% identical, at least 80% identical, at least 90% identical, or at least 95% identical to each other. In some embodiments, two or more sequences can be said to be "highly conserved" if they are about 70% identical, about 80% identical, about 90% identical, about 95%, about 98%, or about 99% identical to each other. In some embodiments, two or more sequences can be said to be "conserved" if they are at least 30% identical, at least 40% identical, at least 50% identical, at least 60% identical, at least 70% identical, at least 80% identical, at least 90% identical, or at least 95% identical to each other. In some embodiments, two or more sequences can be said to be "conserved" if they are about 30% identical, about 40% identical, about 50% identical, about 60% identical, about 70% identical, about 80% identical, about 90% identical, about 95% identical, about 98% identical, or about 99% identical to one another. Sequence conservation can apply to the entire length of a polynucleotide or polypeptide, or to portions, regions, or features thereof.
[0138] Contacting: As used herein, the term "contacting" means establishing a physical connection between two or more elements. For example, contacting a mammalian cell with a nanoparticle composition means causing the mammalian cell and the nanoparticle to share a physical connection. Methods for contacting cells with external entities both in vivo and ex vivo are well known in the biological arts. For example, contacting a nanoparticle composition with mammalian cells placed within a mammal can be accomplished by various routes of administration (e.g., intravenous, intramuscular, intradermal, and subcutaneous) and can involve various amounts of the nanoparticle composition. Furthermore, two or more mammalian cells can be contacted by the nanoparticle composition.
[0139] Sustained release: As used herein, the term "sustained release" refers to a release profile of a pharmaceutical composition or compound that conforms to a specific release pattern and provides a therapeutic result.
[0140] Covalent Derivatives: The term "covalent derivatives," when referring to polypeptides, includes modifications of the native or starting protein with organic proteinaceous or non-proteinaceous derivatizing agents and / or post-translational modifications. Covalent modifications are traditionally introduced by reacting targeted amino acid residues of the protein with organic derivatizing agents capable of reacting with selected side chains or terminal residues, or by exploiting post-translational modification mechanisms operative in selected recombinant host cells. The resulting covalent derivatives are useful in programs to identify residues important for biological activity, immunoassays, or the preparation of anti-protein antibodies for immunoaffinity purification of recombinant glycoproteins. Such modifications are within the skill of the art and are performed without undue experimentation.
[0141] Circular or cyclized: As used herein, the term "circular" means that there is a continuous ring. A circular molecule need not be circular, but merely linked to form an unbroken chain of subunits. Circular molecules, such as engineered RNAs or mRNAs of the present disclosure, can be single units or multimers, or can contain one or more components of a complex or higher-order structure.
[0142] Cytotoxic: As used herein, "cytotoxic" means killing or causing a harmful, toxic, or lethal effect on a cell (e.g., a mammalian cell (e.g., a human cell)), bacteria, virus, fungus, protozoan, protozoan parasite, prion, or combination thereof.
[0143] Delivering: As used herein, the term "delivering" means providing a substance to a destination. For example, delivering a polynucleotide to a subject can involve administering a nanoparticle composition comprising the polynucleotide to the subject (e.g., by intravenous, intramuscular, intradermal, or subcutaneous routes). Administering a nanoparticle composition to a mammal or mammalian cells can involve contacting one or more cells with the nanoparticle composition.
[0144] Delivery agent: As used herein, "delivery agent" means any substance that facilitates, at least in part, the in vivo, in vitro, or ex vivo delivery of a polynucleotide to a targeted cell.
[0145] Destabilized: As used herein, the terms "destabilized," "destabilize," or "destabilized region" refer to a region or molecule that is less stable than the same region or molecule in its starting wild-type or native form.
[0146] Detectable Label: As used herein, "detectable label" refers to one or more markers, signals, or moieties bound to, incorporated into, or associated with another substance that are readily detected by methods known in the art, including radiography, fluorescence, chemiluminescence, enzymatic activity, light absorbance, etc. Detectable labels include radioisotopes, fluorophores, chromophores, enzymes, dyes, metal ions, ligands (such as biotin, avidin, streptavidin, and haptens), quantum dots, and the like. Detectable labels can be present at any position in the polynucleotides (e.g., mRNA) disclosed herein and can be used to determine, for example, tissue distribution, metabolism, biological stability, excretion, etc.
[0147] Diastereomers: As used herein, the term "diastereomers" means stereoisomers that are not mirror images of each other and are not superimposable with respect to one another.
[0148] Digest: As used herein, the term "digest" means to break down into smaller pieces or components. When referring to polypeptides or proteins, digestion results in the production of peptides.
[0149] Distal: As used herein, the term "distal" means located away from the center or away from a point or area of interest.
[0150] Domain: As used herein, when referring to a polypeptide, the term "domain" refers to a motif in a polypeptide that has one or more distinguishable structural or functional features or properties (e.g., binding ability that serves as a site for protein-protein interaction). As used herein, the term "domain" also encompasses nucleic acid sequences (e.g., mRNA sequences) that encode a polypeptide domain.
[0151] Dosage regimen: As used herein, a "dosage regimen" or "dosing regimen" is a dosing schedule or a physician-determined therapeutic, preventative, or palliative care plan.
[0152] Effective amount: As used herein, the term "effective amount" of an agent is an amount sufficient to produce a beneficial or desired result, e.g., a clinical result; therefore, "effective amount" depends on the context in which the term is applied. For example, in the context of administering an agent to treat a tumor, an effective amount of the agent is an amount sufficient to, for example, shrink or reduce tumor size or inhibit tumor growth compared to the response obtained without administering the agent. The term "effective amount" can be used interchangeably with "effective dose," "therapeutically effective amount," or "therapeutically effective dose."
[0153] Enantiomer: As used herein, the term "enantiomer" refers to each individual optically active form of a compound of the present disclosure having an optical purity or enantiomeric excess (as measured by standard methods in the art) of at least 80% (i.e., at least 90% of one enantiomer and up to 10% of another enantiomer), at least 90%, or at least 98%.
[0154] Encapsulate: As used herein, the term "encapsulate" means to enclose, surround, or encase.
[0155] Encapsulation efficiency: As used herein, "encapsulation efficiency" refers to the amount of polynucleotide that becomes part of a nanoparticle composition compared to the initial total amount of polynucleotide used to prepare the nanoparticle composition. For example, if 97 mg of polynucleotide is encapsulated in the nanoparticle composition out of a total of 100 mg of polynucleotide initially provided in the composition, the encapsulation efficiency can be expressed as 97%. As used herein, "encapsulation" can refer to complete, substantial, or partial confinement, enclosure, surrounding, or wrapping.
[0156] Encoded protein cleavage signal: As used herein, "encoded protein cleavage signal" means a nucleotide sequence that encodes a protein cleavage signal.
[0157] Engineered: As used herein, an embodiment of the present disclosure is "engineered" if it is designed to have structural or chemical characteristics or properties that differ from the starting, wild-type, or naturally occurring molecule.
[0158] Enhanced delivery: As used herein, the term "enhanced delivery" means that a nanoparticle delivers more polynucleotide to a target tissue (e.g., the mammalian liver) compared to the amount of polynucleotide delivered to a target tissue (e.g., MC3, KC2, or DLinDMA) by a control nanoparticle (e.g., at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, or at least 10-fold). The amount of nanoparticle delivered to a particular tissue can be measured by comparing the amount of protein produced in the tissue to the weight of the tissue, the amount of polynucleotide in the tissue to the weight of the tissue, the amount of protein produced in the tissue to the total amount of protein in the tissue, or the amount of polynucleotide in the tissue to the total amount of polynucleotide in the tissue. It will be understood that enhanced delivery of nanoparticles to a target tissue need not be measured in a subject being treated, but can be measured in a surrogate organism, such as an animal model (e.g., a rat model).
[0159] Exosome: As used herein, an "exosome" is a vesicle secreted by mammalian cells or a complex involved in RNA degradation.
[0160] Expression: As used herein, "expression" of a nucleic acid sequence refers to one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription), (2) processing of the RNA transcript (e.g., by splicing, editing, 5' capping, and / or 3' end processing), (3) translation of the RNA into a polypeptide or protein, and (4) post-translational modification of the polypeptide or protein. The term "protein expression" (and related terms such as "expressed protein") specifically refers to the translation of RNA into a polypeptide or protein.
[0161] Ex vivo: As used herein, the term "ex vivo" refers to an event that occurs outside of a living organism (e.g., an animal, plant, or microorganism, or cells or tissues thereof). An ex vivo event can occur in an environment that is minimally altered from the natural (e.g., in vivo) environment.
[0162] Feature: As used herein, "feature" means a property, quality, or unique element. When referring to a polypeptide, a "feature" is defined as a component of the molecule with respect to its unique amino acid sequence. Features of polypeptides encoded by the polynucleotides of the present disclosure include surface expression, local structural shape, folds, loops, half-loops, domains, half-domains, sites, termini, or any combination thereof.
[0163] Formulation: As used herein, a "formulation" includes at least a polynucleotide and one or more of a carrier, excipient, and delivery agent.
[0164] Fragment: As used herein, "fragment" refers to a portion. For example, a fragment of a protein can include a polypeptide obtained by digesting a full-length protein isolated from cultured cells. In some embodiments, the fragment is a subsequence of the full-length protein (e.g., one of the subunits of IL23) in which an N-terminal, C-terminal, and / or internal subsequence has been deleted. In some preferred aspects of the present disclosure, a fragment of a protein of the present disclosure is a functional fragment.
[0165] Functional: As used herein, a "functional" biological molecule is a biological molecule in a form that exhibits a property and / or activity by which it is characterized. Thus, a "functional fragment" of a polynucleotide of the present disclosure is a polynucleotide that is capable of expressing a functional polypeptide, such as, for example, an interleukin fragment. As used herein, a "functional fragment" of a biological molecule, e.g., an interleukin, refers to a fragment of a wild-type molecule, e.g., a wild-type interleukin (i.e., a fragment of a naturally occurring form of an interleukin), or a variant or variant thereof, wherein the fragment retains at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% of the biological activity of the corresponding full-length protein.
[0166] Helper lipid: As used herein, the term "helper lipid" refers to a compound or molecule that contains a lipid moiety (for insertion into a lipid layer, e.g., a lipid bilayer) and a polar moiety (for interaction with physiological solutions at the surface of the lipid layer). Typically, helper lipids are phospholipids. The function of helper lipids is to "assist" amino lipids, increasing the fusogenicity of the bilayer and / or, for example, to help facilitate endosomal escape of nucleic acids to be delivered to cells. Helper lipids are also believed to be key structural components for the surface of LNPs.
[0167] Homology: As used herein, the term "homology" refers to the overall relationship between polymer molecules, e.g., between nucleic acid molecules (e.g., DNA molecules and / or RNA molecules) and / or between polypeptide molecules. In some embodiments, polymer molecules are considered to be "homologous" to one another if the sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical or similar. The term "homologous" necessarily refers to a comparison between at least two sequences (polynucleotide or polypeptide sequences). In accordance with the present disclosure, two polynucleotide sequences are considered to be homologous if the encoded polypeptides are at least 50%, 60%, 70%, 80%, 90%, 95%, or even 99% identical over at least one stretch of at least about 20 amino acids. In some embodiments, homologous polynucleotide sequences are characterized by the ability to encode a stretch of at least 4-5 uniquely specified amino acids. For polynucleotide sequences less than 60 nucleotides in length, homology is measured by the ability to encode a stretch of at least 4-5 uniquely specified amino acids. In accordance with the present disclosure, two protein sequences are considered to be homologous if the proteins are at least about 50%, 60%, 70%, 80%, or 90% identical over at least one stretch of at least about 20 amino acids.
[0168] Identity: As used herein, the term "identity" refers to overall monomer conservation between polymer molecules, e.g., between polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or between polypeptide molecules. Calculation of the percent identity of two polynucleotide sequences can be performed, for example, by aligning the two sequences for optimal comparison purposes (e.g., for optimal alignment, gaps can be introduced into one or both of the first and second nucleic acid sequences, and non-identical sequences can be ignored for comparison purposes). In certain embodiments, the length of the aligned sequences for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% of the length of the reference sequence. Nucleotides at corresponding nucleotide positions are then compared. If a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, the molecules are identical at that position. The percentage identity between two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps and the length of each gap that need to be introduced for optimal alignment of the two sequences. Comparing sequences and determining the percentage identity between two sequences can be accomplished using mathematical algorithms. When comparing DNA and RNA, thymine (T) and uracil (U) can be considered equivalent.
[0169] Suitable software programs are available from a variety of sources and for aligning both protein and nucleotide sequences. One suitable program for measuring percent sequence identity is bl2seq, which is part of the BLAST suite of programs available from the U.S. government's National Center for Biotechnology Information BLAST website (blast.ncbi.nlm.nih.gov). Bl2seq performs a comparison of two sequences using either the BLASTN or BLASTP algorithm. BLASTN is used to compare nucleic acid sequences, while BLASTP is used to compare amino acid sequences. Other suitable programs are, for example, Needle, Stretcher, Water, or Matcher, which are part of the EMBOSS suite of bioinformatics programs and are also available from the European Bioinformatics Institute (EBI) (www.ebi.ac.uk / Tools / psa).
[0170] Sequence alignment can be performed using methods known in the art, such as MAFFT, Clustal (ClustalW, Clustal X, or Clustal Omega), MUSCLE, etc. Unless otherwise stated, the percentage identity values disclosed in this application are obtained using the MAFFT (Multiple Alignment using Fast Fourier Transform) version 7 implementation, with default parameters, available from the European Bioinformatics Institute (www.ebi.ac.uk / Tools / msa / mafft / ).
[0171] Different regions within a single polynucleotide or polypeptide target sequence that are aligned with a polynucleotide or polypeptide reference sequence can each have their own sequence identity percentage. Note that the sequence identity percentage value is rounded to two decimal places. For example, 80.11, 80.12, 80.13, and 80.14 are rounded to 80.1, and 80.15, 80.16, 80.17, 80.18, and 80.19 are rounded to 80.2. Note also that length values are always integers.
[0172] In certain embodiments, the percent identity (%ID) of a first amino acid sequence (or nucleic acid sequence) to a second amino acid sequence (or nucleic acid sequence) is calculated as %ID=100×(Y / Z), where Y is the number of amino acid residues (or nucleic acid bases) scored as identical matches in an alignment of the first and second sequences (aligned by visual inspection or a specific sequence alignment program), and Z is the total number of residues in the second sequence. If the length of the first sequence is longer than the second sequence, the percent identity of the first sequence to the second sequence will be higher than the percent identity of the second sequence to the first sequence.
[0173] Those skilled in the art will understand that generating a sequence alignment for calculating percent sequence identity is not limited to secondary sequence-sequence comparisons driven exclusively by primary sequence data. It will further be understood that sequence alignments can be generated by combining sequence data with data from heterogeneous sources, such as structural data (e.g., crystal protein structures), functional data (e.g., mutation locations), or phylogenetic data. A suitable program for incorporating heterogeneous data to generate multiple sequence alignments is T-Coffee, available at www.tcoffee.org or, for example, from EBI. It will further be understood that the final alignment used to calculate percent sequence identity can be curated automatically or manually.
[0174] Immune response: The term "immune response" refers to the actions of lymphocytes, antigen-presenting cells, phagocytes, granulocytes, and soluble macromolecules produced by such cells or the liver, including antibodies, cytokines, and complement, that selectively damage, destroy, or remove from the body, for example, invading pathogens, pathogen-infected cells or tissues, cancerous cells, or, in the case of autoimmunity or pathological inflammation, normal human cells or tissues.
[0175] Inflammatory response: "Inflammatory response" refers to an immune response involving the specific and nonspecific defense systems. A specific defense system response is a specific immune system reaction to an antigen. Examples of specific defense system responses include antibody responses. A nonspecific defense system response is an inflammatory response mediated by white blood cells that are not normally capable of immunological memory, such as macrophages, eosinophils, and neutrophils. In some embodiments, the immune response includes the secretion of inflammatory cytokines, resulting in increased levels of inflammatory cytokines.
[0176] Inflammatory cytokine: The term "inflammatory cytokine" refers to a cytokine that is increased in an inflammatory response. Examples of inflammatory cytokines include interleukin-6 (IL-6), CXCL1 (chemokine (CXC motif) ligand 1, also known as GROα), interferon-γ (IFNγ), tumor necrosis factor α (TNFα), interferon-γ-inducible protein 10 (IP-10), or granulocyte-colony stimulating factor (G-CSF). The term "inflammatory cytokine" also includes other cytokines known in the art that are associated with inflammatory responses, such as interleukin-1 (IL-1), interleukin-8 (IL-8), interleukin-12 (IL12), interleukin-13 (IL-13), interferon α (IFN-α), etc.
[0177] In vitro: As used herein, the term "in vitro" refers to events that occur not in a living organism (e.g., an animal, plant, or microorganism) but in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, or in a Petri dish.
[0178] In vivo: As used herein, the term "in vivo" refers to an event that takes place within a living organism (e.g., an animal, plant, or microorganism, or a cell or tissue thereof).
[0179] Insertional and Deletional Variants: When referring to a polypeptide, an "insertional variant" is a variant that has one or more amino acids inserted immediately adjacent to an amino acid at a particular position in a native or starting sequence. "Immediately adjacent to" an amino acid means attached to either the alpha-carboxy or alpha-amino functionality of the amino acid. When referring to a polypeptide, a "deletional variant" is a variant in which one or more amino acids of the native or starting amino acid sequence have been removed. Typically, deletion variants have one or more amino acids deleted in a particular region of the molecule.
[0180] Intact: As used herein, in the context of a polypeptide, the term "intact" means retaining the amino acids corresponding to the wild-type protein, e.g., the wild-type amino acids have not been mutated or substituted. Conversely, in the context of a nucleic acid, the term "intact" means retaining the nucleobases corresponding to the wild-type nucleic acid, e.g., the wild-type nucleobases have not been mutated or substituted.
[0181] Ionizable amino lipids: The term "ionizable amino lipids" includes lipids having one, two, three, or more fatty acid or aliphatic alkyl chains and a pH-titratable amino head group (e.g., alkylamino or dialkylamino head group). Ionizable amino lipids are typically protonated (i.e., positively charged) at pH levels below the pKa of the amino head group, and are essentially uncharged at pH levels above the pKa. Examples of such ionizable amino lipids include, but are not limited to, DLin-MC3-DMA (MC3) and (13Z,165Z)-N,N-dimethyl-3-nonidocosa-13-16-dien-1-amine (L608).
[0182] Isolated: As used herein, the term "isolated" refers to a substance or component that is separated from at least some of the components with which it is associated (whether in natural form or in an experimental setting). Isolated substances (e.g., nucleotide sequences or protein sequences) can have various levels of purity relative to the substances with which they are associated. Isolated substances and / or components can be at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or more separated from other components with which they were initially associated. In some embodiments, an isolated agent is greater than about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% pure. As used herein, a substance is "pure" if it is substantially free of other components.
[0183] The term "substantially isolated" means that the compound is substantially separated from the environment in which it was formed or detected. Partial isolation can include, for example, a composition enriched in the compounds of the present disclosure. Substantial isolation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of a compound of the present disclosure, or a salt thereof.
[0184] An "isolated" polynucleotide, vector, polypeptide, cell, or any composition disclosed herein is a polynucleotide, vector, polypeptide, cell, or composition in a form not found in nature. Isolated polynucleotides, vectors, polypeptides, or compositions include those that have been purified to the extent that they are not in a form found in nature. In some embodiments, an isolated polynucleotide, vector, polypeptide, or composition is substantially pure.
[0185] Isomer: As used herein, the term "isomer" refers to any tautomer, stereoisomer, enantiomer, or diastereomer of any compound of the present disclosure. It is recognized that the compounds of the present disclosure can have one or more chiral centers and / or double bonds and therefore exist as stereoisomers, e.g., double bond isomers (i.e., geometric E / Z isomers), or diastereomers (e.g., enantiomers (i.e., (+) or (-)), or cis / trans isomers). In accordance with the present disclosure, the chemical structures depicted herein, and therefore, the compounds of the present disclosure, encompass all corresponding stereoisomers, i.e., stereomerically pure forms (e.g., geometrically pure, enantiomerically pure, or diastereomeric pure), as well as both enantiomeric and stereoisomeric mixtures (e.g., racemates). Enantiomeric and stereoisomeric mixtures of the compounds of the present disclosure can typically be resolved into the component enantiomers or stereoisomers by well-known methods, such as chiral-phase gas chromatography, chiral-phase high-performance liquid chromatography, crystallization of the compounds as chiral salt complexes, or crystallization of the compounds in chiral solvents. Enantiomers and stereoisomers can also be obtained from stereomerically or enantiomerically pure intermediates, reagents, and catalysts by well-known asymmetric synthetic methods.
[0186] Linker: As used herein, "linker" refers to a group of atoms, e.g., 10 to 1,000 atoms, which may be composed of atoms or groups such as, but not limited to, carbon, amino, alkylamino, oxygen, sulfur, sulfoxide, sulfonyl, carbonyl, and imine. The linker can be attached to a modified nucleoside or nucleotide at the nucleobase or sugar moiety at one end and to a payload (e.g., a detectable drug or therapeutic agent) at the second end. The linker can be of sufficient length so as not to interfere with incorporation into the nucleic acid sequence. Linkers can be used for any useful purpose, such as to form polynucleotide multimers or polynucleotide conjugates (e.g., by joining two or more chimeric polynucleotide molecules or IVT polynucleotides) and to administer a payload, as described herein. Examples of chemical groups that can be incorporated into linkers include, but are not limited to, alkyl, alkenyl, alkynyl, amide, amino, ether, thioether, ester, alkylene, heteroalkylene, aryl, or heterocyclyl, each of which can be optionally substituted as described herein. Examples of linkers include, but are not limited to, unsaturated alkanes, polyethylene glycols (e.g., ethylene or propylene glycol monomer units, e.g., diethylene glycol, dipropylene glycol, triethylene glycol, tripropylene glycol, tetraethylene glycol, or tetraethylene glycol), and dextran polymers, and derivatives thereof. Other examples include, but are not limited to, cleavable sites within the linker, such as disulfide bonds (-SS-) or azo bonds (-N=N-), which can be cleaved using reducing agents or photolysis. Non-limiting examples of selectively cleavable bonds include amide bonds, which can be cleaved by, for example, tris(2-carboxyethyl)phosphine (TCEP) or other reducing agents, and / or photolysis, and ester bonds, which can be cleaved by, for example, acidic or basic hydrolysis.
[0187] Administration method: As used herein, "administration method" may include intravenous administration, intramuscular administration, intradermal administration, subcutaneous administration, or other methods of delivering a composition to a subject. The administration method can be selected to target (e.g., specifically deliver) delivery to a particular area or system of the body.
[0188] Modified: As used herein, "modified" refers to a change in the state or structure of a molecule of the present disclosure. Molecules can be modified in many ways, including chemical, structural, and functional ways. In some embodiments, mRNA molecules of the present disclosure are modified by the introduction of non-natural nucleosides and / or nucleotides, for example, as they relate to the natural ribonucleotides A, U, G, and C. Non-standard nucleotides, such as cap structures, although different in chemical structure from the A, C, G, and U ribonucleotides, are not considered "modified."
[0189] Nanoparticle composition: As used herein, a "nanoparticle composition" is a composition containing one or more lipids. Nanoparticle compositions typically have a size of approximately micrometers or less and can include a lipid bilayer membrane. Nanoparticle compositions include lipid nanoparticles (LNPs), liposomes (e.g., lipid vesicles), and lipoplexes. For example, the nanoparticle composition can be a liposome having a lipid bilayer membrane with a diameter of 500 nm or less.
[0190] Naturally-occurring: As used herein, "naturally-occurring" means existing in nature without artificial assistance.
[0191] Non-human vertebrate: As used herein, "non-human vertebrate" includes all vertebrates, except humans, including wild and domestic species. Examples of non-human vertebrates include, but are not limited to, mammals such as alpacas, banteng, bison, camels, cats, cows, deer, dogs, donkeys, gayal, goats, guinea pigs, horses, llamas, mules, pigs, rabbits, reindeer, sheep, water buffalo, and yaks.
[0192] Nucleic acid sequence: The terms "nucleic acid sequence," "nucleotide sequence," or "polynucleotide sequence" are used interchangeably and refer to a contiguous nucleic acid sequence. The sequence can be either single-stranded or double-stranded DNA or RNA (e.g., mRNA).
[0193] The term "nucleic acid," in its broadest sense, includes any compound and / or substance comprising a polymer of nucleotides. These polymers are often referred to as polynucleotides. Exemplary nucleic acids or polynucleotides of the present disclosure include, but are not limited to, ribonucleic acid (RNA), deoxyribonucleic acid (DNA), threose nucleic acid (TNA), glycol nucleic acid (GNA), peptide nucleic acid (PNA), locked nucleic acid (including LNA, LNA having a β-D-ribonucleotide structure, α-LNA having an α-L-ribonucleotide structure (a diastereomer of LNA), 2'-amino-functionalized 2'-amino-LNA, and 2'-amino-functionalized 2'-amino-α-LNA), ethylene nucleic acid (ENA), cyclohexenyl nucleic acid (CeNA), or hybrids or combinations thereof.
[0194] The phrase "nucleotide sequence encoding" refers to a nucleic acid (e.g., an mRNA or DNA molecule) coding sequence that encodes a polypeptide. The coding sequence can further include initiation and termination signals operably linked to regulatory elements, including a promoter or polyadenylation signal, capable of directing expression in the cells of an individual or mammal to which the nucleic acid is administered. The coding sequence can further include a sequence encoding a signal peptide.
[0195] Off-target: As used herein, "off-target" means any unintended effect on any one or more targets, genes, or cellular transcripts.
[0196] Open reading frame: As used herein, "open reading frame" or "ORF" means a sequence that does not contain a stop codon within a given reading frame.
[0197] Operably linked: As used herein, the phrase "operably linked" refers to a functional connection between two or more molecules, constructs, transcripts, elements, or sites, etc.
[0198] Optimized sequence: The term "optimized sequence" refers to the product of a sequence optimization process.
[0199] Optionally substituted: As used herein, phrases of the form "optionally substituted X" (e.g., optionally substituted alkyl) are intended to be equivalent to "X, where X is optionally substituted" (e.g., "alkyl, where the alkyl is optionally substituted"). It is not intended to imply that the feature "X" (e.g., alkyl) itself is optional.
[0200] Portion: As used herein, a "portion" or "region" of a polynucleotide is defined as any portion of the polynucleotide that is less than the entire length of the polynucleotide.
[0201] Patient: As used herein, "patient" means a subject who may be seeking or in need of treatment, who is in need of treatment, who is receiving treatment, who will receive treatment, or who is receiving care by a trained professional for a particular disease or condition.
[0202] Pharmaceutically acceptable: The phrase "pharmaceutically acceptable" is used herein to refer to compounds, materials, compositions, and / or dosage forms that are within the bounds of good medical practice and are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, and are commensurate with a reasonable benefit-risk ratio.
[0203] Pharmaceutically acceptable excipient: As used herein, the phrase "pharmaceutically acceptable excipient" refers to any ingredient (e.g., a vehicle capable of suspending or dissolving an active compound) that is substantially non-toxic and non-inflammatory to a patient, other than the compounds described herein. Excipients can include, for example, antiadhesives, antioxidants, binders, coating materials, compression aids, disintegrants, dyes (colorants), emollients, emulsifiers, fillers (diluents), film-forming agents or coatings, flavors, fragrances, glidants (flow improvers), lubricants, preservatives, printing inks, adsorbents, suspending or dispersing agents, sweeteners, and water for hydration. Exemplary excipients include, but are not limited to, butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, cross-linked polyvinylpyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropylmethylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methylparaben, microcrystalline cellulose, polyethylene glycol, polyvinylpyrrolidone, povidone, pregelatinized starch, propylparaben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethylcellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.
[0204] Pharmaceutically acceptable salts: The present disclosure also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds in which the parent compound is modified by converting an existing acid or basic moiety into its salt form (e.g., by reacting a free base group with a suitable organic acid). Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues (e.g., amines), alkali or organic salts of acidic residues (e.g., carboxylic acids), etc. Exemplary acid addition salts include acetate, acetic acid, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzenesulfonic acid, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy- Examples of suitable salts include ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate, and the like. Exemplary alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations, including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. Pharmaceutically acceptable salts of the present disclosure include conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.The pharmaceutically acceptable salts of the present disclosure can be synthesized from parent compounds containing a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of the appropriate base or acid in water or an organic solvent, or a mixture of the two (generally using a non-aqueous medium such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile). A list of suitable salts can be found in Remington's Pharmaceutical Sciences, 17. th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418, Pharmaceutical Salts: Properties, Selection, and Use, P.H. Stahl and C.G. Wermuth (eds.), Wiley-VCH, 2008, and Berge et al., Journal of Pharmaceutical Science, 66, 1-19 (1977), each of which is incorporated herein by reference in its entirety.
[0205] Pharmaceutically acceptable solvate: As used herein, the term "pharmaceutically acceptable solvate" refers to a compound of the present disclosure in which molecules of a suitable solvent are incorporated into the crystal lattice. A suitable solvent is physiologically acceptable at the dosage level. For example, solvates can be prepared by crystallization, recrystallization, or precipitation from a solution containing an organic solvent, water, or a mixture thereof. Examples of suitable solvents include ethanol, water (e.g., mono-, di-, and trihydrates), N-methylpyrrolidone (NMP), dimethyl sulfoxide (DMSO), N,N'-dimethylformamide (DMF), N,N'-dimethylacetamide (DMAC), 1,3-dimethyl-2-imidazolidinone (DMEU), 1,3-dimethyl-3,4,5,6-tetrahydro-2-(1H)-pyrimidinone (DMPU), acetonitrile (ACN), propylene glycol, ethyl acetate, benzyl alcohol, 2-pyrrolidone, benzyl benzoate, and the like. When water is the solvent, the solvate is referred to as a "hydrate."
[0206] Pharmacokinetics: As used herein, "pharmacokinetics" refers to any one or more properties of a molecule or compound as they relate to determining the fate of a substance administered to an organism. Pharmacokinetics is divided into several areas, including the extent and rate of absorption, distribution, metabolism, and excretion. This is commonly referred to as ADME, where (A) absorption is the process by which a substance enters the blood circulation; (D) distribution is the dispersion or propagation of a substance throughout the body's fluids and tissues; (M) metabolism (or biotransformation) is the irreversible conversion of a parent compound to daughter metabolites; and (E) excretion (or excretion) refers to the release of a substance from the body. In rare cases, some drugs irreversibly accumulate in body tissues.
[0207] Physicochemical: As used herein, "physicochemical" means or relates to physical and / or chemical properties.
[0208] Polynucleotide: As used herein, the term "polynucleotide" refers to a polymer of nucleotides of any length, comprising ribonucleotides, deoxyribonucleotides, their analogs, or mixtures thereof. The term refers to the primary structure of the molecule. Thus, the term includes triple-, double-, and single-stranded deoxyribonucleic acid ("DNA"), as well as triple-, double-, and single-stranded ribonucleic acid ("RNA"). It also includes modified, for example, by alkylation and / or by capping, as well as unmodified forms of polynucleotides. More specifically, the term "polynucleotide" includes polydeoxyribonucleotides (containing 2-deoxy-D-ribose), polyribonucleotides (containing D-ribose) (including tRNA, rRNA, hRNA, siRNA, and mRNA), whether spliced or unspliced, any other type of polynucleotide that is an N- or C-glycoside of a purine or pyrimidine base, as well as other polymers containing non-nucleotide backbones, such as polyamides (e.g., peptide nucleic acids, "PNAs") and polymorpholino polymers, and other synthetic sequence-specific nucleic acid polymers, where the polymer contains nucleobases in structures that allow for base pairing and base stacking, such as those found in DNA and RNA. In certain embodiments, the polynucleotide comprises an mRNA. In other embodiments, the mRNA is synthetic mRNA. In some embodiments, the synthetic mRNA comprises at least one unnatural nucleobase. In some embodiments, all of the nucleobases of a particular class are substituted with unnatural nucleobases (e.g., all uridines in the polynucleotides disclosed herein can be substituted with unnatural nucleobases, such as 5-methoxyuridine). In some embodiments, the polynucleotides (e.g., synthetic RNA or synthetic DNA) contain only natural nucleobases, i.e., A, C, T, and U in the case of synthetic DNA, or A, C, T, and U in the case of synthetic RNA.
[0209] Those skilled in the art will understand that while T bases in the codon maps disclosed herein are present in DNA, they are replaced by U bases in the corresponding RNA. For example, when a codon-nucleotide sequence disclosed herein is in DNA form, e.g., a vector or in vitro translation (IVT) template, the T base is transcribed to a U base in the corresponding transcribed mRNA. In this regard, both codon-optimized DNA sequences (containing T) and their corresponding RNA sequences (containing U) are considered codon-optimized nucleotide sequences of the present disclosure. Those skilled in the art will also understand that equivalent codon maps can be generated by replacing one or more bases with unnatural bases. Thus, for example, the TTC codon (DNA map) corresponds to the UUC codon (RNA map), which in turn corresponds to the ΨΨC codon (RNA map in which U is replaced with pseudouridine).
[0210] Standard AT and GC base pairs are formed under conditions that allow hydrogen bonds to form between the N3-H and C4-oxy of thymidine, and between the N1 and C6-NH2 of adenosine, respectively, and between the C2-oxy, N3 and C4-NH2 of cytidine, and between the C2-NH2, N'-H, and C6-oxy of guanosine, respectively. Thus, for example, guanosine (2-amino-6-oxy-9-β-D-ribofuranosyl-purine) can be modified to form isoguanosine (2-oxy-6-amino-9-β-D-ribofuranosyl-purine). Such modifications result in nucleoside bases that no longer effectively form standard base pairs with cytosine. However, modification of cytosine (1-β-D-ribofuranosyl-2-oxy-4-amino-pyrimidine) to form isocytosine (1-β-D-ribofuranosyl-2-amino-4-oxy-pyrimidine-) results in a modified nucleotide that does not base pair efficiently with guanosine but does base pair with isoguanosine (U.S. Pat. No. 5,681,702 (Collins et al.)). Isocytosine is available from Sigma Chemical Co. (St. Louis, Mo.); isocytidine can be prepared by the method described in Switzer et al. (1993) Biochemistry 32:10489-10496 and the references cited therein; 2'-deoxy-5-methyl-isocytidine can be prepared by the method described in Tor et al., 1993, J. Am. Chem. Soc. 115:4461-4467 and the references cited therein; and isoguanine nucleotides can be prepared using the methods described in Switzer et al., 1993 (supra) and Mantsch et al., 1993, Biochem. 14:5593-5601, or by the method described in U.S. Pat. No. 5,780,610 (Collins et al.).Other unnatural base pairs can be synthesized by the method described in Piccirilli et al., 1990, Nature 343:33-37, for the synthesis of 2,6-diaminopyrimidine and its complement (1-methylpyrazolo-[4,3]pyrimidine-5,7-(4H,6H)-dione). Other such modified nucleotide units that form unique base pairs are known, such as those described in Leach et al. (1992) J. Am. Chem. Soc. 114:3675-3683 and Switzer et al. (supra).
[0211] Nucleic acid sequence: The terms "nucleic acid sequence," "nucleotide sequence," or "polynucleotide" are used interchangeably and refer to a contiguous nucleic acid sequence. The sequence can be either single-stranded or double-stranded DNA or RNA (e.g., mRNA).
[0212] The phrase "nucleotide sequence encoding" and variations thereof refers to a nucleic acid (e.g., mRNA or DNA molecule) coding sequence comprising a nucleotide sequence that encodes a polypeptide or functional fragment thereof, as described herein. The coding sequence can further include initiation and termination signals operably linked to regulatory elements, including a promoter or polyadenylation signal, capable of directing expression in the cells of an individual or mammal to which the nucleic acid is administered. The coding sequence can further include a sequence encoding a signal peptide.
[0213] Polypeptide: The terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to polymers of amino acids of any length. A polymer can contain modified amino acids. The term also encompasses amino acid polymers that are naturally modified or modified by intervening (e.g., disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation), or any other manipulation or modification, such as conjugation with a labeling component. The definition also includes, for example, polypeptides containing one or more analogs of an amino acid (including, for example, homocysteine, ornithine, p-acetylphenylalanine, D-amino acids, and creatine), as well as other modifications known in the art.
[0214] As used herein, the term refers to proteins, polypeptides, and peptides of any size, structure, or function. Polypeptides include gene products, naturally occurring polypeptides, synthetic polypeptides, homologs, orthologs, paralogs, fragments, and other equivalents, variants, and analogs of the foregoing. Polypeptides can be a single polypeptide or a complex of multiple molecules, such as a dimer, trimer, or tetramer. These can also include single-chain or multi-chain polypeptides. Disulfide bonds are most commonly found in multi-chain polypeptides. The term "polypeptide" can also apply to amino acid polymers in which one or more amino acid residues are artificial chemical analogs of the corresponding naturally occurring amino acids. In some embodiments, a "peptide" can be 50 amino acids or less in length, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids in length.
[0215] Polypeptide variant: As used herein, the term "polypeptide variant" refers to a molecule whose amino acid sequence differs from that of a native or reference sequence. Amino acid sequence variants can have substitutions, deletions, and / or insertions at certain positions within the amino acid sequence compared to the native or reference sequence. Typically, variants have at least about 50% identity, at least about 60% identity, at least about 70% identity, at least about 80% identity, at least about 90% identity, at least about 95% identity, or at least about 99% identity to the native or reference sequence. In some embodiments, variants are at least about 80% or at least about 90% identical to the native or reference sequence.
[0216] Polypeptide per Unit Drug (PUD): As used herein, PUD or product per unit drug is defined as a fraction of the total daily dose (usually 1 mg, pg, kg, etc.) of a product (e.g., a polypeptide) measured in a body fluid or tissue, usually defined as a concentration such as pmol / mL, mmol / mL, etc., divided by the index in the body fluid.
[0217] Preventing: As used herein, the term "preventing" means partially or completely delaying the onset of an infection, disease, disorder, and / or condition; partially or completely delaying the onset of one or more symptoms, characteristics, or clinical manifestations of a particular infection, disease, disorder, and / or condition; partially or completely delaying the onset of one or more symptoms, characteristics, or signs of a particular infection, disease, disorder, and / or condition; partially or completely delaying the progression of an infection, a particular disease, disorder, and / or condition; and / or reducing the risk of developing a condition associated with an infection, disease, disorder, and / or condition.
[0218] Prodrugs: The present disclosure also includes prodrugs of the compounds described herein. As used herein, "prodrug" refers to any substance, molecule, or entity that, upon chemical or physical modification, is in a form that renders the substance, molecule, or entity active as a therapeutic agent. Prodrugs can be covalently attached or sequestered in some manner and released or converted to an active drug moiety before, during, or after administration to a mammalian subject. Prodrugs can be prepared by modifying functional groups present in the compound such that the modifications are cleaved to the parent compound by routine manipulation or in vivo. Prodrugs include compounds in which a hydroxyl, amino, sulfhydryl, or carboxyl group is bonded to any group that, upon administration to a mammalian subject, is cleaved to form a free hydroxyl, amino, sulfhydryl, or carboxyl group, respectively. The preparation and use of prodrugs is discussed in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the ACS Symposium Series, and Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference in their entireties.
[0219] Proliferate: As used herein, the term "proliferate" means to grow, expand, or increase rapidly, or to cause rapid growth, expansion, or increase. "Proliferative" means having the capacity to proliferate. "Antiproliferative" means having properties opposite to or incompatible with the properties of proliferation.
[0220] Prophylactic: As used herein, "prophylactic" refers to a treatment or course of action used to prevent the spread of disease.
[0221] Prophylaxis: As used herein, "prophylaxis" refers to a measure to maintain health and prevent the spread of disease. "Immunoprophylaxis" refers to a measure to prevent the spread of disease by producing active or passive immunity.
[0222] Proteolytic cleavage site: As used herein, "proteolytic cleavage site" means a site at which controlled cleavage of an amino acid chain can be achieved by chemical, enzymatic, or photochemical means.
[0223] Protein cleavage signal: As used herein, "protein cleavage signal" means at least one amino acid that marks or labels a polypeptide for cleavage.
[0224] Protein of interest: As used herein, the term "protein of interest" or "desired protein" includes the proteins provided herein, as well as fragments, mutants, variants, and variations thereof.
[0225] Proximal: As used herein, the term "proximal" means located closer to a center or point or area of interest.
[0226] Pseudouridine: As used herein, pseudouridine refers to the C-glycoside isomer of the nucleoside uridine. A "pseudouridine analog" is any modification, variant, isoform, or derivative of pseudouridine. For example, pseudouridine analogs include 1-carboxymethyl-pseudouridine, 1-propynyl-pseudouridine, 1-taurinomethyl-pseudouridine, 1-taurinomethyl-4-thio-pseudouridine, 1-methylpseudouridine (m 1 Ψ), 1-methyl-4-thio-pseudouridine (m 1 s 4 Ψ), 4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m 3Ψ), 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydropseudouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, N1-methyl-pseudouridine, 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp 3 Examples of suitable uridine include, but are not limited to, 2'-O-methyl-pseudouridine (Ψm), and 2'-O-methyl-pseudouridine (Ψm).
[0227] Purified: As used herein, "purify," "purified," or "purified" means to make substantially pure or to remove unwanted components, material contaminants, impurities, or imperfections.
[0228] Reference nucleic acid sequence: The term "reference nucleic acid sequence" or "reference nucleic acid" or "reference nucleotide sequence" or "reference sequence" refers to a starting nucleic acid sequence (e.g., an RNA, e.g., an mRNA sequence) that can be sequence-optimized. In some embodiments, the reference nucleic acid sequence is a wild-type nucleic acid sequence, a fragment, or a variant thereof. In some embodiments, the reference nucleic acid sequence is a nucleic acid sequence that has previously been sequence-optimized.
[0229] Repeated transfection: As used herein, the term "repeated transfection" refers to transfecting the same cell culture with a polynucleotide multiple times. The cell culture can be transfected at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, at least 10 times, at least 11 times, at least 12 times, at least 13 times, at least 14 times, at least 15 times, at least 16 times, at least 17 times, at least 18 times, at least 19 times, at least 20 times, at least 25 times, at least 30 times, at least 35 times, at least 40 times, at least 45 times, at least 50 times, or more.
[0230] Salts: In some embodiments, the pharmaceutical compositions for intratumoral delivery disclosed herein comprise salts of some of the lipid components. The term "salt" includes any anionic and cationic complexes. Non-limiting examples of anions include inorganic and organic anions such as fluoride, chloride, bromide, iodide, oxalate (e.g., hemioxalate), phosphate, phosphonate, hydrogen phosphate, dihydrogen phosphate, oxide, carbonate, bicarbonate, nitrate, nitrite, nitride, bisulfite, sulfide, sulfite, bisulfate, sulfate, thiosulfate, hydrogen sulfate, borate, formate, acetate, benzoate, citrate, tartrate, lactate, acrylate, polyacrylate, furan, and the like. Examples of ions include phosphate ions, maleate ions, itaconate ions, glycolate ions, gluconate ions, malate ions, mandelate ions, tiglate ions, ascorbate ions, salicylate ions, polymethacrylate ions, perchlorate ions, chlorate ions, chlorite ions, hypochlorite ions, bromate ions, hypobromite ions, iodate ions, alkylsulfonate ions, arylsulfonate ions, arsenate ions, arsenite ions, chromate ions, dichromate ions, cyanide ions, cyanate ions, thiocyanate ions, hydroxide ions, peroxide ions, permanganate ions, and mixtures thereof.
[0231] Sample: As used herein, the term "sample" or "biological sample" refers to a subset of tissues, cells, or components (e.g., bodily fluids, including, but not limited to, blood, mucus, lymph, synovial fluid, cerebrospinal fluid, saliva, amniotic fluid, amniotic cord blood, urine, vaginal fluid, and semen). A sample can also include a whole organism or a subset of some of its tissues, cells, or components, including, but not limited to, plasma, serum, spinal fluid, lymph, integumentary parts, respiratory, intestinal, and genitourinary tracts, tears, saliva, breast milk, blood cells, tumors, organs, or homogenates, lysates, or extracts prepared from fractions or portions thereof. Sample also refers to media, such as nutrient broths or gels, which may contain cellular components (e.g., proteins or nucleic acid molecules).
[0232] Sequence optimization: The term "sequence optimization" refers to a process or set of processes in which nucleobases in a reference nucleic acid sequence are replaced with alternative nucleobases to obtain a nucleic acid sequence with improved properties, e.g., improved protein expression or reduced immunogenicity.
[0233] Generally, the goal of sequence optimization is to produce a similar nucleotide sequence that encodes the same polypeptide sequence as encoded by the reference nucleotide sequence, such that there are no amino acid substitutions (as a result of codon optimization) in the polypeptide encoded by the optimized nucleotide sequence relative to the polypeptide encoded by the reference nucleotide sequence.
[0234] Signal sequence: As used herein, the terms "signal sequence," "signal peptide," and "transit peptide" are used interchangeably and refer to a sequence that enables the transport or localization of a protein to a particular organelle, cellular compartment, or extracellular export. The term encompasses both signal sequence polypeptides and nucleic acid sequences that encode signal sequences. Thus, in the context of nucleic acids, reference to a signal sequence actually refers to the nucleic acid sequence that encodes the signal sequence polypeptide.
[0235] Signal Transduction Pathway: "Signal Transduction Pathway" refers to the biochemical association between various signaling molecules that play a role in transmitting a signal from one part of a cell to another part of the cell. As used herein, the phrase "cell surface receptor" includes, for example, molecules and molecular complexes that are capable of receiving a signal and transmitting such a signal across the plasma membrane of a cell.
[0236] Similarity: As used herein, the term "similarity" refers to the overall relatedness between polymer molecules, e.g., between polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or between polypeptide molecules. Calculation of percent similarity of polymer molecules to each other can be performed in the same manner as calculation of percent identity, except that calculation of percent similarity takes into account conservative substitutions, as understood in the art.
[0237] Specific delivery: As used herein, the terms "specific delivery," "specifically deliver," or "specific delivery" refer to the delivery of more (e.g., at least 1.5-fold, at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 6-fold, at least 7-fold, at least 8-fold, at least 9-fold, at least 10-fold) polynucleotide by a nanoparticle to a target tissue of interest (e.g., the liver of a mammal) compared to an off-target tissue (e.g., the spleen of a mammal). The amount of nanoparticle delivered to a particular tissue can be measured by comparing the amount of protein produced in the tissue to the weight of the tissue, comparing the amount of polynucleotide in the tissue to the weight of the tissue, comparing the amount of protein produced in the tissue to the amount of total protein in the tissue, or comparing the amount of polynucleotide in the tissue to the amount of total polynucleotide in the tissue. For example, with respect to renal vascular targeting, a polynucleotide is specifically provided to the kidney of a mammal compared to the liver and spleen if 1.5, 2, 3, 5, 10, 15, or 20 times more polynucleotide is delivered to the kidney per gram of tissue compared to the polynucleotide delivered to the liver or spleen following systemic administration of the polynucleotide. It will be understood that the ability to specifically deliver nanoparticles to target tissues need not be measured in a subject being treated, but can be measured in a surrogate organism, such as an animal model (e.g., a rat model).
[0238] Stable: As used herein, "stable" means a compound that is sufficiently robust to survive isolation to a useful purity from a reaction mixture, and, in some cases, amenable to formulation into an effective therapeutic agent.
[0239] Stabilized: As used herein, the terms "stabilize," "stabilized," and "stabilized region" mean to stabilize or to become stable.
[0240] Stereoisomers: As used herein, the term "stereoisomers" refers to all possible different isomeric forms and structural forms that a compound (e.g., a compound of any formula described herein) may possess, in particular all possible stereochemical and structural isomeric forms, all diastereomers, enantiomers, and / or conformational isomers of the basic molecular structure. Some compounds of the present disclosure can exist in different tautomeric forms, all of the latter being included within the scope of the present disclosure.
[0241] Subject: "Subject" or "individual" or "animal" or "patient" or "mammal" refers to any subject for which diagnosis, prognosis, or treatment is desired, particularly a mammalian subject. Mammalian subjects include, but are not limited to, humans, domestic animals, farm animals, zoo animals, sport animals, pet animals (e.g., dogs, cats, guinea pigs, rabbits, rats, mice, horses, cows, cows), primates (e.g., apes, monkeys, orangutans, and chimpanzees), canines (e.g., dogs and wolves), felines (e.g., cats, lions, and tigers), equines (e.g., horses, donkeys, and zebras), bears, food animals (e.g., cows, pigs, and sheep), ungulates (e.g., deer and giraffes), rodents (e.g., mice, rats, hamsters, and guinea pigs), and the like. In certain embodiments, the mammal is a human subject. In other embodiments, the subject is a human patient. In certain embodiments, the subject is a human patient in need of cancer treatment.
[0242] Substantially: As used herein, the term "substantially" refers to the qualitative state of completely or nearly completely exhibiting a desired characteristic or property. Those skilled in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completeness and / or progress toward completeness or achieve or avoid absolute results. Thus, as used herein, the term "substantially" captures the potential lack of completeness inherent in many biological and chemical phenomena.
[0243] Substantially equal: As used herein in relation to the time difference between doses, this term means ±2%.
[0244] Substantially simultaneous: As used herein in reference to multiple administrations, this term means within 2 seconds.
[0245] Suffering from: An individual "suffering from" a disease, disorder, and / or condition has been diagnosed with or exhibits one or more symptoms of the disease, disorder, and / or condition.
[0246] Susceptible to: An individual who is "susceptible to" a disease, disorder, and / or condition may not have been diagnosed with and / or may not exhibit symptoms of the disease, disorder, and / or condition, but has a propensity to develop the disease or its symptoms. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition (e.g., cancer) can be characterized by one or more of the following: (1) a genetic mutation associated with the development of the disease, disorder, and / or condition, (2) a genetic polymorphism associated with the development of the disease, disorder, and / or condition, (3) an increase and / or decrease in protein and / or nucleic acid expression and / or activity associated with the disease, disorder, and / or condition, (4) habits and / or lifestyle associated with the development of the disease, disorder, and / or condition, (5) a family history of the disease, disorder, and / or condition, and (6) exposure to and / or infection with a microorganism associated with the development of the disease, disorder, and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition develops the disease, disorder, and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition does not develop the disease, disorder, and / or condition.
[0247] Sustained release: As used herein, the term "sustained release" refers to a release profile of a pharmaceutical composition or compound that matches a release rate over a specific period of time.
[0248] Synthetic: The term "synthetic" means made, prepared, and / or manufactured by the hand of man. Synthesis of polynucleotides or other molecules of the disclosure can be chemical or enzymatic.
[0249] Targeted cell: As used herein, "targeted cell" means any one or more cells of interest. The cells may be found in vitro, in vivo, in situ, or in a tissue or organ of an organism. The organism may be an animal, preferably a mammal, more preferably a human, and most preferably a patient.
[0250] Target tissue: As used herein, "target tissue" refers to any one or more tissue types of interest to which delivery of a polynucleotide will result in a desired biological and / or pharmacological effect. Examples of target tissues of interest include specific tissues, organs, and systems or groups thereof. In certain applications, the target tissue may be kidney, lung, spleen, vascular endothelium (e.g., intracoronary or intrafemoral), or tumor tissue (e.g., via intratumoral injection). "Off-target tissue" refers to any one or more tissue types in which expression of the encoded protein does not result in a desired biological and / or pharmacological effect. In certain applications, off-target tissues may include the liver and spleen.
[0251] Targeting sequence: As used herein, the phrase "targeting sequence" means a sequence that is capable of directing the transport or localization of a protein or polypeptide.
[0252] Terminus: As used herein, when referring to a polypeptide, the term "terminus" or "terminus" refers to the end of a peptide or polypeptide. Such terminus is not limited to the first or last position of a peptide or polypeptide, but can also include additional amino acids in the terminal region. Polypeptide molecules of the present disclosure can be characterized as having both an N-terminus (terminating with an amino acid having a free amino group (NH)) and a C-terminus (terminating with an amino acid having a free carboxyl group (COOH)). Proteins of the present disclosure are optionally made up of multiple polypeptide chains (multimers, oligomers) held together by disulfide bonds or non-covalent forces. These types of proteins have multiple N- and C-termini. Alternatively, the termini of a polypeptide can be optionally modified to begin or end at a non-polypeptide moiety, such as an organic conjugate.
[0253] Therapeutic Agent: The term "therapeutic agent" refers to an agent (e.g., mRNA) that has a therapeutic, diagnostic, and / or prophylactic effect and / or induces a desired biological and / or pharmacological effect when administered to a subject. For example, in some embodiments, an mRNA encoding an IL12, IL15, IL18, IL23, or IL36 polypeptide, or a combination thereof, can be a therapeutic agent.
[0254] Therapeutically effective amount: As used herein, the term "therapeutically effective amount" means the amount of an agent (e.g., nucleic acid, drug, therapeutic agent, diagnostic agent, prophylactic agent, etc.) delivered that, when administered to a subject suffering from or susceptible to an infection, disease, disorder, and / or condition, is sufficient to treat, ameliorate the symptoms of, diagnose, prevent, and / or delay the onset of the infection, disease, disorder, and / or condition.
[0255] Therapeutically Effective Result: As used herein, the term "therapeutically effective result" means a result sufficient to treat, ameliorate the symptoms of, diagnose, prevent, and / or delay the onset of an infection, disease, disorder, and / or condition in a subject suffering from or susceptible to the infection, disease, disorder, and / or condition.
[0256] Total daily dose: As used herein, the "total daily dose" is the amount administered or prescribed in a 24-hour period. The total daily dose can be administered in a single unit dose or in divided doses.
[0257] Transcription factor: As used herein, the term "transcription factor" refers to a DNA-binding protein that controls transcription of DNA into RNA, for example, by activating or repressing transcription. Some transcription factors alone mediate transcriptional regulation, while others act in concert with other proteins. Some transcription factors can both activate and repress transcription under certain conditions. Generally, transcription factors bind to specific target sequence(s) that closely resemble specific consensus sequences within the regulatory regions of target genes. Transcription factors can control the transcription of target genes alone or in complexes with other molecules.
[0258] Transcription: As used herein, the term "transcription" refers to a method for introducing exogenous nucleic acid into a cell. Transcription methods include, but are not limited to, chemical methods, physical treatments, and cationic lipids or mixtures.
[0259] Transfection: As used herein, "transfection" refers to the introduction of a polynucleotide into a cell such that a polypeptide encoded by the polynucleotide is expressed (e.g., mRNA) or the polypeptide regulates a cellular function (e.g., siRNA, miRNA). As used herein, "expression" of a nucleic acid sequence refers to the translation of the polynucleotide (e.g., mRNA) into a polypeptide or protein and / or the post-translational modification of the polypeptide or protein.
[0260] Treating, therapy, therapy: As used herein, the terms "treating" or "treatment" or "therapy" refer to partially or completely alleviating, ameliorating, ameliorating, curing, delaying the onset of, inhibiting progression of, reducing the severity of, and / or reducing the occurrence of one or more signs or characteristics of a hyperproliferative disease (e.g., cancer). For example, "treating" cancer can refer to inhibiting tumor survival, growth, and / or spread. Treatment can be administered to subjects who do not show signs of a disease, disorder, and / or condition and / or who show only early signs of a disease, disorder, and / or condition, with the intent of reducing the risk of developing a condition associated with the disease, disorder, and / or condition.
[0261] Unmodified: As used herein, "unmodified" refers to any substance, compound, or molecule before it has been altered in any way. Unmodified can, but does not necessarily, refer to a biomolecule in its wild-type or naturally occurring form. A molecule can undergo a series of modifications, whereby each modified molecule can serve as the "unmodified" starting molecule for subsequent modifications.
[0262] Uracil: Uracil is one of the four nucleobases in RNA nucleic acids and can be represented by the letter U. Uracil can be attached to a ribose ring, or more specifically, to a ribofuranose, via a β-N1-glycosidic bond to give the nucleoside uridine. The nucleoside uridine can also be generally abbreviated according to the one-letter code of its nucleobase (i.e., U). Therefore, in the context of the present disclosure, when a monomer of a polynucleotide sequence is U, such U is referred to interchangeably as "uracil" or "uridine."
[0263] Uridine content: The terms "uridine content" and "uracil content" are interchangeable and refer to the amount of uracil or uridine present in a particular nucleic acid sequence. Uridine or uracil content can be expressed as an absolute value (the total number of uridines or uracils in the sequence) or a relative value (the percentage of uridines or uracils relative to the total number of nucleobases in the nucleic acid sequence).
[0264] Uridine-modified sequence: The term "uridine-modified sequence" refers to a sequence-optimized nucleic acid (e.g., a synthetic mRNA sequence) that has a different overall or local uridine content (high or low uridine content) or a different uridine pattern (e.g., gradient distribution or clustering) relative to the uridine content and / or uridine pattern of a candidate nucleic acid sequence. In the context of the present disclosure, the terms "uridine-modified sequence" and "uracil-modified sequence" are considered equivalent and interchangeable.
[0265] A "high uridine codon" is defined as a codon containing two or three uridines, a "low uridine codon" is defined as a codon containing one uridine, and a "non-uridine codon" is a codon that does not contain any uridines. In some embodiments, uridine-modified sequences include substitutions of a high uridine codon with a low uridine codon, a high uridine codon with a non-uridine codon, a low uridine codon with a high uridine codon, a low uridine codon with a non-uridine codon, a non-uridine codon with a low uridine codon, a non-uridine codon with a high uridine codon, and combinations thereof. In some embodiments, a high uridine codon can be replaced with another high uridine codon. In some embodiments, a low uridine codon can be replaced with another low uridine codon. In some embodiments, a non-uridine codon can be replaced with another non-uridine codon. The uridine modified sequence can be a uridine-rich sequence or a uridine-poor sequence.
[0266] Uridine-rich: As used herein, the term "uridine-rich" and grammatical variations thereof refer to an increase in the uridine content (expressed in absolute terms or as a percentage) in a nucleic acid (e.g., a synthetic mRNA sequence) being sequence-optimized relative to the uridine content of a corresponding candidate nucleic acid sequence. Uridine enrichment can be achieved by replacing codons in the candidate nucleic acid sequence with synonymous codons that contain fewer uridine nucleobases. Uridine enrichment can be global (i.e., across the entire length of the candidate nucleic acid sequence) or local (i.e., across a subsequence or region of the candidate nucleic acid sequence).
[0267] Uridine-scarce: As used herein, the term "uridine-scarce" and grammatical variations thereof refer to a reduction in the uridine content (expressed in absolute terms or as a percentage) in a nucleic acid (e.g., a synthetic mRNA sequence) being sequence-optimized relative to the uridine content of a corresponding candidate nucleic acid sequence. Uridine scarcity can be achieved by replacing codons in the candidate nucleic acid sequence with synonymous codons that contain fewer uridine nucleobases. Uridine scarcity can be global (i.e., across the entire length of the candidate nucleic acid sequence) or local (i.e., across a subsequence or region of the candidate nucleic acid sequence).
[0268] Variant: As used in this disclosure, the term "variant" refers to both natural variants (e.g., polymorphisms, isoforms, etc.) and artificial variants in which at least one amino acid residue in a native or starting sequence (e.g., a wild-type sequence) has been removed and a different amino acid inserted in its place at the same position. These variants can be described as "substitutional variants." The substitutions can be single, where only one amino acid in the molecule has been substituted, or multiple, where two or more amino acids in the same molecule have been substituted. When amino acids are inserted or deleted, the resulting variants are "insertion variants" or "deletion variants," respectively.
[0269] Antibody: The terms "antibody" and "immunoglobulin" are used interchangeably herein and include whole antibodies and any antigen-binding portion thereof, or single chains. A typical antibody comprises at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each heavy chain is composed of a heavy chain variable region (abbreviated herein as VH or VH) and a heavy chain constant region. The heavy chain constant region is composed of three domains, CH1, CH2, and CH3. Each light chain is composed of a light chain variable region (abbreviated herein as VL or VL) and a light chain constant region. The light chain constant region is composed of one domain (CL). The VH and VL regions can be further subdivided into highly variable regions called complementarity-determining regions (CDRs), interspersed with regions that are relatively conserved, called framework regions (FW). Each VH and VL is composed of three CDRs and four FWs, arranged from the amino terminus to the carboxy terminus in the following order: FW1, CDR1, FW2, CDR2, FW3, CDR3, and FW4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant regions of the antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.
[0270] The term "antibody" encompasses any immunoglobulin molecule that recognizes and specifically binds to a target (e.g., CTLA-4) through at least one antigen recognition site within the variable region of the immunoglobulin molecule. The term "antibody" encompasses intact polyclonal antibodies, intact monoclonal antibodies, antibody fragments (e.g., Fab, Fab', F(ab')2, and Fv fragments), single-chain Fv (scFv) variants, multispecific antibodies such as bispecific antibodies generated from at least two intact antibodies, chimeric antibodies, humanized antibodies, human antibodies, fusion proteins containing an antigenic determinant of an antibody, and any other modified immunoglobulin molecule containing an antigen recognition site, so long as the antibody exhibits the desired biological activity.
[0271] Antibodies can be any of five major immunoglobulin classes: IgA, IgD, IgE, IgG, and IgM, or their subclasses (isotypes, e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), based on the identity of their heavy chain constant domains, called alpha, delta, epsilon, gamma, and mu, respectively. Different classes of immunoglobulins have different and well-known subunit structures and three-dimensional configurations.
[0272] The term "antibody" also encompasses molecules comprising an immunoglobulin domain (e.g., a VH, CL, CL, CH1, CH2, or CH3 domain) of an antibody fused to another molecule, i.e., a fusion protein. In some embodiments, such a fusion protein comprises an antigen-binding site (e.g., an scFv). The antibody portion of the fusion protein comprising the antigen-binding site can be used to target a therapeutic agent (e.g., a cytotoxin) to a desired cell or tissue location, as determined by the specificity of the antigen-binding site.
[0273] Therapeutic antibody: The term "therapeutic antibody" is used broadly to encompass any antibody or functional fragment thereof that functions to deplete target cells in a patient. Such target cells include, for example, tumor cells. Therapeutic antibodies can mediate cytotoxic effects or cytolysis, for example, by antibody-dependent cellular cytotoxicity (ADCC), among others. Therapeutic antibodies according to the present disclosure can be directed against surface epitopes that are overexpressed by cancer cells.
[0274] Blocking antibody: In some embodiments, a therapeutic antibody is a blocking antibody. The term "blocking antibody" or "antagonist antibody" refers to an antibody that inhibits or reduces the biological activity of the antigen to which it binds. In certain embodiments, a blocking or antagonist antibody substantially or completely inhibits the biological activity of the antigen. In some embodiments, the biological activity is reduced by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or even 100%.
[0275] Antigen-binding portion thereof: As used herein, the term "antigen-binding portion," when used in reference to an antibody disclosed herein, is intended to refer to a portion of an antibody that is capable of specifically binding to the antigen specifically bound by the antibody. The term "antigen-binding portion" also refers to constructs derived from antibodies that function as blocking or targeting antibodies, e.g., scFvs. Whether a binding portion is still capable of specifically binding to its antigen can be determined using binding assays known in the art (e.g., BIACORE).
[0276] Variable region: The "variable region" of an antibody refers to the variable region of the antibody light chain or the variable region of the antibody heavy chain, either alone or in combination. The heavy and light chain variable regions each consist of four FW regions connected by three CDR regions. The CDRs of each chain are held together in close proximity by the FW regions and, together with the CDRs of the other chain, contribute to the formation of the antigen-binding site of the antibody. Several techniques exist for determining the location of CDRs. When referring to residues within the variable domain (approximately residues 1-107 in the light chain and residues 1-113 in the heavy chain), the Kabat numbering system is commonly used (e.g., Kabat et al., Sequences of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)).
[0277] The boundaries of the structural components of antibodies presented in this disclosure, i.e., CDR1, CDR2, and CDR3 of the VH or VL domain, the VH and VL domains, and the constant regions CL, CH1, CH2, and CH3, can be identified according to methods known to those of skill in the art. For example, boundaries of structural components within antibodies can be identified from sequence data alone using the Paratome tool, available at URL: tools.immuneepitope.org / paratome / . See Kunik et al. (2012) PLoS Comput. Biol. 8:2; Kunik et al. (2012). Nucleic Acids Res. 40 (Web Server issue):W521-4.
[0278] Epitope: As used herein, the term "epitope" refers to an antigenic protein determinant capable of binding to an antibody or antigen-binding portion thereof disclosed herein. Epitopes are typically composed of chemically active surface groupings of molecules such as amino acids or sugar side chains and typically have specific three-dimensional structural and charge characteristics. The portion of an antibody or binding molecule that recognizes an epitope is called a paratope. Epitopes of protein antigens are divided into two categories based on their structure and interaction with the paratope: conformational epitopes and linear epitopes. Conformational epitopes are composed of discontinuous sections of the antigen's amino acid sequence. These epitopes interact with the paratope based on the antigen's 3D surface characteristics and shape or tertiary structure. In contrast, linear epitopes interact with the paratope based on their primary structure. Linear epitopes are formed by the contiguous sequence of amino acids in the antigen.
[0279] II. mRNA Combination Therapy for Cancer Treatment The present disclosure provides a novel approach to treating cancer, i.e., cancer immunotherapy, which involves preventing or treating the disease with polynucleotides (e.g., mRNA) that include open reading frames encoding polypeptides that stimulate an immune response to the cancer.
[0280] In particular, the present disclosure provides, for example, compositions for treating cancer (e.g., tumors) comprising at least two polynucleotides (e.g., mRNA), wherein the at least two polynucleotides are: (i) a polynucleotide (e.g., mRNA) comprising an ORF encoding an immune response primer polypeptide; (ii) a polynucleotide (e.g., mRNA) comprising an ORF encoding an immune response costimulatory signal polypeptide; (iii) a polynucleotide (e.g., mRNA) comprising an ORF encoding a checkpoint inhibitor polypeptide, or a checkpoint inhibitor polypeptide; and (iv) combinations thereof; is selected from the group consisting of:
[0281] In some embodiments, the polynucleotides in the composition are in a single formulation.
[0282] The present disclosure also provides methods for treating cancer using the compositions disclosed herein. Accordingly, the present disclosure provides a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, the method comprising administering to the subject at least two polynucleotides (e.g., mRNA) and optionally a checkpoint inhibitor polypeptide, wherein the at least two polynucleotides are: (i) a polynucleotide (e.g., mRNA) comprising an ORF encoding an immune response primer polypeptide; (ii) a polynucleotide (e.g., mRNA) comprising an ORF encoding an immune response costimulatory signal polypeptide; (iii) a polynucleotide (e.g., mRNA) comprising an ORF encoding a checkpoint inhibitor polypeptide, or a checkpoint inhibitor polypeptide; and (iv) combinations thereof; is selected from the group consisting of:
[0283] The present disclosure also provides a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, the method comprising administering to the subject at least one polynucleotide and a checkpoint inhibitor polypeptide, wherein the at least one polynucleotide is (i) a polynucleotide (e.g., mRNA) comprising an ORF encoding an immune response primer polypeptide; (ii) a polynucleotide (e.g., mRNA) comprising an ORF encoding an immune response costimulatory signal polypeptide; and (iii) any combination thereof; is selected from the group consisting of:
[0284] As used throughout this disclosure, the term "combination therapy" refers to a combination of polynucleotides (e.g., mRNAs) where each polynucleotide includes an ORF encoding an immune response primer polypeptide, an immune response costimulatory signal polypeptide, or a checkpoint inhibitor polypeptide, which can be administered simultaneously, concurrently, or sequentially to a subject in need thereof, either as a single formulation or as part of multiple formulations. For example, the combination therapy can include (i) a first polynucleotide (e.g., mRNA) that includes a first ORF that encodes a first polypeptide (e.g., an immune response primer polypeptide such as IL23), and (ii) a second polynucleotide (e.g., mRNA) that includes a second ORF that encodes a second polypeptide (e.g., an immune response costimulatory signal polypeptide such as OX40L). Or, for example, a combination therapy can include (i) a first polynucleotide (e.g., mRNA) comprising a first ORF encoding a first polypeptide, (ii) a second polynucleotide (e.g., mRNA) comprising a second ORF encoding a second polypeptide, and (iii) a third polynucleotide (e.g., mRNA) comprising a third ORF encoding a third polypeptide. It is understood that the term "combination therapy" is not limited to the physical combination of polynucleotides, but also encompasses the separate administration of both of these polynucleotides simultaneously, concurrently, or sequentially to a subject in need thereof, either as part of a single formulation or multiple formulations.
[0285] As used herein, the term "doublet" refers to two components (polynucleotides, polypeptides, or combinations thereof), i.e., (i) a first polynucleotide comprising a first ORF encoding a first polypeptide, and a second polynucleotide comprising a second ORF encoding a second polypeptide, or (ii) a first polynucleotide comprising a first ORF encoding a first polypeptide, and a second polypeptide; This refers to combination therapy including:
[0286] As used herein, the term "triplet" refers to three components (polynucleotide, polypeptide, or combination thereof), i.e., (i) a first polynucleotide comprising a first ORF encoding a first polypeptide, a second polynucleotide comprising a second ORF encoding a second polypeptide, and a third polynucleotide comprising a third ORF encoding a third polypeptide; or (ii) a first polynucleotide comprising a first ORF encoding a first polypeptide, a second polynucleotide comprising a second ORF encoding a second polypeptide, and a third polypeptide; or (iii) a first polynucleotide comprising a first ORF encoding a first polypeptide, a second polypeptide, and a third polypeptide; This refers to combination therapy including:
[0287] Thus, as shown in the examples above, the term combination therapy encompasses the use of any of immune response primers (polynucleotides or polypeptides), immune response costimulatory signals (polynucleotides or polypeptides), and checkpoint inhibitors (polynucleotides or polypeptides), provided that at least one of the components in the combination therapy is a polynucleotide, and in particular, mRNA. For example, in certain embodiments, immune response primers, immune response costimulatory signals, and checkpoint inhibitors, such as IL12, IL18, IL23, IL36 gamma, TLR4, CD80, OX40L, anti-CTLA-4, anti-PD-1, or anti-PD-L1, can be administered either as polypeptides or as polynucleotides encoding such polypeptides.
[0288] As used herein, the term "immune response primer" refers to a molecule that enhances antigen presentation and / or recognition. In some embodiments, the immune response primer is IL12 or IL23. In certain embodiments of the methods and compositions disclosed herein, the immune response primer is interleukin 12 (IL12), interleukin (IL23), toll-like receptor 4 (TLR4), interleukin 36 gamma (IL36 gamma), interleukin 18 (IL18), or a combination thereof. The combination therapies of the present disclosure, i.e., those treatments that combine immune response primers, immune response costimulatory signals, checkpoint inhibitors, and combinations thereof, can also incorporate other immune response primers (either as polypeptides or as polynucleotides encoding such polypeptides) known in the art.
[0289] As used herein, the term "immune response costimulatory signal" refers to an immune stimulatory molecule that promotes T / NK cell recruitment, proliferation, activation, survival, or a combination thereof. In some embodiments, the immune response costimulatory signal enhances T cell proliferation, function, and memory formation (e.g., OX40L). In certain embodiments of the methods and compositions disclosed herein, the immune response costimulatory signal is tumor necrosis factor receptor superfamily member 4 ligand (OX40L), cluster of differentiation 80 (CD80), interleukin-15 (IL15), or a combination thereof. The combination therapies of the present disclosure, i.e., those treatments that combine immune response primers, immune response costimulatory signals, checkpoint inhibitors, and combinations thereof, can also incorporate other immune response costimulatory signals known in the art, either as polypeptides or as polynucleotides encoding such polypeptides.
[0290] As used herein, the term "checkpoint inhibitor" refers to a molecule that prevents immune cells from being "blocked" by cancer cells. As used herein, the term checkpoint inhibitor refers to a polypeptide (e.g., an antibody) or a polynucleotide (e.g., mRNA) encoding such a polypeptide, which neutralizes or inhibits inhibitory checkpoint molecules, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed death 1 receptor (PD-1), or PD-1 ligand 1 (PD-L1), and combinations thereof. Thus, in some embodiments, the checkpoint inhibitor polypeptide is an antibody or a polynucleotide encoding the antibody. In some embodiments, the antibody is an anti-CTLA-4 antibody or antigen-binding fragment thereof that specifically binds to CTLA-4, an anti-PD-1 antibody or antigen-binding fragment thereof that specifically binds to PD-1, an anti-PD-L1 antibody or antigen-binding fragment thereof that specifically binds to PD-L1, and combinations thereof. In some embodiments, the anti-PD-L1 antibody is atezolizumab, avelumab, or durvalumab. In some embodiments, the anti-CTLA-4 antibody is tremelimumab or ipilimumab. In some embodiments, the anti-PD-1 antibody is nivolumab or pembrolizumab. The combination therapies of the present disclosure, i.e., those treatments combining immune response primers, immune response costimulatory signals, checkpoint inhibitors, and combinations thereof, can also incorporate other checkpoint inhibitors known in the art, either as polypeptides or as polynucleotides encoding such polypeptides.
[0291] These examples include, but are not limited to, that the combination therapies disclosed herein intervene at multiple points of intervention in the immune system, e.g., (a) stimulating an immune response by administering an immune response primer, and / or (b) boosting an immune response triggered by or improved by administration of an immune response primer(s), or boosting an existing immune response by administering an immune response costimulatory signal, and / or (c) removing or preventing inhibition of the immune response by inhibitory checkpoint molecules by administering one or more checkpoint inhibitors (e.g., by co-administration of an anti-CTLA-4 antibody and / or an anti-PD-1 antibody, at one or more points of intervention); This simply demonstrates that it is possible to fine-tune the immune response to cancer.
[0292] In certain embodiments of the methods disclosed herein, the at least two polynucleotides administered in the combination therapy are (i) a first polynucleotide (e.g., mRNA) comprising an ORF encoding a first immune response primer polypeptide, and a second polynucleotide (e.g., mRNA) comprising an ORF encoding a second immune response primer polypeptide; (ii) a first polynucleotide (e.g., mRNA) comprising an ORF encoding an immune response primer polypeptide, and a second polynucleotide (e.g., mRNA) comprising an ORF encoding an immune response costimulatory signal polypeptide; or (iii) (i) or (ii) a polynucleotide (e.g., mRNA) comprising an ORF encoding a checkpoint inhibitor polypeptide, or further comprising a checkpoint inhibitor polypeptide; is.
[0293] The present disclosure also provides a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, the method comprising administering to the subject at least two polynucleotides (e.g., mRNAs) encoding a first polypeptide and a second polypeptide, wherein (1) the first polypeptide is selected from the group consisting of an IL12 polypeptide, an IL23 polypeptide, an IL36 gamma polypeptide, an OX40L polypeptide, a CD80 polypeptide (e.g., CD80-Fc), a TLR4 polypeptide (e.g., caTLR4), an IL18 polypeptide, an IL15 polypeptide, an anti-CTLA-4 antibody, and combinations thereof, and (2) the second polypeptide is an immune response primer polypeptide, an immune response costimulatory signal polypeptide, or a checkpoint inhibitor polypeptide.
[0294] In some embodiments, the present disclosure includes a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, the method comprising administering to the subject (i) at least one polynucleotide (e.g., mRNA) encoding a first polypeptide, and (ii) a checkpoint inhibitor polypeptide, wherein the first polypeptide is selected from the group consisting of: (i) an IL12 polypeptide, (ii) an IL23 polypeptide, (iii) an IL36 gamma polypeptide, (iv) an OX40L polypeptide, (v) a CD80 polypeptide (e.g., CD80-Fc), (vi) a TLR4 polypeptide (e.g., caTLR4), (vii) an IL18 polypeptide, (viii) an IL15 polypeptide, (ix) an anti-CTLA-4 antibody, and (x) a combination thereof. In some embodiments, the checkpoint inhibitor is an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, or any combination thereof.
[0295] The present disclosure provides a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, the method comprising administering at least two polynucleotides, wherein a first polynucleotide (an "IL12 polynucleotide") comprises an ORF encoding an IL12 polypeptide and a second polynucleotide comprises an ORF encoding an immune response primer polypeptide, an immune response costimulatory signal polypeptide, or a checkpoint inhibitor polypeptide, or a polynucleotide encoding the same. In some embodiments, the second polynucleotide comprises an ORF encoding an OX40L polypeptide. In other embodiments, the disclosure provides a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, the method comprising administering an IL12 polynucleotide and a checkpoint inhibitor polypeptide comprising an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, or any combination thereof. In other embodiments, the method of the invention comprises administering an IL12 polynucleotide, e.g., mRNA, in combination with an anti-PD-1 antibody. In some embodiments, the method of the invention comprises administering an IL12 polynucleotide, e.g., mRNA, and an anti-PD-L1 antibody. In other embodiments, the methods of the invention comprise administering an IL12 polynucleotide, e.g., mRNA, and an anti-CTLA-4 antibody. In certain embodiments, the methods of the invention comprise administering an IL12 polynucleotide, e.g., mRNA, and a polynucleotide comprising an ORF encoding an OX40L polypeptide (an "OX40L polynucleotide"). In other embodiments, the methods of the invention comprise administering an IL12 polynucleotide, an OX40L polynucleotide, and a checkpoint inhibitor polypeptide, e.g., an anti-CTLA-4 antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, or any combination thereof.
[0296] The present disclosure also provides a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, the method comprising administering at least two polynucleotides, wherein a first polynucleotide (an "IL15 polynucleotide") comprises an ORF encoding an IL15 polypeptide and a second polynucleotide comprises an ORF encoding an immune response primer polypeptide, an immune response costimulatory signal polypeptide, or a checkpoint inhibitor polypeptide. In other embodiments, the present disclosure includes a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, the method comprising administering at least one polynucleotide and a checkpoint inhibitor, wherein the first polynucleotide comprises an IL15 polynucleotide and the checkpoint inhibitor comprises an anti-CTLA-4 antibody, an anti-PD-1 antibody, an anti-PD-L1 antibody, or any combination thereof.
[0297] The present disclosure also provides a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, the method comprising administering at least two polynucleotides, wherein a first polynucleotide (an "IL18 polynucleotide") comprises an ORF encoding an IL18 polypeptide, and a second polynucleotide comprises an ORF encoding an immune response primer polypeptide, an immune response costimulatory signal polypeptide, or a checkpoint inhibitor polypeptide. In some embodiments, the second polynucleotide comprises an ORF encoding a polypeptide selected from the group consisting of an IL12 polypeptide, an IL23 polypeptide, a TLR4 polypeptide (e.g., caTLR4), an OX40L polypeptide, an anti-CTLA-4 antibody, and any combination thereof. In other embodiments, the present disclosure provides a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, the method comprising administering an IL18 polynucleotide and a checkpoint inhibitor polypeptide comprising an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, or any combination thereof. In some embodiments, the method of the present invention comprises administering an IL18 polynucleotide and an OX40L polynucleotide. In other embodiments, the methods of the invention comprise administering an IL18 polynucleotide and a polynucleotide comprising an ORF encoding an IL23 polypeptide (an "IL23 polynucleotide"). In some embodiments, the methods of the invention comprise administering an IL18 polynucleotide and a polynucleotide comprising an ORF encoding a TLR4 polypeptide, e.g., caTLR4 (a "TLR4 polynucleotide"). In other embodiments, the methods of the invention comprise administering an IL18 polynucleotide and an IL12 polynucleotide. In some embodiments, the methods of the invention comprise administering an IL18 polynucleotide, an IL12 polynucleotide, and an IL23 polynucleotide in combination.In yet another embodiment, the methods of the invention comprise administering an IL18 polynucleotide, an IL12 polynucleotide, an IL23 polynucleotide, a TLR4 polynucleotide, an OX40L polynucleotide, an anti-CTLA-4 antibody or a polynucleotide encoding the same, an anti-PD1 antibody, and / or an anti-PD-L1 antibody, in any combination.
[0298] Also provided are methods of reducing tumor size or inhibiting tumor growth in a subject in need thereof, the methods comprising administering at least two polynucleotides, wherein a first polynucleotide (an "IL23 polynucleotide") comprises an ORF encoding an IL23 polypeptide, and a second polynucleotide comprises an ORF encoding an immune response primer polypeptide, an immune response costimulatory signal polypeptide, or a checkpoint inhibitor polypeptide. In some embodiments, the second polynucleotide comprises an ORF encoding a polypeptide selected from the group consisting of an IL12 polypeptide, an IL18 polypeptide, an OX40L polypeptide, and any combination thereof. In other embodiments, the present disclosure provides methods of reducing tumor size or inhibiting tumor growth in a subject in need thereof, the methods comprising administering an IL23 polynucleotide and a checkpoint inhibitor polypeptide comprising an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, or any combination thereof. In some embodiments, the methods of the invention comprise administering an IL23 polynucleotide and an OX40L polynucleotide. In some embodiments, the methods of the invention comprise administering an IL23 polynucleotide and an IL12 polynucleotide. In another embodiment, the method of the invention comprises administering an IL23 polynucleotide and an anti-CTLA-4 antibody. In another embodiment, the method of the invention comprises administering an IL23 polynucleotide, an OX40L polynucleotide, an IL12 polypeptide, an IL18 polypeptide, and an anti-CTLA-4 antibody in combination. In another embodiment, the method of the invention comprises administering an IL23 polynucleotide, an IL12 polypeptide, an IL18 polypeptide, and an anti-CTLA-4 antibody in any combination.
[0299] Also provided is a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, the method comprising administering at least two polynucleotides, wherein a first polynucleotide (an "IL36 gamma polynucleotide") comprises an ORF encoding an IL36 gamma polypeptide, and a second polynucleotide comprises an ORF encoding an immune response primer polypeptide, an immune response costimulatory signal polypeptide, or a checkpoint inhibitor polypeptide.
[0300] The present disclosure also provides a method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, the method comprising administering at least two polynucleotides, wherein a first polynucleotide (a "TLR4 polynucleotide") comprises an ORF encoding a TLR4 polypeptide (e.g., caTLR4), and a second polynucleotide comprises an ORF encoding an immune response primer polypeptide, an immune response costimulatory signal polypeptide, or a checkpoint inhibitor polypeptide.
[0301] Also provided are methods of reducing tumor size or inhibiting tumor growth in a subject in need thereof, the methods comprising administering at least two polynucleotides, wherein a first polynucleotide (a "CD80 polynucleotide") comprises an ORF encoding a CD80 polypeptide and a second polynucleotide comprises an ORF encoding an immune response primer polypeptide, an immune response costimulatory signal polypeptide, or a checkpoint inhibitor polypeptide. In some embodiments, the second polynucleotide comprises an ORF encoding an anti-CTLA-4 antibody.
[0302] Also provided are methods of reducing tumor size or inhibiting tumor growth in a subject in need thereof, the methods comprising at least two polynucleotides, wherein a first polynucleotide (an "OX40L polynucleotide") comprises an ORF encoding an OX40L polypeptide and a second polynucleotide comprises an ORF encoding an immune response primer polypeptide, an immune response costimulatory signal polypeptide, or a checkpoint inhibitor polypeptide. In some embodiments, the methods of the invention comprise administering an OX40L polynucleotide and an IL18 polynucleotide. In some embodiments, the methods of the invention comprise administering an OX40L polynucleotide and a TLR4 (e.g., caTLR4) polynucleotide. In some embodiments, the methods of the invention comprise administering an OX40L polynucleotide, an IL12 polynucleotide, and an IL23 polynucleotide in combination. In some embodiments, the methods of the invention comprise administering an OX40L polynucleotide and a TLR4 (e.g., caTLR4) polynucleotide. In some embodiments, the methods of the invention comprise administering an OX40L polynucleotide, a TLR4 (e.g., caTLR4) polynucleotide, and an IL18 polynucleotide in combination. In some embodiments, the methods of the invention comprise administering an OX40L polynucleotide and a TLR4 (e.g., caTLR4) polynucleotide. In some embodiments, the methods of the invention comprise administering an OX40L polynucleotide and an anti-CTLA-4 antibody or a polynucleotide encoding same. In some embodiments, the methods of the invention comprise administering an OX40L polynucleotide and an anti-PD-1 antibody or an anti-PD-L1 antibody. In other embodiments, the methods of the invention comprise administering an OX40L polynucleotide, an IL12 polynucleotide, an IL23 polynucleotide, and an anti-CTLA-4 antibody or a polynucleotide encoding same.In certain embodiments, the methods of the invention comprise administering an OX40L polynucleotide, an IL12 polynucleotide, an IL23 polynucleotide, and an anti-PD-1 antibody or an anti-PD-L1 antibody. In other embodiments, the methods of the invention comprise administering an OX40L polynucleotide, a TLR4 (e.g., caTLR4) polynucleotide, an IL18 polynucleotide, and an anti-PD-1 antibody or an anti-PD-L1 antibody. In other embodiments, the methods of the invention comprise administering an OX40L polynucleotide, a TLR4 (e.g., caTLR4) polynucleotide, an IL18 polynucleotide, and an anti-CTLA-4 antibody, or a polynucleotide encoding the same.
[0303] Also provided are methods of reducing tumor size or inhibiting tumor growth in a subject in need thereof, the methods comprising administering at least two polynucleotides, wherein a first polynucleotide (an "anti-CTLA-4 polynucleotide") comprises an ORF encoding an anti-CTLA-4 antibody and a second polynucleotide comprises an ORF encoding an immune response primer polypeptide, an immune response costimulatory signal polypeptide, or a checkpoint inhibitor polypeptide. In some embodiments, the methods of the invention comprise administering an anti-CTLA-4 polynucleotide and an IL18 polynucleotide. In some embodiments, the methods of the invention comprise administering an anti-CTLA-4 polynucleotide and an IL12 polynucleotide. In some embodiments, the methods of the invention comprise administering an anti-CTLA-4 polynucleotide and an IL23 polynucleotide. In some embodiments, the methods of the invention comprise administering an anti-CTLA-4 polynucleotide and a TLR4 polynucleotide. In other embodiments, the methods of the invention comprise administering an anti-CTLA-4 polynucleotide, an IL18 polynucleotide, an IL23 polynucleotide, an OX40L polynucleotide, a TLR4 polynucleotide, or any combination thereof.
[0304] In certain embodiments, the IL12 polynucleotide comprises at least one polynucleotide comprising an ORF encoding an IL12 polypeptide, wherein the IL12 polypeptide comprises an interleukin-12p40 subunit (IL12B) polypeptide and an interleukin-12p35 subunit (IL12A) polypeptide. The IL12B polypeptide can be operably linked to the IL12A polypeptide via a linker. In some embodiments, the polynucleotide encoding the IL12 polypeptide can further comprise a nucleic acid encoding a signal peptide, for example, an IL12B signal peptide. Additionally, in some embodiments, the sequence of the IL12 polypeptide has the following structure: [SP]-[IL12B]-[L]-[IL12A] where [SP] is the signal peptide, [IL12B] is the polypeptide corresponding to mature IL12B, [L] is a peptide linker, and [IL12A] is the polypeptide corresponding to mature IL12A. In another embodiment, the sequence of the IL12 polypeptide has the following structure: [SP]-[IL12A]-[L]-[IL12B]
[0305] In certain embodiments, the IL18 polynucleotide comprises an ORF encoding an IL18 polypeptide, wherein the IL18 polypeptide has the structure [SP]-[IL18], where [SP] is a signal peptide and [IL18] is a polypeptide corresponding to mature IL18. In some embodiments, the signal peptide is a native IL18 signal peptide. In other embodiments, the signal peptide is a heterologous signal peptide, such as tissue plasminogen activator (tPA) signal peptide or interleukin-12 (IL12) signal peptide.
[0306] In some specific embodiments, a CD80 polynucleotide comprises an ORF encoding the CD80 extracellular domain. In some embodiments, the CD80 polynucleotide comprises a nucleic acid sequence encoding an Fc portion, which is operably linked to the nucleic acid encoding the CD80 extracellular domain. As a result, in some embodiments, an ORF within the CD80 polynucleotide encodes a CD80Fc fusion protein. In some embodiments, the CD80 polypeptide, e.g., a CD80Fc fusion protein, has the following structure: [SP]-[CD80]-[Fc] where [SP] is the signal peptide, [CD80] is the extracellular domain of CD80 or a functional portion thereof, and [Fc] is the Fc portion. In some embodiments, the signal peptide is the endogenous CD80 signal peptide.
[0307] In some embodiments, the TLR4 polynucleotide comprises an ORF encoding a constitutively active TLR4 (caTLR4) polypeptide comprising the intracellular domain and transmembrane region of TLR4. In some embodiments, the TLR4 polypeptide encoded by an ORF in the TLR polynucleotide has the following structure: [SP]-[TLR4] where [SP] is a signal peptide and [TLR4] is a TLR4 polypeptide, e.g., a caTLR4 polypeptide. In some embodiments, the signal peptide is a heterologous signal peptide, where the heterologous signal peptide is a lysosomal membrane glycoprotein 1 (LAMP1) signal peptide.
[0308] In some embodiments, the IL15 polynucleotide comprises an ORF encoding a fusion protein comprising an IL15 polypeptide fused to an IL15R polypeptide by a linker. In some embodiments, the IL15R polypeptide consists of, or consists essentially of, the extracellular domain of IL15Rα. In some embodiments, the IL15-IL15R fusion polypeptide further comprises an Fc domain. As a result, in some embodiments, the IL15 polypeptide encoded by an ORF within the IL15 polynucleotide has the following structure: [SP]-[Fc]-[IL15R]-[L]-[IL15] where [SP] is the signal peptide, [IL15] is the mature IL15 sequence, [L] is the polypeptide linker, [IL15R] is the extracellular portion of IL15Rα, and [Fc] is the Fc portion. In some embodiments, the signal peptide is a heterologous signal peptide, such as the tPA signal peptide.
[0309] In some embodiments, the IL23 polynucleotide comprises an ORF encoding an IL23 polypeptide, wherein the IL23 polypeptide comprises an IL12p40 polypeptide and an IL23p19 polypeptide. In some embodiments, the IL12p40 polypeptide is fused to the IL23p19 polypeptide via a linker. In some embodiments, the IL23 polypeptide further comprises a signal peptide. As a result, in some embodiments, the IL23 polypeptide encoded by the ORF within the IL23 polynucleotide has the following structure: [SP]-[IL12p40]-[L]-[IL23p19] where [SP] is the signal peptide, [IL12p40] is the IL12p40 subunit of IL23, [L] is a polypeptide linker, and [IL23p19] is the IL23p19 subunit of IL23. In some embodiments, the signal peptide is the IL12p40 signal peptide. In other embodiments, for example, when transporting an IL23 subunit into an IL23 construct, the signal peptide is the IL23p19 signal peptide.
[0310] In some embodiments, the IL36 gamma polynucleotide comprises an ORF encoding an IL36 gamma polypeptide. In some embodiments, the IL36 gamma polypeptide further comprises a nucleic acid encoding a signal peptide. As a result, in some embodiments, the IL36 gamma polypeptide encoded by an ORF within the IL36 gamma polynucleotide has the following structure: [SP]-[IL36 Gamma] where [SP] is a signal peptide and [IL36 gamma] is IL36 gamma, e.g., mature IL36 gamma. In some embodiments, the signal peptide is a heterologous signal peptide, e.g., hIgKV4 signal peptide.
[0311] In some embodiments, the anti-CTLA-4 polynucleotide encodes an antibody or antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof is (i) an antibody or antigen-binding portion thereof comprising a heavy chain variable region (VH) of SEQ ID NO: 9, 28, or 39 and a light chain variable region (VL) of SEQ ID NO: 11, 29, or 41; or (ii) an antibody or antigen-binding portion thereof comprising a VH of SEQ ID NO: 183 and a VL of SEQ ID NO: 185; It specifically binds to the same CTLA-4 epitope as
[0312] In some embodiments, the anti-CTLA-4 polynucleotide encodes an antibody or antigen-binding portion thereof that specifically binds to CTLA-4, (i) an antibody or antigen-binding portion thereof comprising a VH of SEQ ID NO: 9, 28, or 39 and a VL of SEQ ID NO: 11, 29, or 41; or (ii) an antibody or antigen-binding portion thereof comprising a VH of SEQ ID NO: 183 and a VL of SEQ ID NO: 185; competitively inhibits CTLA-4 binding.
[0313] In some embodiments, the anti-CTLA-4 polynucleotide is (i) an antibody or antigen-binding portion thereof that specifically binds to CTLA-4, comprising a VH of SEQ ID NO: 9, 28, or 39 and a VL of SEQ ID NO: 11, 29, or 41; or (ii) an antibody or antigen-binding portion thereof that specifically binds to CTLA-4, comprising a VH of SEQ ID NO: 183 and a VL of SEQ ID NO: 185; The present invention includes one or more mRNAs (e.g., two, three, or more mRNAs) encoding the
[0314] In some embodiments, the anti-CTLA-4 polynucleotide comprises a VH and a VL, wherein the VL is (i) a VL complementarity determining region 1 (VL-CDR1) amino acid sequence identical to, or identical to except for 4, 3, 2, or 1 amino acid substitutions of, SEQ ID NO: 17, 33, or 47, or SEQ ID NO: 189; (ii) a VL complementarity-determining region 1 (VL-CDR2) amino acid sequence identical to, or identical to, SEQ ID NO: 18, 34, or 48, or SEQ ID NO: 190, except for 4, 3, 2, or 1 amino acid substitutions; and (iii) a VL complementarity-determining region 1 (VL-CDR3) amino acid sequence identical to, or identical to except for 4, 3, 2, or 1 amino acid substitutions of, SEQ ID NO: 19, 35, or 49, or SEQ ID NO: 191; is selected from the group consisting of So VH (iv) a VH complementarity-determining region 1 (VH-CDR1) amino acid sequence identical to, or identical to except for 4, 3, 2, or 1 amino acid substitutions in, SEQ ID NO: 14, 30, or 44, or SEQ ID NO: 186; (v) a VH complementarity-determining region 1 (VH-CDR2) amino acid sequence identical to, or identical to except for 4, 3, 2, or 1 amino acid substitutions of, SEQ ID NO: 15, 31, or 45, or SEQ ID NO: 187; and (vi) a VH complementarity-determining region 1 (VH-CDR3) amino acid sequence identical to, or identical to except for 4, 3, 2, or 1 amino acid substitutions of, SEQ ID NO: 16, 32, or 46, or SEQ ID NO: 188; is selected from the group consisting of:
[0315] In some embodiments, one or more of the polynucleotides in the combination therapy disclosed herein are sequence-optimized. In some embodiments, one or more of the polynucleotides in the combination therapy disclosed herein comprises at least one chemically modified nucleoside.
[0316] In certain embodiments, a polynucleotide (e.g., RNA such as mRNA) comprising a sequence-optimized nucleotide sequence (e.g., ORF) encoding an immune response primer polypeptide, an immune response costimulatory signal polypeptide, or a checkpoint inhibitor polypeptide can be used in combination with one or more anti-cancer agents. In some embodiments, the combination therapy disclosed herein can include one or more standard therapies. In certain embodiments, the one or more anti-cancer agents is an mRNA encoding a tumor antigen. In other embodiments, the one or more anti-cancer agents is not a tumor antigen or an mRNA encoding a tumor antigen. In other embodiments, the one or more anti-cancer agents is a protein, e.g., an antibody.
[0317] In some embodiments, one or more anti-cancer agents are approved by the U.S. Food and Drug Administration. In other embodiments, one or more anti-cancer agents are pre-approved by the U.S. Food and Drug Administration.
[0318] In another embodiment, the subject has been treated with an anti-PD-1 antagonist prior to administration of a combination therapy disclosed herein. In another embodiment, the subject has been treated with a monoclonal antibody that binds to PD-1 prior to administration of a combination therapy disclosed herein. In another embodiment, the subject has been treated with an anti-PD-1 monoclonal antibody therapy prior to administration of a combination therapy disclosed herein. In some embodiments, the anti-PD-1 monoclonal antibody therapy comprises nivolumab, pembrolizumab, pidilizumab, or any combination thereof.
[0319] In another embodiment, the subject has been treated with a monoclonal antibody that binds to PD-L1 prior to administration of a combination therapy disclosed herein. In another embodiment, the subject has been treated with an anti-PD-L1 monoclonal antibody therapy prior to administration of a combination therapy disclosed herein. In other embodiments, the anti-PD-L1 monoclonal antibody therapy comprises durvalumab, avelumab, MEDI473, BMS-936559, atezolizumab, or any combination thereof.
[0320] In some embodiments, the subject has been treated with a CTLA-4 antagonist prior to administration of the combination therapy disclosed herein. In another embodiment, the subject has been previously treated with a monoclonal antibody that binds to CTLA-4 prior to administration of the combination therapy disclosed herein. In another embodiment, the subject has been previously treated with an anti-CTLA-4 monoclonal antibody prior to administration of the combination therapy disclosed herein. In other embodiments, the anti-CTLA-4 antibody treatment comprises ipilimumab or tremelimumab.
[0321] Thus, administration of mRNA as referred to in this disclosure is not in the form of dendritic cells comprising mRNA encoding an immune response primer polypeptide, an immune response costimulatory signal polypeptide, or a checkpoint inhibitor polypeptide (e.g., IL12, IL15, IL18, IL23, IL36 gamma, TLR4, CD80, OX40L, anti-CTLA-4, or a combination thereof) as disclosed herein. Rather, administration in the present disclosure is direct administration to a subject (e.g., to a tumor in a subject) of at least one mRNA encoding an immune response primer polypeptide, immune response costimulatory signal polypeptide, checkpoint inhibitor polypeptide, or combinations thereof (e.g., IL12, IL15, IL18, IL23, IL36 gamma, TLR4, CD80, OX40L, anti-CTLA-4, or combinations thereof) disclosed herein, or a composition comprising at least one mRNA encoding an immune response primer polypeptide, immune response costimulatory signal polypeptide, checkpoint inhibitor polypeptide, or combinations thereof (e.g., IL12, IL15, IL18, IL23, IL36 gamma, TLR4, CD80, OX40L, anti-CTLA-4, or combinations thereof) disclosed herein.
[0322] In some embodiments, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding a CD80 polypeptide or an Fc polypeptide is administered in combination with a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an antibody, or antigen-binding portion thereof, that specifically binds to CTLA-4. In one embodiment, the antibody, or antigen-binding portion thereof, is tremelimumab. In another embodiment, the antibody, or antigen-binding portion thereof, is ipilimumab. In some embodiments, the compositions disclosed herein comprise, in a single formulation or separate formulations, (i) a polynucleotide comprising an ORF encoding a CD80 polypeptide or an Fc polypeptide, and (ii) a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an antibody, or antigen-binding portion thereof, that specifically binds to CTLA-4.
[0323] In other embodiments, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding a TLR4 polypeptide, e.g., caTLR4 (e.g., a wild-type sequence, a functional fragment, or a variant thereof) is administered in combination with a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an OX40L polypeptide, either in a single formulation or in separate formulations.
[0324] In other embodiments, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding a TLR4 polypeptide, e.g., caTLR4 (e.g., a wild-type sequence, a functional fragment, or a variant thereof) is administered in combination with a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an IL18 polypeptide, either in a single formulation or in separate formulations.
[0325] In other embodiments, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding a TLR4 polypeptide, e.g., caTLR4 (e.g., a wild-type sequence, a functional fragment, or a variant thereof) is administered in combination with a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an antibody or antigen-binding portion thereof that specifically binds to CTLA-4, either in a single formulation or in separate formulations.
[0326] In other embodiments, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding a TLR4 polypeptide, e.g., caTLR4 (e.g., a wild-type sequence, a functional fragment, or a variant thereof) is administered in combination with a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an antibody, or antigen-binding portion thereof, that specifically binds to the PD-1 or PD-L1 receptor, either in a single formulation or in separate formulations.
[0327] In other embodiments, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding a TLR4 polypeptide, e.g., caTLR4 (e.g., a wild-type sequence, a functional fragment, or a variant thereof) is administered in combination with a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an OX40L polypeptide, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an IL18 polypeptide, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an antibody that specifically binds to CTLA-4 or an antigen-binding portion thereof, or any combination thereof, either in a single formulation or in separate formulations.
[0328] In other embodiments, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding a TLR4 polypeptide, e.g., caTLR4 (e.g., a wild-type sequence, a functional fragment, or a variant thereof) is administered in combination with a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an OX40L polypeptide, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an IL18 polypeptide, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an antibody or antigen-binding portion thereof that specifically binds to the PD-1 or PD-L1 receptor, or any combination thereof, either in a single formulation or in separate formulations.
[0329] In other embodiments, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding a TLR4 polypeptide, e.g., caTLR4 (e.g., a wild-type sequence, a functional fragment, or a variant thereof) is administered in combination with a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an OX40L polypeptide, a polynucleotide comprising an ORF encoding an IL18 polypeptide, and a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an antibody or antigen-binding portion thereof that specifically binds to CTLA-4, either in a single formulation or in separate formulations.
[0330] In other embodiments, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding a TLR4 polypeptide, e.g., caTLR4 (e.g., a wild-type sequence, a functional fragment, or a variant thereof) is administered in combination with a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an OX40L polypeptide, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an IL18 polypeptide, and a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an antibody or antigen-binding portion thereof that specifically binds to a PD-1 or PD-L1 receptor, either in a single formulation or in separate formulations.
[0331] In some embodiments, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding a TLR4 polypeptide, e.g., caTLR4 (e.g., a wild-type sequence, a functional fragment, or a variant thereof) is administered in combination with a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an OX40L polypeptide, either in a single formulation or in separate formulations.
[0332] In some embodiments, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding a TLR4 polypeptide, e.g., caTLR4 (e.g., a wild-type sequence, a functional fragment, or a variant thereof) is administered in combination with a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an IL18 polypeptide, either in a single formulation or in separate formulations.
[0333] In some embodiments, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding a TLR4 polypeptide, e.g., caTLR4 (e.g., a wild-type sequence, a functional fragment, or a variant thereof) is administered in combination with a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an antibody or antigen-binding portion thereof that specifically binds to CTLA-4, either in a single formulation or in separate formulations.
[0334] In some embodiments, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding a TLR4 polypeptide, e.g., caTLR4 (e.g., a wild-type sequence, a functional fragment, or a variant thereof) is administered in combination with a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an antibody, or antigen-binding portion thereof, that specifically binds to the PD-1 or PD-L1 receptor, either in a single formulation or in separate formulations.
[0335] In some embodiments, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding a TLR4 polypeptide, e.g., caTLR4 (e.g., a wild-type sequence, a functional fragment, or a variant thereof) is administered in combination with a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an OX40L polypeptide, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an IL18 polypeptide, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an antibody that specifically binds CTLA-4 or an antigen-binding portion thereof, or any combination thereof, either in a single formulation or in separate formulations.
[0336] In some embodiments, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding a TLR4 polypeptide, e.g., caTLR4 (e.g., a wild-type sequence, a functional fragment, or a variant thereof) is administered in combination with a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an OX40L polypeptide, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an IL18 polypeptide, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an antibody or antigen-binding portion thereof that specifically binds to the PD-1 or PD-L1 receptor, or any combination thereof, either in a single formulation or in separate formulations.
[0337] In some embodiments, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding a TLR4 polypeptide, e.g., caTLR4 (e.g., a wild-type sequence, a functional fragment, or a variant thereof) is administered in combination with a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an OX40L polypeptide, a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an IL18 polypeptide, and a polynucleotide (e.g., RNA, e.g., mRNA) comprising an ORF encoding an antibody that specifically binds to CTLA-4, or an antigen-binding portion thereof, in a single formulation or in separate formulations.
[0338] In some embodiments, a polynucleotide (e.g., RNA, e....
Claims
1. 1. A method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to said subject at least two polynucleotides and optionally a checkpoint inhibitor polypeptide, said at least two polynucleotides comprising: (i) a polynucleotide encoding an immune response primer polypeptide; (ii) a polynucleotide encoding an immune response costimulatory signal polypeptide; (iii) a polynucleotide encoding a checkpoint inhibitor polypeptide, and (iv) Combinations thereof The method of claim 1, wherein the
2. 1. A method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to said subject at least one polynucleotide and a checkpoint inhibitor polypeptide, wherein said at least one polynucleotide is (i) a polynucleotide encoding an immune response primer polypeptide; (ii) a polynucleotide encoding an immune response costimulatory signal polypeptide; (iii) Combinations thereof The method of claim 1, wherein the
3. 3. The method of claim 1 or 2, wherein the immune response primer polypeptide comprises interleukin 12 (IL12), interleukin (IL23), toll-like receptor 4 (TLR4), interleukin 36 gamma (IL36 gamma), interleukin 18 (IL18), or a combination thereof.
4. The method of any one of claims 1 to 3, wherein the immune response costimulatory signal polypeptide comprises tumor necrosis factor receptor superfamily member 4 ligand (OX40L), cluster of differentiation 80 (CD80), interleukin 15 (IL15), or a combination thereof.
5. 5. The method of any one of claims 1 to 4, wherein the checkpoint inhibitor polypeptide inhibits programmed cell death protein 1 (PD1), programmed cell death ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
6. (a) a first polynucleotide encodes an IL23 polypeptide and a second polynucleotide encodes an IL18 polypeptide; (b) the first polynucleotide encodes an IL23 polypeptide and the second polynucleotide encodes an IL12 polypeptide; (c) the first polynucleotide encodes an IL23 polypeptide and the second polynucleotide encodes an OX40L polypeptide; (d) the first polynucleotide encodes an IL12 polypeptide and the second polynucleotide encodes an anti-CTLA-4 antibody; (e) the first polynucleotide encodes an IL12 polypeptide and the second polynucleotide encodes an anti-PD-1 antibody or an anti-PD-L1 antibody; (f) the first polynucleotide encodes an IL23 polypeptide and the second polynucleotide encodes an anti-CTLA-4 antibody; (g) the first polynucleotide encodes an IL18 polypeptide, and the second polynucleotide encodes an anti-PD-1 antibody or an anti-PD-L1 antibody; (h) a first polynucleotide encodes an IL18 polypeptide and a second polynucleotide encodes an anti-CTLA-4 antibody; (i) a first polynucleotide encodes an IL18 polypeptide and a second polynucleotide encodes an OX40L polypeptide; (j) a first polynucleotide encodes an IL18 polypeptide and a second polynucleotide encodes a TLR4 polypeptide; (k) the first polynucleotide encodes an IL18 polypeptide and the second polynucleotide encodes an IL12 polypeptide; (l) a first polynucleotide encodes an OX40L polypeptide and a second polynucleotide encodes an anti-CTLA-4 antibody; (m) a first polynucleotide encodes an OX40L polypeptide, and a second polynucleotide encodes an anti-PD-1 antibody or an anti-PD-L1 antibody; (n) a first polynucleotide encodes an OX40L polypeptide and a second polynucleotide encodes a caTLR4 polypeptide; (o) a first polynucleotide encodes an OX40L polypeptide and a second polynucleotide encodes an IL23 polypeptide; (p) a first polynucleotide encodes an OX40L polypeptide and a second polynucleotide encodes an IL12 polypeptide; (q) a first polynucleotide encodes a CD80 polypeptide and a second polynucleotide encodes an anti-CTLA-4 antibody; (r) a first polynucleotide encodes a TLR4 polypeptide and a second polynucleotide encodes an anti-CTLA-4 antibody; (s) administering a first polynucleotide encoding an IL18 polypeptide, a second polynucleotide encoding an IL12 polypeptide, and a third polynucleotide encoding an IL23 polypeptide; (t) administering a first polynucleotide encoding an OX40L polypeptide, a second polynucleotide encoding a TLR4 polypeptide, and a third polynucleotide encoding an IL18 polypeptide; (u) administering a first polynucleotide encoding an OX40L polypeptide, a second polynucleotide encoding an IL12 polypeptide, and a third polynucleotide encoding an IL23 polypeptide; (v) administering a first polynucleotide encoding an IL23 polypeptide, a second polynucleotide encoding an IL12 polypeptide, and a third polynucleotide encoding an anti-CTLA-4 antibody; (w) administering a first polynucleotide encoding an IL23 polypeptide, a second polynucleotide encoding an IL18 polypeptide, and a third polynucleotide encoding an anti-CTLA-4 antibody; (x) a first polynucleotide encodes an IL23 polypeptide, a second polynucleotide encodes an IL12 polypeptide, and further comprising administering a third polynucleotide encoding an IL18 polypeptide and administering a fourth polynucleotide encoding an anti-CTLA-4 antibody; (y) the first polynucleotide encodes an IL23 polypeptide, the second polynucleotide encodes an IL12 polypeptide, and further comprising administering a third polynucleotide encoding an IL18 polypeptide and administering a fourth polynucleotide encoding an anti-PD-1 antibody or an anti-PD-L1 antibody; (z) a first polynucleotide encodes an OX40L polypeptide, a second polynucleotide encodes an IL18 polypeptide, and further comprising administering a third polynucleotide encoding a TLR4 polypeptide and administering a fourth polynucleotide encoding an anti-CTLA-4 antibody; or (aa) a first polynucleotide encodes an OX40L polypeptide, a second polynucleotide encodes an IL18 polypeptide, and further comprising administering a third polynucleotide encoding a TLR4 polypeptide and administering a fourth polynucleotide encoding an anti-PD-1 antibody or an anti-PD-L1 antibody. The method of claim 1.
7. The at least two polynucleotides (i) a first polynucleotide encoding an immune response primer polypeptide and a second polynucleotide encoding an immune response primer polypeptide; (ii) a first polynucleotide encoding an immune response primer polypeptide and a second polynucleotide encoding an immune response costimulatory signal polypeptide; or (iii) (i) or (ii) further comprising a polynucleotide encoding a checkpoint inhibitor polypeptide. The method according to any one of claims 1 and 3 to 5,
8. 1. A method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to said subject at least two polynucleotides encoding a first polypeptide and a second polypeptide, and optionally a checkpoint inhibitor polypeptide, wherein said first polypeptide and said second polypeptide are (i) an IL12 polypeptide, (ii) an IL23 polypeptide, (iii) an IL36 gamma polypeptide, (iv) an OX40L polypeptide, (v) a CD80 polypeptide, (vi) a TLR4 polypeptide, (vii) an IL18 polypeptide, (viii) an IL15 polypeptide, (ix) anti-CTLA-4 antibody, and (x) combinations of these The method of claim 1, wherein the
9. 1. A method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to said subject at least one polynucleotide encoding a first polypeptide in combination with a second polypeptide that is a checkpoint inhibitor polypeptide, said first polypeptide being: (i) an IL12 polypeptide, (ii) an IL23 polypeptide, (iii) an IL36 gamma polypeptide, (iv) an OX40L polypeptide, (v) a CD80 polypeptide, (vi) a TLR4 polypeptide, (vii) an IL18 polypeptide, (viii) an IL15 polypeptide, and (ix) combinations thereof The method of claim 1, wherein the
10. 1. A method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to said subject at least two polynucleotides comprising a first polynucleotide and a second polynucleotide, and optionally a checkpoint inhibitor polypeptide, wherein said first polynucleotide encodes an IL12 polypeptide and said second polynucleotide encodes: (i) an immune response primer polypeptide; (ii) an immune response costimulatory signal polypeptide; (iii) a checkpoint inhibitor polypeptide, and (iv) any combination thereof A method comprising encoding a polypeptide selected from the group consisting of:
11. 1. A method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering (a) at least one polynucleotide encoding a first polypeptide and (b) a second polypeptide that is a checkpoint inhibitor polypeptide, wherein the first polypeptide comprises an IL12 polypeptide.
12. 12. The method of claim 11, further comprising administering a third polynucleotide encoding a third polypeptide selected from the group consisting of an immune response primer polypeptide, an immune response costimulatory signal polypeptide, and a checkpoint inhibitor polypeptide.
13. 1. A method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to said subject at least two polynucleotides comprising a first polynucleotide and a second polynucleotide, and optionally a checkpoint inhibitor polypeptide, wherein said first polynucleotide encodes an IL23 polypeptide and said second polynucleotide encodes: (i) an immune response primer polypeptide; (ii) an immune response costimulatory signal polypeptide; (iii) a checkpoint inhibitor polypeptide, and (iv) any combination thereof A method comprising encoding a polypeptide selected from the group consisting of:
14. 1. A method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering (a) at least one polynucleotide encoding a first polypeptide and (b) a second polypeptide that is a checkpoint inhibitor polypeptide, wherein the first polypeptide comprises an IL23 polypeptide.
15. 15. The method of claim 14, further comprising administering a third polynucleotide encoding a third polypeptide selected from the group consisting of an immune response primer polypeptide, an immune response costimulatory signal polypeptide, and a checkpoint inhibitor polypeptide.
16. 1. A method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to said subject at least two polynucleotides comprising a first polynucleotide and a second polynucleotide, and optionally a checkpoint inhibitor polypeptide, wherein said first polynucleotide encodes an OX40L polypeptide and said second polynucleotide encodes: (i) an immune response primer polypeptide; (ii) an immune response costimulatory signal polypeptide; (iii) a checkpoint inhibitor polypeptide, and (iv) any combination thereof A method comprising encoding a polypeptide selected from the group consisting of:
17. A method for reducing tumor size or inhibiting tumor growth in a subject in need thereof, the method comprising administering (a) at least one polynucleotide encoding a first polypeptide and (b) a second polypeptide that is a checkpoint inhibitor polypeptide, wherein the first polypeptide comprises an OX40L polypeptide.
18. 20. The method of claim 17, further comprising administering a third polynucleotide encoding a third polypeptide selected from the group consisting of an immune response primer polypeptide, an immune response costimulatory signal polypeptide, and a checkpoint inhibitor polypeptide.
19. 1. A method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to said subject at least two polynucleotides comprising a first polynucleotide and a second polynucleotide, and optionally a checkpoint inhibitor polypeptide, wherein said first polynucleotide encodes a CD80 polypeptide and said second polynucleotide encodes: (i) an immune response primer polypeptide; (ii) an immune response costimulatory signal polypeptide; (iii) a checkpoint inhibitor polypeptide, and (iv) any combination thereof A method comprising encoding a polypeptide selected from the group consisting of:
20. 1. A method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, the method comprising administering (a) at least one polynucleotide encoding a first polypeptide and (b) a second polypeptide that is a checkpoint inhibitor polypeptide, wherein the first polypeptide comprises a CD80 polypeptide.
21. 21. The method of claim 20, further comprising administering a third polynucleotide encoding a third polypeptide selected from the group consisting of an immune response primer polypeptide, an immune response costimulatory signal polypeptide, and a checkpoint inhibitor polypeptide.
22. 1. A method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to said subject at least two polynucleotides comprising a first polynucleotide and a second polynucleotide, and optionally a checkpoint inhibitor polypeptide, wherein said first polynucleotide encodes a TLR4 polypeptide and said second polynucleotide encodes: (i) an immune response primer polypeptide; (ii) an immune response costimulatory signal polypeptide; (iii) a checkpoint inhibitor polypeptide, and (iv) any combination thereof A method comprising encoding a polypeptide selected from the group consisting of:
23. 1. A method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, the method comprising administering (a) at least one polynucleotide encoding a first polypeptide and (b) a second polypeptide that is a checkpoint inhibitor polypeptide, wherein the first polypeptide comprises a TLR4 polypeptide.
24. 24. The method of claim 23, further comprising administering a third polynucleotide encoding a third polypeptide selected from the group consisting of an immune response primer polypeptide, an immune response costimulatory signal polypeptide, and a checkpoint inhibitor polypeptide.
25. 1. A method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to said subject at least two polynucleotides comprising a first polynucleotide and a second polynucleotide, and optionally a checkpoint inhibitor polypeptide, wherein said first polynucleotide encodes an IL18 polypeptide and said second polynucleotide encodes: (i) an immune response primer polypeptide; (ii) an immune response costimulatory signal polypeptide; (iii) a checkpoint inhibitor polypeptide, and (iv) any combination thereof A method comprising encoding a polypeptide selected from the group consisting of:
26. 1. A method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering (a) at least one polynucleotide encoding a first polypeptide and (b) a second polypeptide that is a checkpoint inhibitor polypeptide, wherein the first polypeptide comprises an IL18 polypeptide.
27. 27. The method of claim 26, further comprising administering a third polynucleotide encoding a third polypeptide selected from the group consisting of an immune response primer polypeptide, an immune response costimulatory signal polypeptide, and a checkpoint inhibitor polypeptide.
28. 1. A method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to said subject at least two polynucleotides comprising a first polynucleotide and a second polynucleotide, and optionally a checkpoint inhibitor polypeptide, wherein said first polynucleotide encodes an IL15 polypeptide and said second polynucleotide encodes: (i) an immune response primer polypeptide; (ii) an immune response costimulatory signal polypeptide; (iii) a checkpoint inhibitor polypeptide, and (iv) any combination thereof A method comprising encoding a polypeptide selected from the group consisting of:
29. 1. A method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering (a) at least one polynucleotide encoding a first polypeptide and (b) a second polypeptide that is a checkpoint inhibitor polypeptide, wherein the first polypeptide comprises an IL15 polypeptide.
30. 30. The method of claim 29, further comprising administering a third polynucleotide encoding a third polypeptide selected from the group consisting of an immune response primer polypeptide, an immune response costimulatory signal polypeptide, and a checkpoint inhibitor polypeptide.
31. 1. A method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, comprising administering to said subject at least two polynucleotides comprising a first polynucleotide and a second polynucleotide, and optionally a checkpoint inhibitor polypeptide, wherein said first polynucleotide encodes an IL36 gamma polypeptide and said second polynucleotide encodes: (i) an immune response primer polypeptide; (ii) an immune response costimulatory signal polypeptide; (iii) a checkpoint inhibitor polypeptide, and (iv) any combination thereof A method comprising encoding a polypeptide selected from the group consisting of:
32. A method of reducing tumor size or inhibiting tumor growth in a subject in need thereof, the method comprising administering (a) at least one polynucleotide encoding a first polypeptide and (b) a second polypeptide that is a checkpoint inhibitor polypeptide, wherein the first polypeptide comprises an IL36 gamma polypeptide.
33. 33. The method of claim 32, further comprising administering a third polynucleotide encoding a third polypeptide selected from the group consisting of an immune response primer polypeptide, an immune response costimulatory signal polypeptide, and a checkpoint inhibitor polypeptide.
34. The method of any one of claims 1 to 33, wherein the checkpoint inhibitor polypeptide is an antibody or a polynucleotide encoding said antibody.
35. 35. The method of claim 34, wherein the antibody is an anti-CTLA-4 antibody or antigen-binding fragment thereof that specifically binds to CTLA-4, an anti-PD1 antibody or antigen-binding fragment thereof that specifically binds to PD1, an anti-PD-L1 antibody or antigen-binding fragment thereof that specifically binds to PD-L1, or a combination thereof.
36. 36. The method of claim 35, wherein the anti-PD-L1 antibody is atezolizumab, avelumab, or durvalumab.
37. The method of claim 35, wherein the anti-CTLA-4 antibody is tremelimumab or ipilimumab.
38. 36. The method of claim 35, wherein the anti-PD-1 antibody is nivolumab or pembrolizumab.
39. 39. The method of any one of claims 1-38, wherein the at least one or two polynucleotides reduce the size of an MC38(C)-derived tumor or inhibit the growth of an MC38(C)-derived tumor in a mouse when a 5 μg dose of each polynucleotide is administered to the mouse.
40. 40. The method of any one of claims 1-39, wherein the at least one or two polynucleotides reduce the size of an MC38(M)-derived tumor or inhibit the growth of an MC38(M)-derived tumor in a mouse when a dose of 5 μg of each polynucleotide is administered to the mouse.
41. The method of any one of claims 1 to 40, wherein one or more of the polynucleotides in the combination therapy comprises at least one chemically modified nucleoside.
42. 42. The method of claim 41, wherein the at least one chemically modified nucleoside is selected from the group consisting of any of those listed in Section X ("Chemical Modifications") and combinations thereof.
43. 43. The method of claim 41 or 42, wherein the at least one chemically modified nucleoside is selected from the group consisting of pseudouridine, N1-methylpseudouridine, 5-methylcytosine, 5-methoxyuridine, and combinations thereof.
44. 44. The method of any one of claims 41-43, wherein the nucleosides in one or more of the polynucleotides are at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100% chemically modified.
45. 45. The method of any one of claims 41-44, wherein the chemically modified nucleosides in one or more of the polynucleotides are selected from the group consisting of uridine, adenine, cytosine, guanine, and any combination thereof.
46. 46. The method of any one of claims 1-45, wherein the uridine nucleosides in one or more of said polynucleotides are at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100% chemically modified.
47. 47. The method of any one of claims 1 to 46, wherein the adenosine nucleosides in one or more of the polynucleotides are at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100% chemically modified.
48. 48. The method of any one of claims 1-47, wherein the cytidine nucleosides in one or more of said polynucleotides are at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100% chemically modified.
49. 49. The method of any one of claims 1-48, wherein the guanosine nucleosides in one or more of the polynucleotides are at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99%, or 100% chemically modified.
50. The method of any one of claims 1 to 49, wherein one or more of the polynucleotides comprises a miRNA binding site.
51. The method of claim 50, wherein the miRNA binding site is a miR-122 binding site.
52. The method of claim 50 or 51, wherein the miRNA binding site is a miR-122-3p or miR-122-5p binding site.
53. 51. The method of Claim 50, wherein the miRNA binding site comprises a nucleotide sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to aacgccauua ucacacuaaa ua (SEQ ID NO: 1212), wherein the miRNA binding site binds to miR-122.
54. 51. The method of Claim 50, wherein the miRNA binding site comprises a nucleotide sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to uggaguguga caaugguguu ug (SEQ ID NO: 1214), and wherein the miRNA binding site binds to miR-122.
55. The method of any one of claims 50 to 54, wherein the polynucleotides comprise different miRNA binding sites or the same miRNA binding site.
56. The method of any one of claims 41 to 55, wherein one or more of the polynucleotides comprises a 5' untranslated region (UTR).
57. 57. The method of claim 56, wherein the 5'UTR comprises a nucleic acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a sequence listed in Table 20.
58. The method of any one of claims 41 to 57, wherein one or more of the polynucleotides comprises a 3' untranslated region (UTR).
59. 59. The method of claim 58, wherein the 3'UTR comprises a nucleic acid sequence that is at least 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to a sequence listed in Table 4A or 4B.
60. The method of claim 58 or 59, wherein the miRNA binding site is inserted into the 3'UTR.
61. 61. The method of Claim 60, wherein one or more of said polynucleotides comprises a spacer sequence fused to said miRNA binding site.
62. 61. The method of claim 60, wherein the spacer sequence comprises at least about 10 nucleotides, at least about 20 nucleotides, at least about 30 nucleotides, at least about 40 nucleotides, at least about 50 nucleotides, at least about 60 nucleotides, at least about 70 nucleotides, at least about 80 nucleotides, at least about 90 nucleotides, or at least about 100 nucleotides.
63. The method of any one of claims 41 to 62, wherein one or more of the polynucleotides comprises a 5'-end cap structure.
64. 64. The method of claim 63, wherein the 5' end cap is Cap0, Cap1, ARCA, inosine, N1-methyl-guanosine, 2'fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, 2-azidoguanosine, Cap2, Cap4, a 5' methyl G cap, or an analog thereof.
65. The method of any one of claims 41 to 64, wherein one or more of the polynucleotides comprises a 3' poly-A tail.
66. 66. The method of any one of claims 41-65, wherein the one or more polynucleotides comprise at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 miRNA binding sites.
67. The method of any one of claims 1 to 66, wherein one or more of said polynucleotides are codon optimized.
68. 68. The method of any one of claims 1 to 67, wherein one or more of the polynucleotides are in vitro transcribed (IVT).
69. The method of any one of claims 1 to 68, wherein one or more of said polynucleotides is chimeric.
70. 70. The method of any one of claims 1 to 69, wherein one or more of the polynucleotides is circular.
71. The method of any one of claims 1 to 70, wherein the one or more polynucleotides are formulated with a delivery agent.
72. 72. The method of claim 71, wherein the delivery agent comprises a lipidoid, a liposome, a lipoplex, a lipid nanoparticle, a polymeric compound, a peptide, a protein, a cell, a nanoparticle mimic, a nanotube, or a conjugate.
73. 72. The method of claim 71, wherein the delivery agent is a lipid nanoparticle.
74. 74. The method of claim 73, wherein the lipid nanoparticles comprise a lipid selected from the group consisting of DLin-DMA, DLin-K-DMA, 98N12-5, C12-200, DLin-MC3-DMA, DLin-KC2-DMA, DODMA, PLGA, PEG, PEG-DMG, PEGylated lipids, aminoalcohol lipids, KL22, and combinations thereof.
75. The delivery agent may comprise a compound of formula (I): [68] or a salt or stereoisomer thereof, wherein R 1 But, C 5~20 Alkyl, C 5~20 Alkenyl, -R * -YR", -YR", and -R"M'R'; R 2 and R 3 But, H, C 1~14 Alkyl, C 2~14 Alkenyl, -R * YR", -YR", and -R * OR″, or R 2 and R 3 form a heterocyclic or carbocyclic ring together with the atoms to which they are attached, R 4 But, C 3~6 Carbocycle, -(CH 2 ) n Q, -(CH 2 ) n CHQR, -CHQR, -CQ(R) 2 and unsubstituted C 1~6 alkyl, where Q is a carbocycle, a heterocycle, —OR, —O(CH 2 ) n N (R) 2 , -C(O)OR, -OC(O)R, -CX 3 , -CX 2 H, -CXH 2 , -CN, -N(R) 2 , -C(O)N(R) 2 , -N(R)C(O)R, -N(R)S(O) 2 R, -N(R)C(O)N(R) 2 , -N(R)C(S)N(R) 2 and -C(R)N(R) 2 C(O)OR, where each n is independently selected from 1, 2, 3, 4, and 5; Each R 5 But, C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl and H; Each R 6 But, C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl and H; M and M' are -C(O)O-, -OC(O)-, -C(O)N(R')-, -N(R')C(O)-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR')O-, -S(O) 2 -, an aryl group, and a heteroaryl group; R 7 But, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl and H; Each R is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl and H; Each R' is C 1~18 Alkyl, C 2~18 Alkenyl, -R * independently selected from the group consisting of YR″, -YR″, and H; Each R" is C 3~14 Alkyl and C 3~14 alkenyl, Each R * But, C 1~12 Alkyl and C 2~12 alkenyl, Each Y is independently C 3~6 is a carbocyclic ring, each X is independently selected from the group consisting of F, Cl, Br, and I; m is selected from 5, 6, 7, 8, 9, 10, 11, 12 and 13; However, R 4 But -(CH 2 ) n Q, -(CH 2 ) n CHQR, -CHQR, or -CQ(R) 2 (i) when n is 1, 2, 3, 4, or 5, Q is -N(R) 2or (ii) when n is 1 or 2, Q is not a 5-, 6-, or 7-membered heterocycloalkyl.
72. The method of claim 71.
76. The compound has formula (IA): [69] or a salt or stereoisomer thereof, wherein l is selected from 1, 2, 3, 4 and 5; m is selected from 5, 6, 7, 8 and 9; M 1 is a bond or M′, R 4 is unsubstituted C 1~3 Alkyl or -(CH 2 ) n Q, where n is 1, 2, 3, 4, or 5, and Q is OH, -NHC(S)N(R) 2 or -NHC(O)N(R) 2 and M and M' are independently selected from -C(O)O-, -OC(O)-, -C(O)N(R')-, -P(O)(OR')O-, an aryl group, and a heteroaryl group; R 2 and R 3 But, H, C 1~14 Alkyl and C 2~14 alkenyl 76. The method of claim 74 or 75.
77. 77. The method of any one of claims 74 to 76, wherein m is 5, 7 or 9.
78. The compound has formula (II): [C70] or a salt or stereoisomer thereof, wherein l is selected from 1, 2, 3, 4 and 5; M 1 is a bond or M′, R 4is unsubstituted C 1~3 Alkyl or -(CH 2 ) n Q, where n is 2, 3, or 4, and Q is OH, -NHC(S)N(R) 2 or -NHC(O)N(R) 2 and M and M' are independently selected from -C(O)O-, -OC(O)-, -C(O)N(R')-, -P(O)(OR')O-, an aryl group, and a heteroaryl group; R 2 and R 3 But, H, C 1~14 Alkyl and C 2~14 alkenyl 78. The method of claim 76 or 77.
79. 79. The method of any one of claims 74 to 78, wherein the compound is selected from compound 1 to compound 147, and salts and stereoisomers thereof.
80. The compound has the formula (IIa): [C71] or a salt or stereoisomer thereof.
81. The compound has the formula (IIb): [C72] or a salt or stereoisomer thereof.
82. The compound has the formula (IIc) or (IIe): [C73] or a salt or stereoisomer thereof.
83. R 4 But -(CH 2 ) n Q and -(CH 2 ) n76. The method of claim 74 or 75, wherein Q, R and n are selected from: CHQR, where Q, R and n are as defined in claim 78 or 79 above.
84. The compound has the formula (IId): [C74] or a salt or stereoisomer thereof, In the formula, R 2 and R 3 But, C 5~14 Alkyl and C 5~14 alkenyl, n is selected from 2, 3 and 4; R′, R″, R 5 , R 6 76. The method of claim 74 or 75, wherein and m is as defined in claim 77 or 78 above.
85. R 2 C 8 85. The method of claim 84, wherein said alkyl is alkyl.
86. R 3 But, C 5 Alkyl, C 6 Alkyl, C 7 Alkyl, C 8 Alkyl, or C 9 86. The method of claim 84 or 85, wherein said alkyl is alkyl.
87. The method of any one of claims 84 to 86, wherein m is 5, 7 or 9.
88. Each R 5 The method of any one of claims 84 to 87, wherein is H.
89. Each R 6 The method of claim 88, wherein
90. 90. The method of any one of claims 70 to 89, wherein the delivery agent further comprises a phospholipid.
91. The phospholipid is 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-Hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16:0 PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, Selected from the group consisting of 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), sphingomyelin, and mixtures thereof.
91. The method of claim 90.
92. The phospholipid is 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine (14:0-16:0 PC, MPPC), 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine (14:0-18:0 PC, MSPC), 1-palmitoyl-2-acetyl-sn-glycero-3-phosphocholine (16:0-02:0 PC), 1-palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine (16:0-14:0 PC, PMPC), 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine (16:0-18:0 PC, PSPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (16:0-18:1 PC, POPC), 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine (16:0-18:2 PC, PLPC), 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (16:0-20:4 PC), 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (14:0-22:6 PC), 1-Stearoyl-2-myristoyl-sn-glycero-3-phosphocholine (18:0-14:0 PC, SMPC), 1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine (18:0-16:0 PC, SPPC), 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (18:0-18:1 PC, SOPC), 1-stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine (18:0 to 18:2 PC), 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (18:0 to 20:4 PC), 1-stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (18:0 to 22:6 PC), 1-oleoyl-2-myristoyl-sn-glycero-3-phosphocholine (18:1-14:0 PC, OMPC), 1-oleoyl-2-palmitoyl-sn-glycero-3-phosphocholine (18:1-16:0 PC, OPPC), 1-oleoyl-2-stearoyl-sn-glycero-3-phosphocholine (18:1 to 18:0 PC, OSPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (16:0-18:1 PE, POPE), 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine (16:0 to 18:2 PE), 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine (16:0 to 20:4 PE), 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine (16:0 to 22:6 PE), 1-stearoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (18:0 to 18:1 PE), 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine (18:0 to 18:2 PE), 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine (18:0 to 20:4 PE), 1-Stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine (18:0 to 22:6 PE), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC) and selected from the group consisting of any combination thereof 91. The method of claim 90.
93. 93. The method of any one of claims 70 to 92, wherein the delivery agent further comprises a structured lipid.
94. 94. The method of claim 93, wherein said structured lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and mixtures thereof.
95. 95. The method of any one of claims 70 to 94, wherein the delivery agent further comprises a PEG lipid.
96. 96. The method of claim 95, wherein the PEG lipid is selected from the group consisting of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol, and mixtures thereof.
97. The delivery agent may include 3-(didodecylamino)-N1,N1,4-tridodecyl-1-piperazineethanamine (KL10), N1-[2-(didodecylamino)ethyl]-N1,N4,N4-tridodecyl-1,4-piperazinediethanamine (KL22), 14,25-ditridecyl-15,18,21,24-tetraaza-octatriacontane (KL25), 1,2-Dilinoleyloxy-N,N-dimethylaminopropane (DLin-DMA), 2,2-Dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), Heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (DLin-MC3-DMA), 2,2-Dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA), 1,2-dioleyloxy-N,N-dimethylaminopropane (DODMA), 2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (octyl-CLinDMA), (2R)-2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (octyl-CLinDMA(2R)) and (2S)-2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA(2S)).
97. The method according to any one of claims 70 to 96.
98. 98. The method of any one of claims 70 to 97, wherein the delivery agent further comprises a quaternary amine compound.
99. The quaternary amine compound is 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), 1-[2-(oleoyloxy)ethyl]-2-oleyl-3-(2-hydroxyethyl)imidazolinium chloride (DOTIM), 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE), N-(1,2-dioleoyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethylammonium bromide (DORIE), N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), 1,2-dilauroyl-sn-glycero-3-ethylphosphocholine (DLePC), 1,2-distearoyl-3-trimethylammonium-propane (DSTAP), 1,2-dipalmitoyl-3-trimethylammonium-propane (DPTAP), 1,2-dilinoleoyl-3-trimethylammonium-propane (DLTAP), 1,2-dimyristoyl-3-trimethylammonium-propane (DMTAP), 1,2-distearoyl-sn-glycero-3-ethylphosphocholine (DSePC), 1,2-dipalmitoyl-sn-glycero-3-ethylphosphocholine (DPePC), 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (DMePC), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOePC), 1,2-di-(9Z-tetradecenoyl)-sn-glycero-3-ethylphosphocholine (14:1 EPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-ethylphosphocholine (16:0 to 18:1 EPC) and selected from the group consisting of any combination thereof 99. The method of claim 98.
100. A composition comprising: (i) one or more polynucleotides of any one of claims 1 to 73 and a pharma- ceutically acceptable carrier; or (ii) one or more polynucleotides of any one of claims 1 to 16 formulated in a delivery agent of any one of claims 70 to 99.
101. 101. The composition of claim 100, wherein the delivery agent comprises a lipid nanoparticle.
102. 101. The composition of claim 100, wherein the delivery agent comprises a lipidoid, a liposome, a lipoplex, a polymeric compound, a peptide, a protein, a cell, a nanoparticle mimic, a nanotube, or a conjugate.
103. The composition of claim 101 or 102, wherein the delivery agent comprises a lipid composition of any one of claims 70 to 100.
104. 104. A composition according to any one of claims 100 to 103 for use in reducing or decreasing the size of a tumour, or inhibiting the growth of a tumour, in a subject in need thereof.
105. The method of any one of claims 1 to 99, or the composition of any one of claims 100 to 104, wherein the polynucleotide or composition is formulated for in vivo delivery.
106. 106. The method or composition of claim 105, wherein the polynucleotide or composition is formulated for intramuscular, subcutaneous, intratumoral, or intradermal delivery.
107. 107. The method of any one of claims 1-99, or the composition of any one of claims 100-104, wherein the polynucleotide or composition is administered subcutaneously, intravenously, intramuscularly, intra-articularly, intrasynovially, intrasternally, intrathecally, intrahepatically, intralesionally, intracranially, intraventricularly, orally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implantable reservoir.
108. The method of any one of claims 1-99, or the composition of any one of claims 100-104, wherein said administering treats cancer.
109. The cancer is adrenocortical carcinoma, advanced cancer, anal cancer, aplastic anemia, bile duct cancer, bladder cancer, bone cancer, bone metastasis, brain tumor, brain cancer, breast cancer, childhood cancer, cancer of unknown primary site, Castleman's disease, cervical cancer, colon / rectal cancer, endometrial cancer, esophageal cancer, Ewing's family of tumors, eye cancer, gallbladder cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, gestational trophoblastic disease, Hodgkin's disease, Kaposi's sarcoma, renal cell carcinoma, laryngeal and hypopharyngeal cancer, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myelomonocytic leukemia, liver cancer, hepatocellular carcinoma (HCC), non-small cell lung cancer, small cell lung cancer, lung carcinoid tumor, skin 109. The method of claim 108, wherein the cancer is selected from the group consisting of lymphoma, malignant mesothelioma, multiple myeloma, myelodysplastic syndrome, pharyngeal and hypopharyngeal cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin's lymphoma, oral and oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, penile cancer, pituitary tumors, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, adult soft tissue sarcoma, basal and squamous cell skin cancer, melanoma, small intestine cancer, gastric cancer, testicular cancer, laryngeal cancer, thymic cancer, thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom's macroglobulinemia, Wilms' tumor, secondary cancers resulting from cancer treatment, and any combination thereof.
110. The method of any one of claims 1 to 99, or the composition of any one of claims 100 to 104, wherein the polynucleotide or composition is delivered by a pump, a patch, a drug reservoir, a short-needle device, a single-needle device, a multiple-needle device, a microneedle device, a jet injection device, a ballistic powder / particle delivery device, a catheter, a lumen, a cryoprobe, a cannula, a device comprising a microcannula, or a device utilizing heat, RF energy, electric current, or any combination thereof.
111. The method of any one of claims 1-99, or the composition of any one of claims 100-104, wherein the effective amount is from about 0.10 mg / kg to about 1,000 mg / kg.
112. The method of any one of claims 1 to 199, or the composition of any one of claims 100 to 104, wherein the subject is a human.
113. A kit comprising a composition according to any one of claims 100 to 104 and instructions for use according to the method according to any one of claims 1 to 99 or 105 to 112.
114. 114. The method of any one of claims 1-99 or 105-112, the composition of any one of claims 100-104, or the kit of claim 113, wherein the polynucleotide encoding an IL12 polypeptide comprises at least one polynucleotide comprising an ORF encoding an interleukin-12 p40 subunit (IL12B) polypeptide and an interleukin-12 p35 subunit (IL12A) polypeptide.
115. 115. The method, composition, or kit of claim 114, wherein the IL12B polypeptide is operably linked to the IL12A polypeptide by a linker.
116. 116. The method, composition, or kit of claim 114 or 115, wherein the polynucleotide encoding an IL12 polypeptide comprises a nucleic acid encoding a signal peptide.
117. 117. The method, composition, or kit of claim 116, wherein the signal peptide is an IL12B signal peptide.
118. The method of any one of claims 1-99 or 105-112, the composition of any one of claims 100-104, or the kit of claim 113, wherein said polynucleotide encoding an IL18 polypeptide comprises an ORF encoding a mature IL18 polypeptide.
119. 119. The method, composition, or kit of claim 118, wherein the polynucleotide encoding an IL18 polypeptide comprises a nucleic acid encoding a signal peptide.
120. 120. The method, composition, or kit of claim 119, wherein the signal peptide is a heterologous signal peptide.
121. 121. The method, composition, or kit of claim 120, wherein the heterologous signal peptide is tissue plasminogen activator (tPA) signal peptide or interleukin 12 (IL12) signal peptide.
122. 13. The method of any one of claims 1-99 or 105-112, the composition of any one of claims 100-104, or the kit of claim 113, wherein said polynucleotide encoding a CD80 polypeptide comprises an ORF encoding the CD80 extracellular domain.
123. 123. The method, composition, or kit of claim 122, wherein the polynucleotide encoding a CD80 polypeptide comprises a nucleic acid encoding an Fc portion.
124. 124. The method, composition, or kit of claims 122 or 123, wherein the polynucleotide encoding a CD80 polypeptide comprises a nucleic acid encoding a signal peptide.
125. 125. The method, composition, or kit of claim 124, wherein the signal peptide is an endogenous CD80 signal peptide.
126. 13. The method of any one of claims 1 to 99 or 105 to 112, the composition of any one of claims 100 to 104, or the kit of claim 113, wherein the polynucleotide encoding a TLR4 polypeptide comprises an ORF encoding a constitutively active TLR4 polypeptide comprising the intracellular domain and transmembrane region of TLR4.
127. 127. The method, composition, or kit of claim 126, wherein the polynucleotide encoding a TLR4 polypeptide comprises a nucleic acid encoding a signal peptide.
128. 128. The method, composition, or kit of claim 127, wherein the signal peptide is a heterologous signal peptide, and the heterologous signal peptide is a lysosomal membrane glycoprotein 1 (LAMP1) signal peptide.
129. 114. The method of any one of claims 1-99 or 105-112, the composition of any one of claims 100-104, or the kit of claim 113, wherein said polynucleotide encoding an IL15 polypeptide comprises at least one polynucleotide comprising an ORF encoding an IL15 polypeptide and an IL15R extracellular domain polypeptide.
130. 130. The method, composition, or kit of claim 129, wherein the IL15 polypeptide is operably linked to the IL15R extracellular domain polypeptide by a linker.
131. 131. The method, composition, or kit of claim 129 or 130, wherein the IL15 polypeptide further comprises an Fc domain.
132. 132. The method, composition, or kit of any one of claims 129 to 131, wherein the polynucleotide comprising an ORF encoding an IL15 polypeptide comprises a nucleic acid encoding a signal peptide.
133. 133. The method, composition, or kit of claim 132, wherein the signal peptide is a heterologous signal peptide.
134. 134. The method, composition, or kit of claim 133, wherein the heterologous signal peptide is a tPA signal peptide.
135. 114. The method of any one of claims 1-99 or 105-112, the composition of any one of claims 100-104, or the kit of claim 113, wherein the polynucleotide encoding an IL23 polypeptide comprises an ORF encoding an IL12p40 polypeptide and an IL23p19 polypeptide.
136. 136. The method, composition or kit of claim 135, wherein the IL12p40 polypeptide is operably linked to the IL23p19 polypeptide by a linker.
137. 137. The method, composition, or kit of claim 135 or 136, wherein the polynucleotide encoding an IL23 polypeptide comprises a nucleic acid encoding a signal peptide.
138. 138. The method, composition, or kit of claim 137, wherein the signal peptide is an IL12p40 signal peptide or an IL23p19 signal peptide.
139. The method of any one of claims 1-99 or 105-112, the composition of any one of claims 100-104, or the kit of claim 113, wherein said polynucleotide encoding an IL36 gamma polypeptide comprises an ORF encoding an IL36 gamma polypeptide.
140. 140. The method, composition, or kit of claim 139, wherein the polynucleotide ORF encoding a mature IL36 gamma polypeptide further comprises a nucleic acid encoding a signal peptide.
141. 141. The method, composition, or kit of claim 140, wherein the signal peptide is a heterologous signal peptide.
142. 142. The method, composition, or kit of claim 141, wherein the heterologous signal peptide is a hIgKV4 signal peptide.
143. At least two mRNAs and a pharma- ceutical acceptable carrier, wherein the mRNAs are (i) one or more mRNAs having an open reading frame encoding an immune response primer polypeptide; (ii) one or more mRNAs having an open reading frame encoding an immune response costimulatory signal polypeptide; and (iii) one or more mRNAs having an open reading frame encoding a checkpoint inhibitor polypeptide. A pharmaceutical composition selected from the group consisting of
144. The pharmaceutical composition of claim 143, wherein the composition comprises (i) an mRNA having an open reading frame encoding an immune response primer polypeptide and (ii) an mRNA having an open reading frame encoding an immune response costimulatory signal polypeptide.
145. The pharmaceutical composition of claim 143, wherein the composition comprises two mRNAs, each having an open reading frame encoding an immune response primer polypeptide.
146. The pharmaceutical composition of claim 143, wherein the composition comprises (i) an mRNA having an open reading frame encoding an immune response costimulatory signal polypeptide and (ii) an mRNA having an open reading frame encoding a checkpoint inhibitor polypeptide.
147. The pharmaceutical composition of claim 143, wherein the composition comprises (i) an mRNA having an open reading frame encoding an immune response costimulatory signal polypeptide, (ii) an mRNA having an open reading frame encoding an immune response costimulatory signal polypeptide, and (iii) an mRNA having an open reading frame encoding a checkpoint inhibitor polypeptide.
148. 148. The pharmaceutical composition of any one of claims 143-147, wherein the immune response primer polypeptide comprises interleukin 12 (IL12), interleukin (IL23), toll-like receptor 4 (TLR4), interleukin 36 gamma (IL36 gamma), interleukin 18 (IL18), or a combination thereof.
149. The pharmaceutical composition of any one of claims 143 to 148, wherein the immune response co-stimulatory signal polypeptide comprises tumor necrosis factor receptor superfamily member 4 ligand (OX40L), cluster of differentiation 80 (CD80), interleukin 15 (IL15), or a combination thereof.
150. 150. The pharmaceutical composition of any one of claims 143-149, wherein said checkpoint inhibitor polypeptide inhibits programmed cell death protein 1 (PD1), programmed cell death ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).
151. (a) (i) a 5' untranslated region (5'-UTR); and (ii) an open reading frame (ORF) encoding at least one immune response primer polypeptide, an immune response costimulatory signal polypeptide, a checkpoint inhibitor polypeptide, or a combination thereof, the ORF comprising at least one chemically modified nucleobase, sugar, backbone, or any combination thereof; (iii) at least one stop codon; and (iv) a microRNA (miRNA) binding site; and (v) a 3' untranslated region (3'-UTR); and (vi) a poly-A tail; and (b) Lipid nanoparticle carriers The pharmaceutical composition according to any one of claims 143 to 150, comprising:
152. (a) a first mRNA encodes an IL23 polypeptide and a second mRNA encodes an IL18 polypeptide; (b) the first mRNA encodes an IL23 polypeptide and the second mRNA encodes an IL12 polypeptide; (c) the first mRNA encodes an IL23 polypeptide and the second mRNA encodes an OX40L polypeptide; (d) the first mRNA encodes an IL12 polypeptide and the second mRNA encodes an anti-CTLA-4 antibody; (e) the first mRNA encodes an IL12 polypeptide and the second mRNA encodes an anti-PD-1 antibody or an anti-PD-L1 antibody; (f) a first mRNA encodes an IL23 polypeptide and a second mRNA encodes an anti-CTLA-4 antibody; (g) the first mRNA encodes an IL18 polypeptide and the second mRNA encodes an anti-PD-1 antibody or an anti-PD-L1 antibody; (h) a first mRNA encodes an IL18 polypeptide and a second mRNA encodes an anti-CTLA-4 antibody; (i) a first mRNA encodes an IL18 polypeptide and a second mRNA encodes an OX40L polypeptide; (j) a first mRNA encodes an IL18 polypeptide and a second mRNA encodes a TLR4 polypeptide; (k) the first mRNA encodes an IL18 polypeptide and the second mRNA encodes an IL12 polypeptide; (l) a first mRNA encodes an OX40L polypeptide and a second mRNA encodes an anti-CTLA-4 antibody; (m) a first mRNA encodes an OX40L polypeptide and a second mRNA encodes an anti-PD-1 antibody or an anti-PD-L1 antibody; (n) a first mRNA encodes an OX40L polypeptide and a second mRNA encodes a caTLR4 polypeptide; (o) a first mRNA encodes an OX40L polypeptide and a second mRNA encodes an IL23 polypeptide; (p) a first mRNA encodes an OX40L polypeptide and a second mRNA encodes an IL12 polypeptide; (q) a first mRNA encodes a CD80 polypeptide and a second mRNA encodes an anti-CTLA-4 antibody; (r) a first mRNA encodes a TLR4 polypeptide and a second mRNA encodes an anti-CTLA-4 antibody; (s) a first mRNA encoding an IL18 polypeptide, a second mRNA encoding an IL12 polypeptide, and a third mRNA encoding an IL23 polypeptide; (t) a first mRNA encoding an OX40L polypeptide, a second mRNA encoding a TLR4 polypeptide, and a third mRNA encoding an IL18 polypeptide; (u) a first mRNA encoding an OX40L polypeptide, a second mRNA encoding an IL12 polypeptide, and a third mRNA encoding an IL23 polypeptide; (v) administering a first polynucleotide encoding an IL23 polypeptide, a second polynucleotide encoding an IL12 polypeptide, and a third polynucleotide encoding an anti-CTLA-4 antibody; (w) a first mRNA encoding an IL23 polypeptide, a second mRNA encoding an IL18 polypeptide, and a third mRNA encoding an anti-CTLA-4 antibody; (x) administering a first mRNA encoding an IL23 polypeptide, a second mRNA encoding an IL12 polypeptide, and a third mRNA encoding an IL18 polypeptide and a fourth polynucleotide encoding an anti-CTLA-4 antibody; (y) a first mRNA encoding an IL23 polypeptide, a second mRNA encoding an IL12 polypeptide, and further comprising a third mRNA encoding an IL18 polypeptide and a fourth mRNA encoding an anti-PD-1 antibody or an anti-PD-L1 antibody; (z) a first mRNA encoding an OX40L polypeptide, a second mRNA encoding an IL18 polypeptide, and further comprising a third mRNA encoding a TLR4 polypeptide and a fourth mRNA encoding an anti-CTLA-4 antibody; or (aa) a first mRNA encoding an OX40L polypeptide, a second mRNA encoding an IL18 polypeptide, and further comprising a third mRNA encoding a TLR4 polypeptide and a fourth mRNA encoding an anti-PD-1 antibody or an anti-PD-L1 antibody. The pharmaceutical composition of claim 143.
153. The pharmaceutical composition of claim 152, wherein the composition comprises two, three, four, five, six, or more mRNAs, each of which comprises at least one ORF.
154. The pharmaceutical composition of claim 153, wherein the mRNA comprises at least one chemically modified nucleobase, sugar, backbone, or any combination thereof.
155. The pharmaceutical composition of claim 153 or 154, wherein each mRNA is formulated in the same lipid nanoparticle carrier.
156. The pharmaceutical composition of claims 153 to 155, wherein each mRNA is formulated in a different lipid nanoparticle carrier.
157. 156. The pharmaceutical composition of claim 155, wherein the lipid nanoparticle carrier comprises a lipid selected from the group consisting of DLin-DMA, DLin-K-DMA, 98N12-5, C12-200, DLin-MC3-DMA, DLin-KC2-DMA, DODMA, PLGA, PEG, PEG-DMG, PEGylated lipids, aminoalcohol lipids, KL22, and combinations thereof.
158. The lipid nanoparticle carrier has the formula (I): [C75] or a salt or stereoisomer thereof, wherein R 1 But, C 5~20 Alkyl, C 5~20 Alkenyl, -R * -YR", -YR", and -R"M'R'; R 2 and R 3 But, H, C 1~14 Alkyl, C 2~14 Alkenyl, -R * YR", -YR", and -R * OR″, or R 2 and R 3 form a heterocyclic or carbocyclic ring together with the atoms to which they are attached, R 4 But, C 3~6 Carbocycle, -(CH 2 ) n Q, -(CH 2) n CHQR, -CHQR, -CQ(R) 2 and unsubstituted C 1~6 alkyl, where Q is a carbocycle, a heterocycle, —OR, —O(CH 2 ) n N (R) 2 , -C(O)OR, -OC(O)R, -CX 3 , -CX 2 H, -CXH 2 , -CN, -N(R) 2 , -C(O)N(R) 2 , -N(R)C(O)R, -N(R)S(O) 2 R, -N(R)C(O)N(R) 2 , -N(R)C(S)N(R) 2 and -C(R)N(R) 2 C(O)OR, where each n is independently selected from 1, 2, 3, 4, and 5; Each R 5 But, C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl and H; Each R 6 But, C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl and H; M and M' are -C(O)O-, -OC(O)-, -C(O)N(R')-, -N(R')C(O)-, -C(O)-, -C(S)-, -C(S)S-, -SC(S)-, -CH(OH)-, -P(O)(OR')O-, -S(O) 2 -, an aryl group, and a heteroaryl group; R 7 But, C 1~3 Alkyl, C 2~3 selected from the group consisting of alkenyl and H; Each R is C 1~3 Alkyl, C 2~3 independently selected from the group consisting of alkenyl and H; Each R' is C 1~18 Alkyl, C 2~18 Alkenyl, -R *independently selected from the group consisting of YR″, -YR″, and H; Each R" is C 3~14 Alkyl and C 3~14 alkenyl, Each R * But, C 1~12 Alkyl and C 2~12 alkenyl, Each Y is independently C 3~6 is a carbocyclic ring, each X is independently selected from the group consisting of F, Cl, Br, and I; m is selected from 5, 6, 7, 8, 9, 10, 11, 12 and 13; However, R 4 But -(CH 2 ) n Q, -(CH 2 ) n CHQR, -CHQR, or -CQ(R) 2 (i) when n is 1, 2, 3, 4, or 5, Q is -N(R) 2 or (ii) when n is 1 or 2, Q is not a 5-, 6-, or 7-membered heterocycloalkyl. The pharmaceutical composition of claim 155.
159. The compound has the formula (IA): [C76] or a salt or stereoisomer thereof, wherein l is selected from 1, 2, 3, 4 and 5; m is selected from 5, 6, 7, 8 and 9; M 1 is a bond or M′, R 4 is unsubstituted C 1~3 Alkyl or -(CH 2 ) n Q, where n is 1, 2, 3, 4, or 5, and Q is OH, -NHC(S)N(R) 2 or -NHC(O)N(R) 2 and M and M' are independently selected from -C(O)O-, -OC(O)-, -C(O)N(R')-, -P(O)(OR')O-, an aryl group, and a heteroaryl group; R 2 and R 3 But, H, C 1~14 Alkyl and C 2~14 alkenyl The pharmaceutical composition of claim 158.
160. The pharmaceutical composition of any one of claims 158 to 159, wherein m is 5, 7 or 9.
161. The compound has the formula (II): [C77] or a salt or stereoisomer thereof, wherein l is selected from 1, 2, 3, 4 and 5; M 1 is a bond or M′, R 4 is unsubstituted C 1~3 Alkyl or -(CH 2 ) n Q, where n is 2, 3, or 4, and Q is OH, -NHC(S)N(R) 2 or -NHC(O)N(R) 2 and M and M' are independently selected from -C(O)O-, -OC(O)-, -C(O)N(R')-, -P(O)(OR')O-, an aryl group, and a heteroaryl group; R 2 and R 3 But, H, C 1~14 Alkyl and C 2~14 alkenyl The pharmaceutical composition according to claims 158 to 160.
162. The pharmaceutical composition according to any one of claims 158 to 161, wherein the compound is selected from compound 1 to compound 147, and salts and stereoisomers thereof.
163. The compound has the formula (IIa): [C78] 160. The pharmaceutical composition according to claim 158 or 159, which is:
164. The compound has the formula (IIb): [C79] or a salt or stereoisomer thereof.
165. The compound has the formula (IIc) or (IIe): [C80] or a salt or stereoisomer thereof.
166. R 4 But -(CH 2 ) n Q and -(CH 2 ) n 166. The pharmaceutical composition according to claims 162 to 165, selected from: CHQR, where Q, R and n are as defined in claim 158 or 159 above.
167. The compound has the formula (IId): [chemical 81] or a salt or stereoisomer thereof, In the formula, R 2 and R 3 But, C 5~14 Alkyl and C 5~14 alkenyl, n is selected from 2, 3 and 4; R′, R″, R 5 , R 6 160. The pharmaceutical composition of claim 158 or 159, wherein and m is as defined in claim 158 or 159.
168. R 2 C 8The pharmaceutical composition of claim 167, wherein said compound is alkyl.
169. R 3 But, C 5 Alkyl, C 6 Alkyl, C 7 Alkyl, C 8 Alkyl, or C 9 169. The pharmaceutical composition of claim 167 or 168, wherein said alkyl is aryl.
170. The pharmaceutical composition of any one of claims 167 to 169, wherein m is 5, 7 or 9.
171. Each R 5 The pharmaceutical composition of any one of claims 167 to 170, wherein
172. Each R 6 The pharmaceutical composition of claim 171, wherein is H.
173. 173. The pharmaceutical composition of any one of claims 158 to 172, wherein the lipid nanoparticle carrier further comprises a phospholipid.
174. The phospholipid is 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-Hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16:0 PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, Selected from the group consisting of 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), sphingomyelin, and mixtures thereof. The pharmaceutical composition of claim 173.
175. The phospholipid is 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine (14:0-16:0 PC, MPPC), 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine (14:0-18:0 PC, MSPC), 1-palmitoyl-2-acetyl-sn-glycero-3-phosphocholine (16:0-02:0 PC), 1-palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine (16:0-14:0 PC, PMPC), 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine (16:0-18:0 PC, PSPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (16:0-18:1 PC, POPC), 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine (16:0-18:2 PC, PLPC), 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (16:0-20:4 PC), 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (14:0-22:6 PC), 1-Stearoyl-2-myristoyl-sn-glycero-3-phosphocholine (18:0-14:0 PC, SMPC), 1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine (18:0-16:0 PC, SPPC), 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (18:0-18:1 PC, SOPC), 1-stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine (18:0 to 18:2 PC), 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (18:0 to 20:4 PC), 1-stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (18:0 to 22:6 PC), 1-oleoyl-2-myristoyl-sn-glycero-3-phosphocholine (18:1-14:0 PC, OMPC), 1-oleoyl-2-palmitoyl-sn-glycero-3-phosphocholine (18:1-16:0 PC, OPPC), 1-oleoyl-2-stearoyl-sn-glycero-3-phosphocholine (18:1 to 18:0 PC, OSPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (16:0-18:1 PE, POPE), 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine (16:0 to 18:2 PE), 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine (16:0 to 20:4 PE), 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine (16:0 to 22:6 PE), 1-stearoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (18:0 to 18:1 PE), 1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphoethanolamine (18:0 to 18:2 PE), 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphoethanolamine (18:0 to 20:4 PE), 1-Stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphoethanolamine (18:0 to 22:6 PE), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC) and selected from the group consisting of any combination thereof The pharmaceutical composition of claim 173.
176. 176. The pharmaceutical composition of any one of claims 158 to 175, wherein the lipid nanoparticle carrier further comprises a structured lipid.
177. 177. The pharmaceutical composition of claim 176, wherein said structured lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and mixtures thereof.
178. 178. The pharmaceutical composition of any one of claims 158 to 177, wherein the lipid nanoparticle carrier further comprises a PEG lipid.
179. The pharmaceutical composition of claim 178, wherein the PEG lipid is selected from the group consisting of PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol, and mixtures thereof.
180. The lipid nanoparticle carrier is 3-(didodecylamino)-N1,N1,4-tridodecyl-1-piperazineethanamine (KL10), N1-[2-(didodecylamino)ethyl]-N1,N4,N4-tridodecyl-1,4-piperazinediethanamine (KL22), 14,25-ditridecyl-15,18,21,24-tetraaza-octatriacontane (KL25), 1,2-Dilinoleyloxy-N,N-dimethylaminopropane (DLin-DMA), 2,2-Dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), Heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (DLin-MC3-DMA), 2,2-Dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA), 1,2-dioleyloxy-N,N-dimethylaminopropane (DODMA), 2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (octyl-CLinDMA), (2R)-2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (octyl-CLinDMA(2R)) and (2S)-2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA(2S)).
180. The pharmaceutical composition according to any one of claims 158 to 179.
181. 181. The pharmaceutical composition of any one of claims 158 to 180, wherein the lipid nanoparticle carrier further comprises a quaternary amine compound.
182. The quaternary amine compound is 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), 1-[2-(oleoyloxy)ethyl]-2-oleyl-3-(2-hydroxyethyl)imidazolinium chloride (DOTIM), 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethylammonium bromide (DMRIE), N-(1,2-dioleoyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethylammonium bromide (DORIE), N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), 1,2-dilauroyl-sn-glycero-3-ethylphosphocholine (DLePC), 1,2-distearoyl-3-trimethylammonium-propane (DSTAP), 1,2-dipalmitoyl-3-trimethylammonium-propane (DPTAP), 1,2-dilinoleoyl-3-trimethylammonium-propane (DLTAP), 1,2-dimyristoyl-3-trimethylammonium-propane (DMTAP), 1,2-distearoyl-sn-glycero-3-ethylphosphocholine (DSePC), 1,2-dipalmitoyl-sn-glycero-3-ethylphosphocholine (DPePC), 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (DMePC), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOePC), 1,2-di-(9Z-tetradecenoyl)-sn-glycero-3-ethylphosphocholine (14:1 EPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-ethylphosphocholine (16:0 to 18:1 EPC) and selected from the group consisting of any combination thereof The pharmaceutical composition of claim 181.
183. 183. The method, composition, pharmaceutical composition, or kit of any one of claims 1-182, wherein administering said polynucleotide, composition, or pharmaceutical composition to a subject in need thereof reduces tumor size or inhibits tumor growth at least 1.5-fold, at least 2-fold, at least 2.5-fold, at least 3-fold, at least 3.5-fold, at least 4-fold, at least 4.5-fold, or at least 5-fold better than a monotherapy consisting of administering only one polynucleotide in said composition or pharmaceutical composition.
